

NATIONAL TOXICOLOGY PROGRAM  
Technical Report Series  
No. 337



**TOXICOLOGY AND CARCINOGENESIS**  
**STUDIES OF**  
**NITROFURAZONE**  
**(CAS NO. 59-87-0)**  
**IN F344/N RATS AND B6C3F<sub>1</sub> MICE**  
**(FEED STUDIES)**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
National Institutes of Health

## NATIONAL TOXICOLOGY PROGRAM

The National Toxicology Program (NTP), established in 1978, develops and evaluates scientific information about potentially toxic and hazardous chemicals. This knowledge can be used for protecting the health of the American people and for the primary prevention of disease. By bringing together the relevant programs, staff, and resources from the U.S. Public Health Service, DHHS, the National Toxicology Program has centralized and strengthened activities relating to toxicology research, testing and test development/validation efforts, and the dissemination of toxicological information to the public and scientific communities and to the research and regulatory agencies.

The NTP is made up of four charter DHHS agencies: the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS.

**NTP TECHNICAL REPORT**  
**ON THE**  
**TOXICOLOGY AND CARCINOGENESIS**  
**STUDIES OF NITROFURAZONE**  
**(CAS NO. 59-87-0)**  
**IN F344/N RATS AND B6C3F<sub>1</sub> MICE**  
**(FEED STUDIES)**

**Frank Kari, Ph.D., Chemical Manager**

**NATIONAL TOXICOLOGY PROGRAM**  
**P.O. Box 12233**  
**Research Triangle Park, NC 27709**

**June 1988**

**NTP TR 337**

**NIH Publication No. 88-2593**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**Public Health Service**  
**National Institutes of Health**

## NOTE TO THE READER

This study was performed under the direction of the National Institute of Environmental Health Sciences as a function of the National Toxicology Program. The studies described in this Technical Report have been conducted in compliance with NTP chemical health and safety requirements and must meet or exceed all applicable Federal, state, and local health and safety regulations. Animal care and use were in accordance with the U.S. Public Health Service Policy on Humane Care and Use of Animals. All NTP toxicology and carcinogenesis studies are subjected to a data audit before being presented for public peer review.

Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to identify any mistakes so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP. Comments and questions about the National Toxicology Program Technical Reports on Toxicology and Carcinogenesis Studies should be directed to Dr. J.E. Huff, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709 (919-541-3780).

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709.

## CONTENTS


	PAGE
NOTE TO THE READER .....	2
ABSTRACT .....	5
EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY .....	9
CONTRIBUTORS .....	10
PEER REVIEW PANEL .....	11
SUMMARY OF PEER REVIEW COMMENTS .....	12
I. INTRODUCTION .....	15
II. MATERIALS AND METHODS .....	21
PROCUREMENT AND CHARACTERIZATION OF NITROFURAZONE .....	22
PREPARATION AND CHARACTERIZATION OF FORMULATED DIETS .....	22
FOURTEEN-DAY STUDIES .....	26
THIRTEEN-WEEK STUDIES .....	29
TWO-YEAR STUDIES .....	29
STUDY DESIGN .....	29
SOURCE AND SPECIFICATIONS OF ANIMALS .....	29
ANIMAL MAINTENANCE .....	30
CLINICAL EXAMINATIONS AND PATHOLOGY .....	30
STATISTICAL METHODS .....	30
III. RESULTS .....	33
RATS .....	34
FOURTEEN-DAY STUDIES .....	34
THIRTEEN-WEEK STUDIES .....	34
TWO-YEAR STUDIES .....	36
BODY WEIGHTS, FEED CONSUMPTION, AND CLINICAL SIGNS .....	36
SURVIVAL .....	39
PATHOLOGY AND STATISTICAL ANALYSES OF RESULTS .....	39
MICE .....	45
FOURTEEN-DAY STUDIES .....	45
THIRTEEN-WEEK STUDIES .....	46
TWO-YEAR STUDIES .....	47
BODY WEIGHTS, FEED CONSUMPTION, AND CLINICAL SIGNS .....	47
SURVIVAL .....	50
PATHOLOGY AND STATISTICAL ANALYSES OF RESULTS .....	52

## CONTENTS (Continued)

	PAGE
IV. DISCUSSION AND CONCLUSIONS .....	57
V. REFERENCES .....	63

### APPENDIXES

APPENDIX A	SUMMARY OF LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE .....	69
APPENDIX B	SUMMARY OF LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE .....	91
APPENDIX C	SUMMARY OF LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE .....	111
APPENDIX D	SUMMARY OF LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE .....	135
APPENDIX E	GENETIC TOXICOLOGY OF NITROFURAZONE .....	159
APPENDIX F	SENTINEL ANIMAL PROGRAM .....	165
APPENDIX G	FEED AND COMPOUND CONSUMPTION BY RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE .....	169
APPENDIX H	INGREDIENTS, NUTRIENT COMPOSITION, AND CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION .....	175
APPENDIX I	AUDIT SUMMARY .....	181



## NITROFURAZONE

CAS No. 59-87-0

$C_6H_6N_4O_4$

Molecular weight 198.1

**Synonyms or Trade Names:** 5-Nitro-2-furaldehyde semicarbazone; 2-[(5-Nitro-2-furanyl)methylene]hydrazine carboxamide; Aldomycin; Amifur; Chemfuran; Coxistat; Furacin; Furacinetten; Furaplast; Furazol W; Furesol; Furracocid; Mammex; Nefco; Nifuzon; Nitrofurazone; Vabrocid

### ABSTRACT

Nitrofurazone is a synthetic furan derivative, active against a broad spectrum of bacteria, which has been widely used in veterinary and human medicine. Toxicology and carcinogenesis studies were conducted by feeding diets containing nitrofurazone (99% pure) to groups of F344/N rats and B6C3F<sub>1</sub> mice of each sex for 14 days, 13 weeks, or 2 years.

*Fourteen-Day and Thirteen-Week Studies:* Groups of five males and five females of each species were fed diets containing 0, 630, 1,250, 2,500, 5,000, or 10,000 ppm for 14 consecutive days. Early deaths occurred in all groups of rats receiving 5,000 or 10,000 ppm nitrofurazone. The surviving rats in the lower two dose groups gained weight, but weight gain was decreased as the dose of nitrofurazone was increased. Feed consumption by rats of each sex was decreased at all doses above 630 ppm. In all dosed groups, clinical signs of toxicity included rough hair coats and lethargy. At doses of 2,500 ppm and above, rats of each sex exhibited intermittent episodes of seizures and lethargy.

All mice that received 2,500, 5,000, or 10,000 ppm nitrofurazone and 3/5 males that received 1,250 ppm died before the end of the 14-day studies; the surviving dosed mice (except females at 630 ppm) lost weight. A dose-related decrease in feed consumption was observed at all doses above 630 ppm. Clinical signs included rough hair coats and convulsive seizures.

In the 13-week studies, groups of 10 rats of each sex were given diets containing 0, 150, 310, 620, 1,250, or 2,500 ppm nitrofurazone. No deaths were observed and all animals gained weight, but the magnitude of weight gain was dose dependent with decrements in final mean body weight for the highest dose group reaching 55% in males and 36% in females. Other evidence of chemically related toxicity included convulsive seizures, osteoporosis, degenerative arthropathy, and gonadal hypoplasia in both sexes at the two highest doses.

Groups of 10 mice of each sex were given diets containing 0, 70, 150, 310, 620, or 1,250 ppm nitrofurazone for 13 weeks. Early deaths were observed in the two highest dose groups of each sex. The final mean body weights of male and female mice in the 1,250-ppm groups were about 20% lower than those of the controls; weight gains of the other dosed mice were comparable to those of the controls. Stimulus-induced convulsive seizures were observed for all mice in the two highest dose groups. Testicular hypoplasia was observed in the two highest dose groups of male mice.

*Body Weight and Survival in the Two-Year Studies:* Dietary concentrations for the 2-year studies were 0, 310, or 620 ppm for rats and 0, 150, or 310 ppm for mice (50 animals per dose group). Mean

body weights of high dose male rats were lower than those of the controls after week 39; mean body weights of low dose male rats and of the controls were comparable throughout the study. Final mean body weights of low and high dose female rats were 9% and 21% lower than those of the controls. Dosed rats consumed less feed than did the controls. The average amount of nitrofurazone consumed per day was approximately 11-12 or 24-26 mg/kg by low or high dose male and female rats. The survival of the high dose group of male rats was lower than that of the controls after week 92 (final survival--male: control, 33/50; low dose, 30/50; high dose, 20/50; female: 28/50; 37/50; 31/50).

Mean body weights of dosed mice were similar to or somewhat greater than those of the controls throughout most of the studies. The average daily feed consumption by dosed mice was similar to that of controls. The average amount of nitrofurazone consumed per day was approximately 14-16 or 29-33 mg/kg for low or high dose male and female mice. The survival of the high dose group of male mice was lower than that of the controls after week 88 (final survival--male: 39/50; 31/50; 27/50; female: 39/50; 40/50; 35/50).

In mice of each sex, nitrofurazone administration induced stimulus-sensitive convulsive seizures beginning at week 4 or 5 for high dose mice and week 24 for low dose female mice. These seizures were observed primarily in the first year of the study.

*Nonneoplastic and Neoplastic Effects in the Two-Year Studies:* Degenerative changes involving the vertebral and femoro-tibial (knee) joints were observed at increased incidences in dosed rats. The degenerative changes primarily affected the articular cartilage and were similar to those seen in the 13-week studies. Degeneration of the sternal synchondroses was increased in high dose female rats. The osteoporosis seen in the 13-week studies was not observed in the 2-year studies. Testicular degeneration, characterized by atrophy of the germinal epithelium and aspermatogenesis, was observed at increased incidences in dosed male rats (control, 12/50; low dose, 49/50; high dose, 47/50).

Adenomas of the sebaceous glands and trichoepitheliomas or sebaceous adenomas (combined) of the skin were observed in high dose male rats (0/50; 0/50; 5/50). Carcinomas of the preputial gland were increased in dosed male rats (1/50; 8/50; 5/50). The incidences of preputial gland adenomas or carcinomas (combined) in dosed male rats were not statistically greater than that in the controls (9/50; 16/50; 7/50). However, in the low dose group, the incidence is greater than the highest incidence observed in historical untreated control groups (9/50). In addition, hyperplasia of the preputial gland was observed in six low dose male rats in which neither adenomas nor carcinomas occurred. The incidence of mesotheliomas of the tunica vaginalis in low dose male rats was greater than that in the controls (0/50; 7/50; 2/50).

Fibroadenomas of the mammary gland occurred at markedly increased incidences in dosed female rats (8/49; 36/50; 36/50). Three adenocarcinomas were also observed (1/49; 0/50; 2/50).

Ovarian atrophy (7/47; 44/50; 38/50) and tubular cell hyperplasia of the ovary (1/47; 23/50; 21/50) were observed at markedly increased incidences in dosed female mice. The incidences of benign mixed tumors (0/47; 17/50; 20/50), granulosa cell tumors (1/47; 4/50; 9/50), and granulosa cell tumors or luteomas (combined) (3/47; 6/50; 9/50) of the ovary were increased in exposed female mice.

Mononuclear cell leukemia in rats occurred with negative trends (male: 21/50; 23/50; 6/50; female: 15/49; 2/50; 2/50). In female mice, the incidences of adenomas or carcinomas (combined) of the anterior pituitary gland occurred with a negative trend (10/50; 7/50; 2/49). The incidences of testicular interstitial cell tumors were decreased in dosed male rats (45/50; 30/50; 28/50).

*Genetic Toxicology:* Nitrofurazone was mutagenic in *Salmonella typhimurium* strains TA98 and TA100 both with and without exogenous metabolic activation. The responses in strains TA1535 and



TA1537 were more varied: nitrofurazone was mutagenic in strain TA1535 only in the presence of S9 and produced no consistent increase in gene reversions in strain TA1537 with or without S9. In the absence of metabolic activation, nitrofurazone induced forward mutations at the TK<sup>+/-</sup> locus of mouse L5178Y lymphoma cells; the chemical was not tested with S9. Treatment of cultured Chinese hamster ovary cells with nitrofurazone in the absence of S9 produced a dose-related increase in sister chromatid exchanges and chromosomal aberrations; with S9, sister chromatid exchanges were increased, but no induction of chromosomal aberrations was observed.

**Audit:** The data, documents, and pathology materials from the 2-year studies of nitrofurazone were audited at the NTP Archives. The audit findings show that the conduct of the studies is documented adequately and support the data and results given in this Technical Report.

**Conclusions:** Under the conditions of these 2-year feed studies, there was *equivocal evidence of carcinogenic activity\** of nitrofurazone for male F344/N rats as shown by the occurrence of sebaceous gland adenomas and trichoepitheliomas of the skin, mesotheliomas of the tunica vaginalis, and preputial gland tumors. There was *clear evidence of carcinogenic activity* of nitrofurazone for female F344/N rats as shown by a markedly increased incidence of fibroadenomas of the mammary gland. There was *no evidence of carcinogenic activity* for male B6C3F<sub>1</sub> mice fed diets containing nitrofurazone at concentrations of 150 or 310 ppm. There was *clear evidence of carcinogenic activity* of nitrofurazone for female B6C3F<sub>1</sub> mice as shown by increased incidences of benign mixed tumors and granulosa cell tumors of the ovary.

Administration of nitrofurazone was associated with decreased incidences of mononuclear cell leukemia in male and female rats, testicular interstitial cell tumors in male rats, and pituitary gland neoplasms in female mice. Convulsive seizures in mice of each sex, ovarian atrophy in female mice, testicular degeneration in rats, and degeneration of articular cartilage in rats were all associated with the administration of nitrofurazone.

---

\*Explanation of Levels of Evidence of Carcinogenic Activity is on page 9.  
A summary of the Peer Review comments and the public discussion on this Technical Report appears on pages 12-13.

**SUMMARY OF THE TWO-YEAR FEED AND GENETIC TOXICOLOGY STUDIES OF NITROFURAZONE**

<b>Male F344/N Rats</b>	<b>Female F344/N Rats</b>	<b>Male B6C3F<sub>1</sub> Mice</b>	<b>Female B6C3F<sub>1</sub> Mice</b>
<b>Dietary concentrations</b>			
310 or 620 ppm nitrofurazone	310 or 620 ppm nitrofurazone	150 or 310 ppm nitrofurazone	150 or 310 ppm nitrofurazone
<b>Survival rates in the 2-year study</b>			
33/50; 30/50; 20/50	28/50; 37/50; 31/50	39/50; 31/50; 27/50	39/50; 40/50; 35/50
<b>Body weights in the 2-year study</b>			
High dose lower than controls	Dosed lower than controls	Dosed and controls comparable	Dosed and controls comparable
<b>Nonneoplastic effects</b>			
Degeneration of articular cartilage; gonadal atrophy	Degeneration of articular cartilage	Convulsive seizures	Convulsive seizures; gonadal atrophy
<b>Neoplastic effects</b>			
Sebaceous gland adenomas and trichoepitheliomas of the skin; mesotheliomas of the tunica vaginalis; preputial gland tumors	Mammary gland fibro-adenomas	None	Ovarian granulosa cell and benign mixed tumors
<b>Level of evidence of carcinogenic activity</b>			
Equivocal evidence	Clear evidence	No evidence	Clear evidence
<b>Other considerations</b>			
Decreased incidences of mononuclear cell leukemia and testicular interstitial cell tumors	Decreased incidence of mononuclear cell leukemia	None	Decreased incidence of anterior pituitary gland neoplasms
<b>Genetic toxicology</b>			
Mutagenic in <i>S. typhimurium</i> TA98 and TA100 with and without S9; mutagenic in <i>S. typhimurium</i> TA1535 with S9. Mutagenic in L5178Y lymphoma cells without S9; caused increased frequency of sister chromatid exchanges in cultured CHO cells in the absence and presence of S9; caused increase in chromosomal aberrations in CHO cells in the absence but not the presence of S9.			

## EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection per se is not an indicator of a chemical's carcinogenic potential.

Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans.

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence including: animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results ("Clear Evidence" and "Some Evidence"); one category for uncertain findings ("Equivocal Evidence"); one category for no observable effects ("No Evidence"); and one category for experiments that because of major flaws cannot be evaluated ("Inadequate Study"). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Reports series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following quintet is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to either potency or mechanism.

- **Clear Evidence of Carcinogenic Activity** is demonstrated by studies that are interpreted as showing a dose-related (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- **Some Evidence of Carcinogenic Activity** is demonstrated by studies that are interpreted as showing a chemically related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- **Equivocal Evidence of Carcinogenic Activity** is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemically related.
- **No Evidence of Carcinogenic Activity** is demonstrated by studies that are interpreted as showing no chemically related increases in malignant or benign neoplasms.
- **Inadequate Study of Carcinogenic Activity** is demonstrated by studies that because of major qualitative or quantitative limitations cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. This should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- The adequacy of the experimental design and conduct;
- Occurrence of common versus uncommon neoplasia;
- Progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic lesions;
- Some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to assume that benign neoplasms of those types have the potential to become malignant;
- Combining benign and malignant tumor incidences known or thought to represent stages of progression in the same organ or tissue;
- Latency in tumor induction;
- Multiplicity in site-specific neoplasia;
- Metastases;
- Supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- The presence or absence of dose relationships;
- The statistical significance of the observed tumor increase;
- The concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- Survival-adjusted analyses and false positive or false negative concerns;
- Structure-activity correlations; and
- In some cases, genetic toxicology.

These considerations together with the definitions as written should be used as composite guidelines for selecting one of the five categories. Additionally, the following concepts (as patterned from the International Agency for Research on Cancer Monographs) have been adopted by the NTP to give further clarification of these issues:

The term *chemical carcinogenesis* generally means the induction by chemicals of neoplasms not usually observed, the induction by chemicals of more neoplasms than are generally found, or the earlier induction by chemicals of neoplasms that are commonly observed. Different mechanisms may be involved in these situations. Etymologically, the term *carcinogenesis* means induction of cancer, that is, of malignant neoplasms; however, the commonly accepted meaning is the induction of various types of neoplasms or of a combination of malignant and benign neoplasms. In the Technical Reports, the words *tumor* and *neoplasm* are used interchangeably.

## CONTRIBUTORS

The NTP Technical Report on the Toxicology and Carcinogenesis Studies of Nitrofurazone is based on the 13-week studies that began in July 1980 and ended in October 1980 and on the 2-year studies that began in June 1981 and ended in June 1983 at Physiological Research Laboratories.

### **National Toxicology Program (Evaluated Experiment, Interpreted Results, and Reported Findings)**

Frank Kari, Ph.D., Chemical Manager

John Bucher, Ph.D.  
Scot L. Eustis, D.V.M., Ph.D.

Joseph K. Haseman, Ph.D.  
James Huff, Ph.D.

### **(Discipline Leaders and Principal Contributors)**

Jack Bishop, Ph.D.  
Douglas W. Bristol, Ph.D.  
R. Chhabra, Ph.D.  
C.W. Jameson, Ph.D.

E.E. McConnell, D.V.M.  
G.N. Rao, D.V.M., Ph.D.  
B.A. Schwetz, D.V.M., Ph.D.  
Douglas Walters, Ph.D.

### **NTP Pathology Working Group (Evaluated Slides and Prepared Pathology Report for Rats on 8/28/86)**

Dawn Goodman, V.M.D. (Chair) (PATHCO)  
Michael Elwell, D.V.M., Ph.D. (NTP)  
Scot L. Eustis, D.V.M., Ph.D. (NTP)  
Micheal Jokinen, D.V.M. (Experimental  
Pathology Laboratories, Inc.)

Joel Leininger, D.V.M., Ph.D. (Physiological  
Research Laboratories)  
Robert R. Maronpot, D.V.M. (NTP)  
Charles Montgomery, D.V.M. (NTP)  
James Woodard, D.V.M., Ph.D.  
University of Florida

### **(Evaluated Slides and Prepared Pathology Report for Mice on 7/24/86)**

Linda Uraih, D.V.M. (Chair) (NTP)  
Roger Alison, B.V.Sc., M.R.C.V.S. (NTP)  
Bill Bullock, D.V.M. (Bowman Gray  
Medical School)  
Michael Elwell, D.V.M., Ph.D. (NTP)

Scot L. Eustis, D.V.M., Ph.D. (NTP)  
Micheal Jokinen, D.V.M. (Experimental  
Pathology Laboratories, Inc.)  
Charles Montgomery, D.V.M. (NTP)

### **Principal Contributors at Physiological Research Laboratories (Conducted Studies and Evaluated Tissues)**

M. Cowan, M.S.  
D. Elsberry, D.V.M., Ph.D.  
A. Hall, D.V.M.

R. Pieper, M.S.  
J. Leininger, D.V.M., Ph.D.

### **Principal Contributors at Experimental Pathology Laboratories, Inc. (Provided Pathology Quality Assurance)**

J. Gauchat

Micheal Jokinen, D.V.M.

### **Principal Contributors at Carltech Associates, Inc. (Contractor for Technical Report Preparation)**

William D. Theriault, Ph.D.  
Abigail C. Jacobs, Ph.D.

John Warner, M.S.

## PEER REVIEW PANEL

The members of the Peer Review Panel who evaluated the draft Technical Report on nitrofurazone on July 14, 1987, are listed below. Panel members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, Panel members have five major responsibilities: (a) to ascertain that all relevant literature data have been adequately cited and interpreted, (b) to determine if the design and conditions of the NTP studies were appropriate, (c) to ensure that the Technical Report presents the experimental results and conclusions fully and clearly, (d) to judge the significance of the experimental results by scientific criteria, and (e) to assess the evaluation of the evidence of carcinogenicity and other observed toxic responses.

### National Toxicology Program Board of Scientific Counselors Technical Reports Review Subcommittee

Robert A. Scala, Ph.D. (Chair)

Senior Scientific Advisor, Medicine and Environmental Health Department  
Research and Environmental Health Division, Exxon Corporation  
East Millstone, New Jersey

Michael A. Gallo, Ph.D.

Associate Professor, Director of Toxicology  
Department of Environmental and Community  
Medicine, UMDNJ - Rutgers Medical School  
Piscataway, New Jersey

Frederica Perera, Dr. P.H.\*

Division of Environmental Sciences  
School of Public Health, Columbia  
University  
New York, New York

### Ad Hoc Subcommittee Panel of Experts

John Ashby, Ph.D. (Principal Reviewer)

Imperial Chemical Industries, PLC  
Central Toxicology Laboratory  
Alderley Park, England

William Lijinsky, Ph.D.\*

Director, Chemical Carcinogenesis  
Frederick Cancer Research Facility  
Frederick, Maryland

Charles C. Capen, D.V.M., Ph.D.

Department of Veterinary Pathobiology  
Ohio State University  
Columbus, Ohio

Franklin E. Mirer, Ph.D.

Director, Health and Safety Department  
International Union, United Auto  
Workers, Detroit, Michigan

Vernon M. Chinchilli, Ph.D. (Principal Reviewer)

Department of Biostatistics  
Medical College of Virginia  
Virginia Commonwealth University  
Richmond, Virginia

James A. Popp, D.V.M., Ph.D.

Head, Department of Experimental  
Pathology and Toxicology  
Chemical Industry Institute of Toxicology  
Research Triangle Park, North Carolina

Kim Hooper, Ph.D. (Principal Reviewer)

Hazard Evaluation System and  
Information Services  
Department of Health Services  
State of California  
Berkeley, California

Andrew Sivak, Ph.D.

Vice President, Biomedical Science  
Arthur D. Little, Inc.  
Cambridge, Massachusetts

Donald H. Hughes, Ph.D.

Scientific Coordinator, Regulatory Services  
Division, The Procter and Gamble Company  
Cincinnati, Ohio

\*Unable to attend

**SUMMARY OF PEER REVIEW COMMENTS  
ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF  
NITROFURAZONE**

On July 14, 1987, the draft Technical Report on the toxicology and carcinogenesis studies of nitrofurazone received peer review by the National Toxicology Program Board of Scientific Counselors' Technical Reports Review Subcommittee and associated Panel of Experts. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Dr. F. Kari, NIEHS, introduced the studies by reviewing the experimental design, results, and proposed conclusions (equivocal evidence of carcinogenic activity for male rats; clear evidence of carcinogenic activity for female rats; no evidence of carcinogenic activity for male mice; clear evidence of carcinogenic activity for female mice).

Dr. Chinchilli, a principal reviewer, agreed with the conclusions. He suggested that a sentence might be added to the conclusion for male rats to emphasize the uncertainty as to whether the increased tumor incidences were chemically related. Dr. Kari indicated that the definition of equivocal evidence of carcinogenic activity already emphasized this uncertainty.

As a second principal reviewer, Dr. Hooper agreed with the conclusions for male and female rats and female mice. He stated that the conclusion for male mice should be equivocal evidence of carcinogenic activity, based on marginal increases of subcutaneous tissue fibromas, sarcomas, fibrosarcomas, or neurofibrosarcomas (combined) in high dose animals. Further, he felt that reduced survival in the high dose animals limited the sensitivity of the assay to detect carcinogenic effects. Dr. Kari explained that the large variability in the historical control data base for subcutaneous tumors was a prime reason for not associating these tumors with chemical exposure. Dr. Hooper asked if there was any mechanistic explanation for the decreases in incidence of several tumors in dosed rats and mice. Dr. Kari said he could only speculate that there is some relationship between body weight differences and incidences of certain endocrine-associated tumors.

As a third principal reviewer, Dr. Ashby agreed with the conclusion for male mice. For male rats, he asked whether the incidences of preputial gland adenomas and carcinomas should be analyzed separately, in which case the incidence of carcinomas in exposed groups supported a conclusion of some evidence of carcinogenic activity. Dr. Kari said the progression from adenomas to carcinomas was an established continuum and thus evaluating them combined is more appropriate (although the incidences for benign and malignant tumors are also shown separately). Dr. J. Huff, NIEHS, indicated this was a routine analysis procedure adopted for all tumor sites. Dr. Ashby continued that the conclusion for female rats should be some evidence of carcinogenic activity unless data can be cited that confirm the ability of fibroadenomas to progress to malignancy. Dr. Kari noted that the Discussion section of the Technical Report cited other authors who have shown this progression to occur in a small percentage of observations and that the NTP also has compiled evidence for progression, about which a manuscript is being prepared. Dr. S. Eustis, NIEHS, commented that whether a tumor remains benign or becomes malignant depends on both the intrinsic properties of the tumor and on host factors. He further stated that fibroadenomas have been demonstrated to progress to malignant tumors when transplanted into suitable hosts. Dr. Hooper said that this made it most important that appropriate documentation be provided supporting the potential for progression to malignancy. For female mice, Dr. Ashby thought the conclusion should be some evidence of carcinogenic activity unless progression to malignancy could be shown for the ovarian granuloma cell tumors. Dr. Kari remarked that in the study of nitrofurantoin, malignant granulosa cell tumors were observed. Dr. Ashby emphasized the importance of good data and exact citations in which the distinction between

## SUMMARY OF PEER REVIEW COMMENTS (Continued)

some evidence and clear evidence is supported by evidence of progression from studies of other investigators. Dr. Ashby noted that semicarbazide, a known animal carcinogen which is a substructure of nitrofurazone, was not associated with the carcinogenic effects observed because different site-specific neoplasms occur.

Dr. Chinchilli moved that the Technical Report on nitrofurazone be accepted with revisions as discussed to contain more explanation about progression and with the conclusions as written for male rats, equivocal evidence of carcinogenic activity, for male mice, no evidence of carcinogenic activity, and for female rats and mice, clear evidence of carcinogenic activity. Dr. Hooper seconded the motion, which was approved by seven reviewers with two abstentions (Dr. Capen and Dr. Hughes).





# I. INTRODUCTION

**Use and Production**

**Absorption, Metabolism, and Excretion**

**Toxicity in Animals**

**Carcinogenicity**


**Toxicity in Humans**

**Genetic Toxicology**

**Study Rationale**

# I. INTRODUCTION

---



## NITROFURAZONE

CAS No. 59-87-0

$C_6H_6N_4O_4$

Molecular weight 198.1

Synonyms or Trade Names: 5-Nitro-2-furaldehyde semicarbazone;  
2-[(5-Nitro-2-furanyl)methylene]hydrazine carboxamide; Aldomycin; Amifur; Chemfuran;  
Coxistat; Furacin; Furacinetten; Furaplast; Furazol W; Furesol; Furracoccid; Mammex; Nefco;  
Nifuzon; Nitrofural; Vabrocid

### Use and Production

Nitrofurazone, a synthetic furan derivative active against a broad spectrum of bacteria, has been used widely in veterinary and human medicine. The chemical is available as a National Formulary Grade containing not less than 98% nor more than 102% nitrofurazone after drying at 105° C for 1 hour (National Formulary, 1975). It is available as a topical cream containing 0.2% nitrofurazone in a water-miscible base which is applied daily or several times weekly (PDR, 1984). The annual production of nitrofurazone has been estimated to be approximately  $1.2 \times 10^4$  kg (Chemical Information Services, 1973), most of which is thought to be used in veterinary medicine. Recent marketing surveys indicate that the total quantity of nitrofurazone represented by drug store and hospital purchases averaged about 27 kg in 1985 and 1986 (IMS America Ltd, 1987).

In human medicine, nitrofurazone is used primarily to treat surface infections that have become resistant to antibiotics. The bactericidal activity of nitrofurazone was first described by Dodd and Stillman (1944). The chemical has been used as a topical adjunct for patients who have second- and third-degree burns or who require skin grafts. Nitrofurazone is also used widely in veterinary medicine to treat surface lesions, infectious enteritis in small animals, and skin, eye, ear, and genital tract infections. Nitrofurazone has been used as a coccidiostat in poultry and in the treatment of bovine mastitis (Hayes, 1967).

### Absorption, Metabolism, and Excretion

The disposition of nitrofurazone after oral administration to rats has been well studied. Within 24 hours after a single administration of  $^{14}C$ -labeled nitrofurazone (100 mg/kg), about two-thirds of the radioactivity appeared in the urine, 26% in feces, and approximately 1% in the expired carbon dioxide; complete recovery of the administered dose was observed in 96 hours, with less than 15% of the label being recovered as unchanged parent compound (Tatsumi et al., 1971). Major metabolites of nitrofurazone detected and identified in the urine from dosed Donryu rats included hydroxylaminofuraldehyde semicarbazone, aminofuraldehyde semicarbazone, and 4-cyano-2-oxobutylaldehyde semicarbazone (Paul et al., 1960). Nitrofurazone has been shown to bind to nucleic acids and proteins both in vivo and in vitro (Tatsumi et al., 1977).

It has been proposed that the cytotoxicity and DNA damage observed in animals after administration of nitrofurazone may result from the formation of toxic intermediates upon nitroreduction by mammalian and/or bacterial enzymes. For example, a positive correlation exists between the ability of several organs to reduce nitrofurazone and the DNA damage observed in the thymidine-labeled cells incubated with these tissues (Olive and McCalla, 1975; Olive, 1979). Recent research activity has focused on the relative roles of bacterial versus mammalian metabolism of this compound.

Investigations with various *in vitro* preparations have shown that nitrofurazone can be metabolized by the liver (Mason and Holtzman, 1975; Peterson et al., 1979; Kutcher and McCalla, 1984), kidney (Hoener and Krueger, 1984), and testes (Hollinger and Davis, 1969) under both aerobic and anaerobic conditions. Furthermore, the small intestine has been shown to be a major site of nitrofurazone metabolism *in vivo*, and this activity is not dependent on enteric bacteria but can be attributed to xanthine oxidase activity located in intestinal mucosal cells (Tatsumi et al., 1973). Finally, reduced metabolites of nitrofurazone have been identified in the urine of germ-free animals (Yeung et al., 1983). Considered together, these findings suggest that microbial metabolism is not obligatory for the observed toxicity of nitrofurazone in animals.

## Toxicity in Animals

Oral LD<sub>50</sub> values of 590 mg/kg body weight for Donryu rats and 640 mg/kg for ICR/JCL mice have been reported (Miyaji, 1971). Clinical signs observed in mice and rats administered nitrofurazone at 300 mg/kg or more included hyperirritability, seizures and tremors, and death from respiratory insufficiency (Krantz and Evans, 1945; Dodd, 1946).

Administration of nitrofurazone in a high fat milk replacer (daily dose, 13.9 mg/kg) to male Holstein calves caused hyperirritability and convulsions after 3-5 weeks, and at higher doses (30.7 mg/kg) all six calves showed evidence of severe limb paralysis after several days (Lister and Fisher, 1970).

In rats, oral administration of nitrofurazone was shown to inhibit spermatogenesis at the spermatocyte or spermatid stage, resulting in testicular atrophy when dosing was prolonged. This was generally reversible when administration of the chemical was stopped. Hypertrophy of the adrenal glands was also reported. A similar effect was demonstrated in mice, and interstitial cell hyperplasia and seminal vesicle hypertrophy were also shown (Prior and Ferguson, 1950; Nissim, 1957; Montemurro, 1969).

Investigations of the mode of action of the anti-spermatogenic activity of nitrofurazone reveal

that under conditions where nitrofurazone completely inhibited spermatogenesis, functional and morphologic parameters of Leydig and Sertoli cells proved to be normal, but marked degeneration of germ cells was noted (Hagenas et al., 1978). These abnormalities were characterized by cell death during meiosis, occurrence of multinucleate spermatocytes and spermatids, and acrosomal derangements. All germ cells except spermatogonia and early primary spermatocytes were affected, and damage was shown to be most severe in cells staged from mid-prophase through meiotic division. Long-term administration of nitrofurazone to rats has been shown to inhibit the testicular oxidation of glucose (Hollinger and Davis, 1969). Spermatogonia are relatively independent of glucose oxidation for energy (Davis and Firlit, 1965), and this may partially explain the refractiveness of the undifferentiated germ cells to the morphologic damage observed in spermatids. However, direct effects of nitrofurazone on DNA in these cells cannot be precluded because nitrofurazone has been shown to be clastogenic toward single-stranded DNA (Olive and McCalla, 1975).

In a study of nitrofurazone conducted by the NTP, timed-pregnant CD-1 mice were fed dietary concentrations of nitrofurazone ranging from 38 to 500 ppm on days 6-15 of gestation, with observations continuing through day 17 (Price et al., 1985). No evidence of teratogenic effects was observed. Selective embryotoxicity, expressed as increased incidence of late fetal death and intrauterine growth retardation, was observed at doses that were only marginally toxic to the exposed dams.

## Carcinogenicity

In two separate experiments, nitrofurazone was administered to female Holtzman rats in diets at a concentration of 1,000 ppm for 36 or 44 weeks (Morris et al., 1969). For the first experiment, the control and dosed groups initially contained 20 animals each; in the second experiment, control and dosed groups contained between 30 and 36 animals each. All gross lesions as well as tissue from liver, kidney, and spleen were evaluated histologically. Only mammary gland tumors were observed in these studies; incidences of mammary gland fibroadenomas in the control

# I. INTRODUCTION

---

groups were 0/5 and 3/16 in the two experiments. The remainder of the animals in these control groups did not survive to 36 weeks, presumably due to respiratory infections. In the dosed groups, the incidences of mammary gland tumors among nitrofurazone-dosed animals surviving to 36 weeks were 11/18 and 24/24. Both experiments were plagued by high mortality, reportedly due to chronic respiratory infections. Strict interpretations of these results must be tempered by the fact that known impurities accounted for at least 3% of the study material. Furthermore, in an effort to retard mortality caused by infections in their laboratory, the investigators treated study animals with various antibiotics and nematocides.

In a subsequent 46-week study, the same oral exposure to nitrofurazone, free of detectable impurities, resulted in an increased incidence of benign mammary gland tumors (Erturk et al., 1970). This same study reported the subcutaneous transplantability of mammary fibroadenoma tissue from nitrofurazone-dosed female rats to untreated male and female rats of the same strain.

In another investigation, 40-day-old female Sprague Dawley rats were given 10 equal doses (one every third day for 30 days) of nitrofurazone by gavage in sesame oil (Griswold et al., 1968). Animals in the three dosed groups received a total of 200, 350, or 500 mg of nitrofurazone per rat, and the initial size of these groups was 10, 10, and 20 rats, respectively. The control group contained 140 rats. After 9 months, all surviving animals were killed, and mammary gland tissue, intestinal tract, pituitary gland, liver, ovaries, and adrenal glands were evaluated, as were all gross lesions in additional tissues. Necropsies were performed on 132/140 control animals, and five of these had mammary gland lesions. (Three carcinomas, one fibroadenoma, and five hyperplastic lesions were characterized in these five animals.) Nine of 10 low dose, 10/10 mid dose, and 5/20 high dose animals survived the 9-month observation period, and one animal in each group was found to contain a mammary gland lesion. The lesions were reported as a carcinoma, a hyperplastic lesion, and a fibroadenomatous change.

## Toxicity in Humans

Nitrofurazone causes contact or allergic dermatitis, which may be severe (Shipley and Dodd, 1947). Nitrofurazone is seldom administered orally to humans because of the frequent onset of a severe peripheral polyneuropathy at the doses required for effective therapy (Koch-Weser et al., 1971; Karol, 1960). Hemolytic anemia has also been observed and is thought to be due to decreased activity of glucose-6-phosphate dehydrogenase and to the oxidizing activity of the 5-nitrofurans (Beutler, 1972).

## Genetic Toxicology

The mutagenicity of nitrofurazone and other 5-nitrofurans derivatives has been reviewed in comprehensive articles by Klemencic and Wang (1978) and McCalla (1983). In general, nitrofurazone has consistently exhibited mutagenic activity in vitro in a variety of bacterial and mammalian cell assays. It has not demonstrated mutagenic activity in vivo, but the number and variety of such assays in which it has been tested are limited.

Nitrofurazone induced gene reversion in numerous strains of *Escherichia coli* without metabolic activation (Yahagi et al., 1974; McCalla et al., 1975). Differential growth inhibition after exposure of *E. coli* to nitrofurazone was reported (Haveland-Smith et al., 1979; Ebringer and Bencova, 1980). Similarly, both gene reversion and growth inhibition were observed after treatment of *Bacillus subtilis* cultures with nitrofurazone (Tanooka, 1977).

Reverse gene mutation in *Salmonella typhimurium*, without S9 activation, was observed in strains TA98, TA100, TA1535, TA1537, and TA1538 after treatment with nitrofurazone with a variety of experimental configurations including plate incorporation procedures, spot tests, and fluctuation tests (Sugimura et al., 1976; Chin et al., 1978; Bruce and Heddle, 1979; Ebringer and Bencova, 1980). Results from NTP Salmonella studies that used preincubation protocols were generally similar to those reported in the literature. Nitrofurazone was mutagenic in strains TA98 and TA100 with and without

Aroclor 1254-induced male Sprague Dawley rat or Syrian hamster liver S9. However, S9 activation was required for a significant increase in revertant colonies with strain TA1535, and no consistent increase in gene reversions was observed in strain TA1537 (Zeiger et al., 1987; Appendix E, Table E1).

Although nitrofurazone consistently causes mutagenicity without mammalian activation in bacterial systems, there is evidence to suggest that this compound is not a direct-acting mutagen in bacteria. In the absence of S9 activation, nitrofurazone is nonmutagenic toward *S. typhimurium* strain TA100-FR1, a nitroreductase-deficient strain. However, this strain is responsive to nitrofurazone-induced mutagenicity if a mammalian source of enzymes is provided (Rosenkranz and Speck, 1976). Similarly, *E. coli* strain 343/113/R-9, which lacks nitroreductase activity and is therefore normally resistant to nitrofurans, can be mutated by nitrofurazone if exposure occurs in the presence of microsome extracts from *Drosophila* (Baars et al., 1980) or mouse liver (Olive and Durand, 1978). Considered together, these results indicate an obligatory role for metabolism in the nitrofurazone-induced mutagenicity in bacteria and demonstrate that eukaryotic enzyme preparations are able to activate nitrofurazone to a mutagenic form.

Generally, tests with cultured mammalian cells were also positive, but the role of metabolic activation is uncertain. At concentrations of 100-200 µg/ml, nitrofurazone induced 6-thioguanine resistance in Chinese hamster V79 cells in the absence of exogenous metabolic activation (Olive, 1981). Similarly, in an NTP mouse lymphoma assay, nitrofurazone induced forward mutations at the TK<sup>+/-</sup> locus of L5178Y cells without S9 activation (Table E2).

Tonomura and Sasaki (1973) observed no induction of chromosomal aberrations or unscheduled DNA synthesis after human lymphocytes and fibroblasts were treated with nitrofurazone at concentrations up to 10 mM. Furthermore, no increase in the induction of chromosomal aberrations was observed in Chinese hamster fibroblasts exposed to nitrofurazone over a range of

doses that included a 50% growth inhibition response (Ishidate and Odashima, 1977). However, Matsuoka and coworkers (1979) noted an increase in chromosomal aberrations when Chinese hamster fibroblasts were exposed to nitrofurazone at 0.1 mg/ml in the presence of S9. Results from NTP cytogenetic studies revealed that treatment of cultured Chinese hamster ovary cells with nitrofurazone in the absence of S9 produced a dose-related increase in sister chromatid exchanges (Table E3) and chromosomal aberrations (Table E4). With Aroclor 1254-induced male Sprague Dawley rat liver S9, sister chromatid exchanges were increased, but induction of chromosomal aberrations was not observed at doses up to 500 µg/ml.

In vivo assays for genetic damage resulting from exposure to nitrofurazone were uniformly negative. Feeding nitrofurazone (5-mM solution) to adult male *Drosophila* produced no significant increase in sex-linked recessive lethal mutations in their offspring (Kramers, 1982). No increases in micronuclei, chromosomal aberrations, or morphologically abnormal sperm were observed in rats or mice dosed with up to 60 mg nitrofurazone/kg body weight (Goodman et al., 1977; Bruce and Heddle, 1979).

## Study Rationale

The National Toxicology Program undertook evaluation of nitrofurazone to gain insight into the potential carcinogenicity of chemicals representative of the furan class. The class study of furans was initiated by the National Cancer Institute and was predicated on high levels of human exposure or consumption and on structure-function considerations suggesting that furans may be carcinogenic in rodents. The scope of chemicals considered for carcinogenic evaluation included all furans, dihydrofurans, and nitrofurans.

Nitrofurazone was specifically selected for evaluation because of high levels of human exposure ( $8.5 \times 10^4$  g/year) (National Cancer Institute/Stanford Research Institute Mark II Database) and evidence available in the open literature suggesting that long-term administration of nitrofurazone to rodents might cause cancer.



## **II. MATERIALS AND METHODS**

**PROCUREMENT AND CHARACTERIZATION OF  
NITROFURAZONE**

**PREPARATION AND CHARACTERIZATION OF  
FORMULATED DIETS**

**FOURTEEN-DAY STUDIES**

**THIRTEEN-WEEK STUDIES**

**TWO-YEAR STUDIES**

**Study Design**

**Source and Specifications of Animals**

**Animal Maintenance**

**Clinical Examinations and Pathology**

**Statistical Methods**

## II. MATERIALS AND METHODS

### PROCUREMENT AND CHARACTERIZATION OF NITROFURAZONE

Nitrofurazone was obtained in one lot (lot no. C1206) from Norwich Eaton Pharmaceuticals (Norwich, New York). Purity and identity analyses were conducted at Midwest Research Institute (MRI) (Kansas City, Missouri). (MRI reports on the analyses performed in support of the nitrofurazone studies are on file at NIEHS.)

The identity of lot no. C1206 was confirmed by infrared, ultraviolet/visible, and nuclear magnetic resonance spectroscopy; all spectra were consistent with literature spectra (Sadtler Pharmaceutical Spectra; Sadtler Standard Spectra) (Figures 1 and 2). Purity was determined by elemental analysis, Karl Fischer water analysis, thin-layer chromatography, and high-performance liquid chromatography. Cumulative data indicated that lot no. C1206 was approximately 99% pure. Results of elemental analysis agreed with the theoretical values. The water content was 0.69%. A minor impurity was detected by thin-layer chromatography with activated aluminum oxide plates and a chloroform:methanol:acetic acid (90:5:5) solvent system. One impurity with a relative area equal to 0.1% that of the major peak was detected by high-performance liquid chromatography and ultraviolet detection at 365 nm on a Varian Micropak MCH-10 column with a water:methanol (40:60) solvent system. One additional impurity was detected with this same system and a gradient of 0%-10% methanol; the relative area of this

impurity was less than 1%, but precise quantitation was difficult under the conditions used.

Nitrofurazone was shown to be stable when stored for 2 weeks at temperatures up to 60° C. The study material was stored at 25° C. Periodic characterization of the bulk chemical by infrared or ultraviolet spectroscopy and high-performance liquid chromatography indicated no deterioration over the course of the studies.

### PREPARATION AND CHARACTERIZATION OF FORMULATED DIETS

Formulated diet mixtures were shown to be homogeneous by both the analytical chemistry and study laboratories. Nitrofurazone at 1,500 ppm in feed was shown to be stable for 2 weeks in the dark at temperatures up to 5° C, whereas a 3% reduction in concentration was observed at 25° C after 2 weeks. No decrease in concentration was observed during storage for 7 days under simulated cage conditions with open beakers maintained at normal animal room temperature and lighting conditions. Formulated diets were prepared by blending a premix of nitrofurazone and feed with the bulk feed; the premix was prepared by mixing the appropriate weight of the study material with feed in a beaker (Table 1). Formulated diets were analyzed for nitrofurazone content at the study and analytical chemistry laboratories by extraction of the feed with methanol and quantitation by high-performance liquid chromatography with a Waters  $\mu$ Bondapak C<sub>18</sub> column, ultraviolet detection at 365 nm,

TABLE 1. PREPARATION AND STORAGE OF FORMULATED DIETS IN THE FEED STUDIES OF NITROFURAZONE

Fourteen-Day Studies	Thirteen-Week Studies	Two-Year Studies
<b>Preparation</b> Premix layered between equal quantities of feed in a Patterson-Kelly® 8-qt twin-shell blender and mixed with intensifier bar for 5 min and without intensifier bar for 10 min	Same as 14-d studies	Same as 14-d studies
<b>Maximum Storage Time</b> 14 d	10 d	14 d
<b>Storage Conditions</b> 5° C in the dark	4° C	5° C in the dark






FIGURE 1. INFRARED ABSORPTION SPECTRUM OF NITROFURAZONE (LOT NO. C1206)




FIGURE 2. NUCLEAR MAGNETIC RESONANCE SPECTRUM OF NITROFUZZONE (LOT NO. C1206)

## II. MATERIALS AND METHODS

and a water:acetonitrile (70:30) solvent system. Formulated diets were analyzed twice during the 13-week studies (Table 2). The nitrofurazone concentrations ranged from 76% to 105% of the target concentrations; results of 9/10 analyses were within specifications. Formulated diets were analyzed periodically during the 2-year studies with nitrofurazone concentrations ranging from 95.5% to 118.0% of the target concentrations (Table 3). Because 40/43 formulated

diets analyzed were within  $\pm 10\%$  of the target concentrations, the diets were estimated to have been formulated within specifications 93% of the time during the 2-year studies. Referee analyses were also performed periodically by the analytical chemistry laboratory (Table 4). Generally good agreement was found between the results from the two laboratories. In the 2-year studies, the formulated diets were stored at 5° C for no longer than 14 days.

**TABLE 2. RESULTS OF ANALYSIS OF FORMULATED DIETS IN THE THIRTEEN-WEEK FEED STUDIES OF NITROFURAZONE**

Date Mixed	<u>Concentration of Nitrofurazone in Feed (ppm) (a)</u>		Determined as a Percent of Target
	Target	Determined	
08/06/80	70	(b) 65	93
	150	150	100
	310	290	94
	620	580	94
	1,250	1,200	96
	2,500	(c) 2,300	92
09/10/80	70	70	100
	150	140	93
	(d) 150	100	67
	310	280	90
	620	470	(e) 76
	1,250	1,310	105
	2,500	2,570	103

(a) Results of duplicate analysis

(b) Samples taken from three other locations within the blender had concentrations of 65, 65, and 67 ppm.

(c) Three other samples from different locations within the blender all had concentrations of 2,400 ppm.

(d) Referee analysis by MRI; result of triplicate analysis.

(e) Out of specifications; used in the studies.

**TABLE 3. RESULTS OF ANALYSIS OF FORMULATED DIETS IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE**

Date Mixed	Concentration of Nitrofurazone in Feed for Target Concentration (ppm) (a)		
	150	310	620
06/05/81	160	320	630
07/03/81	157	331	648
09/11/81	151	303	625
10/09/81	148	302	592
01/01/82	160	317	637
03/05/82	150	309	650
04/02/82	150	300	644
06/25/82	148	307	605
07/16/82	147	324	677
08/27/82	160	309	631
12/03/82	(b) 177	(b) 344	(b) 704
12/07/82	(c) 159	(c) 306	(c) 624
01/28/83	157	309	624
03/29/83	154	300	606
04/12/83	163	303	610
06/01/83		303	
Mean (ppm)	155.9	312.1	634.5
Standard deviation	8.1	12.8	29.7
Coefficient of variation (percent)	5.2	4.1	4.7
Range (ppm)	147-177	300-344	592-704
Number of samples	14	15	14

- (a) Results of duplicate analysis
- (b) Out of specifications; not used in studies.
- (c) Remix; not included in the mean.

**TABLE 4. RESULTS OF REFEREE ANALYSIS OF FORMULATED DIETS IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE**

Date Mixed	Target Concentration (ppm)	Determined Concentration (ppm)	
		Study Laboratory (a)	Referee Laboratory (b)
06/05/81	150	160	150
10/09/81	620	592	610
03/05/82	310	309	322
12/03/82	150	177	152
01/28/83	620	624	660
06/01/83	310	303	310

- (a) Results of duplicate analysis
- (b) Results of triplicate analysis

**FOURTEEN-DAY STUDIES**

Male and female F344/N rats and B6C3F<sub>1</sub> mice were obtained from Charles River Breeding Laboratories and held for 18 days before the studies began. Rats were 6-7 weeks old and mice were 6-8 weeks old when placed on study. Groups of five

males and five females of each species were fed diets containing 0, 630, 1,250, 2,500, 5,000, or 10,000 ppm nitrofurazone for 14 consecutive days. Rats and mice were observed twice daily and were weighed once per week. A necropsy was performed on all animals. Details of animal maintenance are presented in Table 5.

**TABLE 5. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE FEED STUDIES OF NITROFURAZONE**

<b>Fourteen-Day Studies</b>	<b>Thirteen-Week Studies</b>	<b>Two-Year Studies</b>
<b>EXPERIMENTAL DESIGN</b>		
<b>Size of Study Groups</b> 5 males and 5 females of each species	10 males and 10 females of each species	50 males and 50 females of each species
<b>Doses</b> 0, 630, 1,250, 2,500, 5,000, or 10,000 ppm nitrofurazone in feed	Rats--0, 150, 310, 620, 1,250, or 2,500 ppm nitrofurazone in feed; mice--0, 70, 150, 310, 620, or 1,250 ppm	Rats--0, 310, or 620 ppm nitrofurazone in feed; mice--0, 150, or 310 ppm
<b>Date of First Dose</b> 9/30/79	7/28/80	Rats--6/24/81; mice--6/8/81
<b>Date of Last Dose</b> 10/13/79	10/25/80	Rats--6/13/83; mice--5/31/83
<b>Duration of Dosing</b> 14 consecutive d	13 wk	103 wk
<b>Type and Frequency of Observation</b> Observed 2 × d; weighed initially and 1 × wk thereafter	Same as 14-d studies	Observed 2 × d; weighed initially, 1 × wk for 12 wk (rats) or 13 wk (mice), and monthly thereafter
<b>Necropsy and Histologic Examination</b> Necropsy performed on all animals; histologic exam performed on 10% of rats and mice	Necropsy performed on all animals; histologic exam performed on all controls, all animals in the highest dose group with at least 60% survival at the end of the studies, and all animals with gross lesions. Tissues examined: adrenal glands, brain, colon, esophagus, eyes (if grossly abnormal), gallbladder (mice), gross lesions, heart, kidneys, liver, lungs and mainstem bronchi, mammary gland, mandibular or mesenteric lymph nodes, pancreas, parathyroid glands, peripheral nerve, pituitary gland, prostate/testes or ovaries/uterus, regional lymph nodes, salivary glands, small intestine, spinal cord, spleen, sternbrae or femur or vertebrae including marrow, stomach, thymus, thyroid gland, tissue masses, trachea, and urinary bladder. Tissues examined for all rats in the other dose groups: femur, muscles, testes or uterus/ ovaries, tibia. Liver weighed at necropsy	Necropsy performed on all animals; histologic exams performed on all controls, all high dose animals, low dose male rats, and low dose male mice. Tissues examined: same as those in the 13-wk studies; tissues examined for low dose female rats: adrenal glands, femur, liver, pituitary gland, spleen, and vertebrae; tissues examined for low dose female mice: liver, lung, ovaries, pituitary gland, and spleen; neurologic exam performed during wk 100 included visual response to threat, righting reflexes, gait, extensor postural thrust, placing response, strength of grasp, flexor reflexes, and muscle atrophy
<b>ANIMALS AND ANIMAL MAINTENANCE</b>		
<b>Strain and Species</b> F344/N rats; B6C3F <sub>1</sub> mice	F344/N rats; B6C3F <sub>1</sub> mice	F344/N rats; B6C3F <sub>1</sub> mice
<b>Animal Source</b> Charles River Breeding Laboratories (Portage, MI)	Charles River Breeding Laboratories (Portage, MI)	Charles River Breeding Laboratories (Kingston, NY)
<b>Study Laboratory</b> Physiological Research Laboratories	Physiological Research Laboratories	Physiological Research Laboratories
<b>Method of Animal Identification</b> Rats--tail mark; mice--ear punch	Toe clip	Toe and ear clip

**TABLE 5. EXPERIMENTAL DESIGN AND MATERIALS AND METHODS IN THE FEED STUDIES OF NITROFURAZONE (Continued)**

<b>Fourteen-Day Studies</b>	<b>Thirteen-Week Studies</b>	<b>Two-Year Studies</b>
<b>ANIMALS AND ANIMAL MAINTENANCE (Continued)</b>		
<b>Time Held Before Study</b> 18 d	Rats--14 d; mice--20 d	Rats--14 d; mice--13 d
<b>Age When Placed on Study</b> Rats--6-7 wk; mice--6-8 wk	Rats--6-8 wk; mice--8 wk	Rats--6-7 wk; mice--7-8 wk
<b>Age When Killed</b> Rats--8-9 wk; mice--8-10 wk	Rats--19-21 wk; mice--21-22 wk	Rats--111 wk; mice--112 wk
<b>Necropsy Dates</b> Rats--10/16/79-10/17/79; mice--10/15/79	10/27/80-10/28/80	Rats--6/20/83-6/24/83; mice--6/6/83-6/9/83
<b>Method of Animal Distribution</b> Animals distributed to weight classes and assigned to cages according to a table of random numbers	Same as 14-d studies	According to tables of random numbers
<b>Feed</b> Rodent Laboratory Chow 5001® meal (Ralston Purina Co., St. Louis, MO); available ad libitum	Same as 14-d studies	NIH 07 Rat and Mouse Ration (Zeigler Bros., Gardners, PA); available ad libitum
<b>Bedding</b> Aspen wood chips (Minnesota Sawdust and Shavings Co., Anoka, MN)	Same as 14-d studies	Same as 14-d studies
<b>Water</b> Automatic watering system (Edstrom Industries, Waterford, WI); softened; available ad libitum	Same as 14-d studies	Same as 14-d studies; softened to < 1 grain/gal hardness through sodium zeolite, then filtered
<b>Cages</b> Polycarbonate (Hazleton Systems, Inc., Aberdeen, MD)	Same as 14-d studies	Same as 14-d studies
<b>Cage Filters</b> (Snow Filtration, Cincinnati, OH)	Same as 14-d studies	Spun-bonded polyester, Dupont 2024® (Snow Filtration, Cincinnati, OH)
<b>Animals per Cage</b> 5	5	5
<b>Other Chemicals on Study in the Same Room</b> None	None	None
<b>Animal Room Environment</b> Temp--22.2°-24.4° C; hum--35%-45%; fluorescent light 12 h/d	Temp--21.1°-26.6° C; hum--33%-74%; fluorescent light 12 h/d	Temp--21.7°-26.1° C; hum--30%-74%; fluorescent light 12 h/d; 5-17 room air changes/h

## II. MATERIALS AND METHODS

### THIRTEEN-WEEK STUDIES

Thirteen-week studies were conducted to evaluate the cumulative toxic effects of repeated exposure to nitrofurazone and to determine the concentrations to be used in the 2-year studies.

Four- to six-week-old male and female F344/N rats and 5-week-old male and female B6C3F<sub>1</sub> mice were obtained from Charles River Breeding Laboratories. Animals were observed for 14 days (rats) or 20 days (mice) and then distributed to weight classes. Animals were assigned to cages and groups according to a table of random numbers. Diets containing 0, 150, 310, 620, 1,250, or 2,500 ppm nitrofurazone were fed to groups of 10 rats of each sex. Diets containing 0, 70, 150, 310, 620, or 1,250 ppm nitrofurazone were fed to groups of 10 mice of each sex.

Animals were housed five per cage. Formulated or control diets and water were available ad libitum. Animals were checked two times per day; moribund animals were killed. Feed consumption was measured weekly by cage. Individual animal weights were recorded weekly.

At the end of the 13-week studies, survivors were killed. A necropsy was performed on all animals except those excessively autolyzed or cannibalized. Tissues and groups examined are listed in Table 5.

### TWO-YEAR STUDIES

#### Study Design

Diets containing 0, 310, or 620 ppm nitrofurazone were fed to groups of 50 male and 50 female rats for 103 weeks. Diets containing 0, 150, or 310 ppm nitrofurazone were fed to groups of 50 male and 50 female mice on the same schedule.

#### Source and Specifications of Animals

The male and female F344/N rats and B6C3F<sub>1</sub> (C57BL/6N, female × C3H/HeN MTV<sup>-</sup>, male) mice used in these studies were produced under strict barrier conditions at Charles River

Breeding Laboratories under a contract to the Carcinogenesis Program. Breeding stock for the foundation colonies at the production facility originated at the National Institutes of Health Repository. Animals shipped for study were progeny of defined microflora-associated parents that were transferred from isolators to barrier-maintained rooms. Rats were shipped to the study laboratory at 4-5 weeks of age and mice, at 5-6 weeks of age. The rats were quarantined at the study laboratory for 14 days and the mice, for 13 days. Thereafter, a complete necropsy was performed on five animals of each sex and species to assess their health status. The rats were 47 days old and the mice were 51 days old when placed on study. The health of the animals was monitored during the course of the studies according to the protocols of the NTP Sentinel Animal Program (Appendix F).

A quality control skin grafting program has been in effect since early 1978 to monitor the genetic integrity of the inbred mice used to produce the hybrid B6C3F<sub>1</sub> study animal. In mid-1981, data were obtained that showed incompatibility between the NIH C3H reference colony and the C3H colony from a Program supplier. In August 1981, inbred parental lines of mice were further tested for genetic integrity via isozyme and protein electrophoresis profiles that demonstrate phenotype expressions of known genetic loci.

The C57BL/6N mice were homogeneous at all loci tested. Eighty-five percent of the C3H mice monitored were variant at one to three loci, indicating some heterogeneity in the C3H line from this supplier. Nevertheless, the genome of this line is more homogeneous than that of randomly bred stocks.

Male mice from the C3H colony and female mice from the C57BL/6N colony were used as parents for the hybrid B6C3F<sub>1</sub> mice used in these studies. The influence of the potential genetic non-uniformity in the hybrid mice on these results is not known, but results of the studies are not affected because concurrent controls were included in each study.

## II. MATERIALS AND METHODS

---

### Animal Maintenance

Animals were housed five per cage and the cages were not rotated within cage racks during the studies. Feed and water were available ad libitum. Further details of animal maintenance are given in Table 5.

### Clinical Examinations and Pathology

All animals were observed two times per day, and clinical signs were recorded at least once per month. Body weights by cage were recorded once per week for the first 12 or 13 weeks of the studies and once per month thereafter. Mean body weights were calculated for each group. Animals found moribund and those surviving to the end of the studies were humanely killed. A necropsy was performed on all animals including those found dead, unless they were excessively autolyzed or cannibalized, missexed, or found missing. Thus, the number of animals from which particular organs or tissues were examined microscopically varies and is not necessarily equal to the number of animals that were placed on study.

During necropsy, all organs and tissues were examined for grossly visible lesions. Tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Histopathologic examination of tissues was performed according to an "inverse pyramid" design (McConnell, 1983a,b). That is, complete histopathologic examinations (Table 5) were performed on all high dose and control animals and on low dose animals dying before the end of the study. In addition, histopathologic examinations were performed on all grossly visible lesions in all dose groups. Potential target organs for chemically related neoplastic and nonneoplastic effects were identified from the short-term studies or the literature and were determined by examination of the pathology data; these target organs/tissues in the lower dose group were examined histopathologically. If mortality in the highest dose group exceeded that in the control group by 15%, complete histopathologic examinations were performed on all animals in the second highest dose group in addition to those in the high dose group.

When the pathology evaluation was completed, the slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were sent to an independent quality assessment laboratory. The individual animal records and tables were compared for accuracy, slides and tissue counts were verified, and histotechnique was evaluated. All tumor diagnoses, all target tissues, and all tissues from a randomly selected 10% of the animals were evaluated by a quality assessment pathologist. The quality assessment report and slides were submitted to the Pathology Working Group (PWG) Chairperson, who reviewed all target tissues and those about which there was a disagreement between the laboratory and quality assessment pathologists.

Representative slides selected by the Chairperson were reviewed by the PWG, which includes the laboratory pathologist, without knowledge of previously rendered diagnoses. When the consensus diagnosis of the PWG differed from that of the laboratory pathologist, the laboratory pathologist was asked to reconsider the original diagnosis. This procedure has been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). The final diagnoses represent a consensus of contractor pathologists and the NTP Pathology Working Group. For subsequent analysis of pathology data, the diagnosed lesions for each tissue type are combined according to the guidelines of McConnell et al. (1986).

Slides/tissues are generally not evaluated in a blind fashion (i.e., without knowledge of dose group) unless lesions in question are subtle or unless there is an inconsistent diagnosis of lesions by the laboratory pathologist. Nonneoplastic lesions are not examined routinely by the quality assessment pathologist or PWG unless they are considered part of the toxic effect of the chemical.

### Statistical Methods

*Data Recording:* Data on this experiment were recorded in the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements



## II. MATERIALS AND METHODS

---

include descriptive information on the chemicals, animals, experimental design, survival, body weight, and individual pathology results, as recommended by the International Union Against Cancer (Berenblum, 1969).

*Survival Analyses:* The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals were censored from the survival analyses at the time they were found to be missing or dead from other than natural causes; animals dying from natural causes were not censored. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) life table test for a dose-related trend. When significant survival differences were detected, additional analyses using these procedures were carried out to determine the time point at which significant differences in the survival curves were first detected. All reported P values for the survival analysis are two-sided.

*Calculation of Incidence:* The incidence of neoplastic or nonneoplastic lesions is given as the ratio of the number of animals bearing such lesions at a specific anatomic site to the number of animals in which that site was examined. In most instances, the denominators include only those animals for which the site was examined histologically. However, when macroscopic examination was required to detect lesions (e.g., skin or mammary tumors) prior to histologic sampling, or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the number of animals on which a necropsy was performed.

*Analysis of Tumor Incidence:* Three statistical methods are used to analyze tumor incidence data: life table tests, incidental tumor analysis, and Fisher exact/Cochran-Armitage trend analyses. Tests of significance include pairwise comparisons of each dosed group with controls and tests for overall dose-response trends. For studies in which administration of the study compound has little effect on survival, the results of the three alternative analyses will generally be similar. When differing results are obtained by the three methods, the final interpretation of the

data will depend on the extent to which the tumor under consideration is regarded as being the cause of death. Continuity-corrected tests are used in the analysis of tumor incidence, and reported P values are one-sided. The procedures described below also were used to evaluate selected nonneoplastic lesions.

*Life Table Analyses--*The first method of analysis assumed that all tumors of a given type observed in animals dying before the end of the study were "fatal"; i.e., they either directly or indirectly caused the death of the animal. According to this approach, the proportions of tumor-bearing animals in the dosed and control groups were compared at each point in time at which an animal died with a tumor of interest. The denominators of these proportions were the total number of animals at risk in each group. These results, including the data from animals killed at the end of the study, were then combined by the Mantel-Haenszel method (1959) to obtain an overall P value. This method of adjusting for intercurrent mortality is the life table method of Cox (1972) and of Tarone (1975). The underlying variable considered by this analysis is time to death due to tumor. If the tumor is rapidly lethal, then time to death due to tumor closely approximates time to tumor onset. In this case, the life table test also provides a comparison of the time-specific tumor incidences.

*Incidental Tumor Analyses--*The second method of analysis assumed that all tumors of a given type observed in animals that died before the end of the study were "incidental"; i.e., they were merely observed at necropsy in animals dying of an unrelated cause. According to this approach, the proportions of tumor-bearing animals in dosed and control groups were compared in each of five time intervals: weeks 0-52, weeks 53-78, weeks 79-92, week 93 to the week before the terminal-kill period, and the terminal-kill period. The denominators of these proportions were the number of animals actually examined for tumors during the time interval. The individual time interval comparisons were then combined by the previously described method to obtain a single overall result. (See Haseman, 1984, for the computational details of both methods.)

## II. MATERIALS AND METHODS

---

**Fisher Exact/Cochran-Armitage Trend Analyses**--In addition to survival-adjusted methods, the results of the Fisher exact test for pairwise comparisons and the Cochran-Armitage linear trend test (Armitage, 1971; Gart et al., 1979) are given in the appendixes containing the analyses of tumor incidence. These two tests are based on the overall proportion of tumor-bearing animals and do not adjust for survival differences.

*Historical Control Data:* Although the concurrent control group is always the first and most appropriate control group used for evaluation, there are certain instances in which historical control data can be helpful in the overall assessment of tumor incidence. Consequently, control tumor incidences from the NTP historical control data base (Haseman et al., 1984, 1985) are included for those tumors appearing to show compound-related effects.

### **III. RESULTS**

#### **RATS**

##### **FOURTEEN-DAY STUDIES**

##### **THIRTEEN-WEEK STUDIES**

##### **TWO-YEAR STUDIES**

**Body Weights, Feed Consumption, and Clinical Signs  
Survival**

**Pathology and Statistical Analyses of Results**

#### **MICE**

##### **FOURTEEN-DAY STUDIES**

##### **THIRTEEN-WEEK STUDIES**

##### **TWO-YEAR STUDIES**

**Body Weights, Feed Consumption, and Clinical Signs  
Survival**

**Pathology and Statistical Analyses of Results**

### III. RESULTS: RATS

#### FOURTEEN-DAY STUDIES

All rats receiving 5,000 or 10,000 ppm nitrofurazone died (Table 6). Surviving animals in the lower two dose groups all gained weight, but the degree of weight gain was dose dependent. Feed consumption was decreased at all doses above 630 ppm. In all dosed groups, clinical signs of toxicity included rough hair coats and evidence of lethargy. At doses of 2,500 ppm and above, rats of each sex exhibited intermittent episodes of seizures and lethargy. Histopathologic examinations indicated that dosed male rats were aspermatogenic.

#### THIRTEEN-WEEK STUDIES

All rats lived to the end of the studies (Table 7). Final mean body weights of rats that received

620, 1,250, or 2,500 ppm nitrofurazone were 11%, 32%, or 55% lower, respectively, than that of the controls for males and 2%, 12%, or 36% lower for females. With the exception of the highest dose group, feed consumption by dosed and control groups was comparable. Liver weight to body weight ratios for dosed rats were significantly greater than those for the controls (Table 8). Stimulus-induced convulsive seizures were observed in males at 2,500 ppm. Females that received 1,250 or 2,500 ppm and males that received 1,250 ppm were hyperexcitable. Atrophy constricture of the hind quarters was seen in males and females that received 2,500 ppm. Moderate to severe degeneration of the seminiferous epithelium in the testis was observed in all male rats in the four highest dose groups. Testes of males that received 150 ppm were normal.

TABLE 6. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF RATS IN THE FOURTEEN-DAY FEED STUDIES OF NITROFURAZONE

Concentration (ppm)	Survival (a)	Mean Body Weights (grams)			Final Weight Relative to Controls (percent)	Feed Consumption (d)	
		Initial (b)	Final	Change (c)		Week 1	Week 2
<b>MALE</b>							
0	5/5	136 ± 5	197 ± 5	+61 ± 2	--	16.1	16.2
630	5/5	135 ± 6	200 ± 7	+65 ± 2	102	14.6	16.3
1,250	5/5	135 ± 3	183 ± 5	+48 ± 2	93	11.6	13.3
2,500	(e) 4/5	133 ± 6	140 ± 5	+2 ± 4	71	6.5	7.3
5,000	(f) 0/5	124 ± 9	(g)	(g)	(g)	4.5	2.5
10,000	(h) 0/5	137 ± 6	(g)	(g)	(g)	3.9	0.4
<b>FEMALE</b>							
0	5/5	97 ± 5	133 ± 3	+36 ± 2	--	10.9	13.3
630	5/5	99 ± 4	132 ± 2	+33 ± 3	99	11.6	11.2
1,250	5/5	110 ± 8	132 ± 6	+22 ± 2	99	8.4	5.9
2,500	5/5	103 ± 2	110 ± 4	+7 ± 3	83	5.7	6.0
5,000	(i) 0/5	101 ± 4	(g)	(g)	(g)	3.9	2.8
10,000	(j) 0/5	95 ± 3	(g)	(g)	(g)	1.5	1.6

(a) Number surviving/number initially in the group

(b) Initial mean group body weight ± standard error of the mean. Subsequent calculations are based on those animals surviving to the end of the study.

(c) Mean body weight change of the survivors ± standard error of the mean

(d) Grams per animal per day; not corrected for scatter.

(e) Day of death: 11

(f) Day of death: 10,11,11,11,11

(g) No data are reported due to 100% mortality in this group.

(h) Day of death: 9,10,10,10,11

(i) Day of death: 11,11,12,12,12

(j) Day of death: 7,7,9,9,11

**TABLE 7. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF RATS IN THE THIRTEEN-WEEK FEED STUDIES OF NITROFURAZONE**

Concentration (ppm)	Survival (a)	Mean Body Weights (grams)			Final Weight Relative to Controls (percent)	Feed Consumption (d)	
		Initial (b)	Final	Change (c)		Week 7	Week 13
<b>MALE</b>							
0	10/10	109 ± 3	349 ± 6	+240 ± 4	--	16	10
150	10/10	105 ± 2	346 ± 5	+241 ± 5	99	16	10
310	10/10	104 ± 2	332 ± 4	+228 ± 4	95	16	10
620	10/10	106 ± 3	310 ± 5	+204 ± 3	89	16	11
1,250	10/10	104 ± 2	239 ± 4	+135 ± 3	68	13	9
2,500	10/10	106 ± 3	158 ± 3	+52 ± 3	45	9	7
<b>FEMALE</b>							
0	10/10	90 ± 2	195 ± 3	+105 ± 2	--	15	10
150	10/10	92 ± 2	200 ± 3	+108 ± 4	103	16	10
310	10/10	89 ± 1	195 ± 3	+106 ± 3	100	15	9
620	10/10	92 ± 2	191 ± 3	+99 ± 2	98	14	10
1,250	10/10	90 ± 2	172 ± 4	+82 ± 3	88	11	9
2,500	10/10	90 ± 2	125 ± 3	+35 ± 2	64	8	6

(a) Number surviving/number initially in the group  
 (b) Initial mean group body weight ± standard error of the mean  
 (c) Mean body weight change of the group ± standard error of the mean  
 (d) Grams per animal per day; not corrected for scatter.

**TABLE 8. ANALYSIS OF LIVER WEIGHTS OF RATS IN THE THIRTEEN-WEEK FEED STUDIES OF NITROFURAZONE (a)**

Concentration (ppm)	No. of Animals Examined	Final Body Weight (grams)	Liver Weight (mg)	Liver Weight/Final Body Weight (mg/g)
<b>MALE</b>				
0	10	348.9 ± 2.95	14,469 ± 814	41.5 ± 2.33
150	10	345.9 ± 4.53	(b) 18,664 ± 303	(b) 54.0 ± 0.63
310	10	332.0 ± 4.41	(c) 16,609 ± 409	(b) 50.1 ± 1.21
620	10	(b) 309.5 ± 4.83	(b) 18,167 ± 536	(b) 58.6 ± 1.23
1,250	10	(b) 238.8 ± 4.13	12,662 ± 405	(b) 53.0 ± 1.33
2,500	10	(b) 158.2 ± 3.30	(b) 9,041 ± 370	(b) 57.0 ± 1.28
<b>FEMALE</b>				
0	10	195.3 ± 2.89	7,272 ± 514	37.2 ± 2.59
150	10	199.9 ± 2.61	(b) 9,578 ± 258	(b) 47.9 ± 1.10
310	10	195.0 ± 3.40	(b) 9,511 ± 312	(b) 48.8 ± 1.42
620	10	191.0 ± 3.02	(b) 9,599 ± 221	(b) 50.3 ± 0.76
1,250	10	(b) 172.1 ± 3.64	(b) 10,148 ± 149	(b) 59.1 ± 1.17
2,500	10	(b) 124.7 ± 2.65	6,743 ± 203	(b) 54.1 ± 1.29

(a) Mean ± standard error; P values vs. the controls by Dunnett's test (Dunnett, 1955).  
 (b) P < 0.01  
 (c) P < 0.05

Chemical-related histopathologic effects were observed in the long bones of male and female rats and in the testis of males. Male and female

rats receiving 1,250 or 2,500 ppm had reduced amounts of trabecular bone in the metaphyseal region (osteoporosis) (Table 9). Subsequent to

**TABLE 9. NUMBER OF RATS WITH SELECTED LESIONS IN THE THIRTEEN-WEEK FEED STUDIES OF NITROFURAZONE (a)**

Site/Lesion	Concentration (ppm)					
	0	150	310	620	1,250	2,500
<b>MALE</b>						
Bone						
Osteoporosis (b)	0	--	0	2	5	9
Testis						
Degeneration	0	0	10	10	10	10
Seminal vesicle						
Hypoplasia	0	--	--	--	2	10
<b>FEMALE</b>						
Bone						
Osteoporosis (b)	0	--	--	0	3	10
Uterus						
Hypoplasia	0	--	--	0	2	10

(a) Ten rats were examined for each group.

(b) A study pathologist used the less exact term *osteomalacia* for this lesion.

the completion of the 2-year studies, degenerative changes in the articular cartilage were characterized by the formation of subchondral cysts and irregularly thickened cartilage containing numerous chondrocyte clones (degenerative arthropathy).

*Dose Selection Rationale:* Based on the lower weight gain and skeletal lesions observed at high doses, dietary concentrations of 310 and 620 ppm nitrofurazone were selected for rats for the 2-year studies.

## TWO-YEAR STUDIES

### Body Weights, Feed Consumption, and Clinical Signs

Mean body weights of high dose male and female rats were progressively lower than those of the controls throughout the studies (Table 10 and Figure 3). Mean body weights of low dose male and female rats were 4%-9% lower than those of the controls from week 39 to the end of the studies. The average daily feed consumption per rat by low and high dose rats was 95% and 90% that

of the controls for males and 92% and 91% for females (Appendix G, Tables G1 and G2). The average amount of nitrofurazone consumed per day was approximately 11 or 24 mg/kg for low or high dose male rats and 12 or 26 mg/kg for low or high dose female rats.

Musculoskeletal impairment of the hind limbs, reported as "bowlegged" or occasionally as "immobile legs," occurred in high dose male and female rats. Rats were subjected to a neurologic evaluation, and in both male and female rats, nitrofurazone was found to cause abnormal posture and pelvic limp gait with atrophy of external pelvic muscles and flexor muscles of the knee. Contracture of the semimembranous and semitendinous muscles, the muscles subserving knee flexion, was also noted. This effect was dose related and by month 21 affected nearly 100% of high dose male and female rats and 44% and 62% of low dose males and females. Further examination revealed preserved strength of grasp of the pelvic limbs with intact sensation to deep painful stimuli and intact position sense. (Full methods and details of these studies are on file at the NTP.)

TABLE 10. MEAN BODY WEIGHTS AND SURVIVAL OF RATS IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE

Weeks on Study	Control		310 ppm			620 ppm		
	Av. Wt. (grams)	No. of Survivors	Av. Wt. (grams)	Wt. (percent of controls)	No. of Survivors	Av. Wt. (grams)	Wt. (percent of controls)	No. of Survivors
<b>MALE</b>								
0	122	50	123	101	50	124	102	50
1	166	50	164	99	50	167	101	50
2	199	50	188	93	50	190	95	50
3	213	50	209	98	50	202	95	50
4	231	50	227	98	50	220	95	50
5	255	50	253	99	50	241	95	50
6	276	50	271	98	50	260	94	50
7	278	50	276	99	50	264	95	50
8	291	50	292	100	50	278	96	50
9	299	50	303	101	50	286	96	50
10	306	50	310	101	50	292	95	50
11	315	50	318	101	50	302	96	50
12	326	50	328	101	50	308	94	50
17	361	50	357	99	50	334	93	50
21	386	50	372	96	50	355	92	50
25	401	50	387	97	50	365	91	50
30	410	50	396	97	50	370	90	50
34	416	50	405	97	50	376	90	50
39	428	50	412	96	50	377	88	50
43	438	50	417	95	50	385	88	49
47	437	50	412	94	50	381	87	49
52	440	50	415	94	50	378	86	49
56	439	50	414	94	50	380	87	48
61	438	49	419	96	48	376	86	46
66	441	49	422	96	48	381	86	45
70	441	48	419	95	46	377	85	42
74	441	48	412	93	46	374	85	42
78	441	47	417	95	46	370	84	40
82	445	47	422	95	45	369	83	38
87	433	45	410	95	44	353	82	37
91	427	42	407	95	42	346	81	33
96	429	39	407	95	37	340	79	25
100	431	37	404	94	36	323	75	25
103	422	33	398	94	31	319	76	21
<b>FEMALE</b>								
0	111	50	109	98	50	111	100	50
1	135	50	133	99	50	133	99	50
2	145	50	144	99	50	142	98	50
3	151	50	149	99	50	146	97	50
4	162	50	158	98	50	158	96	50
5	170	50	164	96	50	164	96	50
6	178	50	171	96	50	169	95	50
7	176	50	168	95	50	166	94	50
8	179	50	175	98	50	171	96	50
9	182	50	176	97	50	172	95	50
10	183	50	179	98	50	174	95	50
11	188	50	184	98	50	179	95	50
12	190	50	187	98	50	180	95	50
17	204	50	198	97	50	190	93	50
21	218	50	208	95	50	199	91	50
25	222	50	213	96	50	204	92	50
30	229	50	218	95	50	209	91	49
34	234	50	223	95	50	213	91	49
39	239	50	227	95	50	217	91	49
43	246	50	233	95	50	223	91	49
47	253	50	239	94	50	226	89	49
52	263	49	250	95	50	233	89	49
56	269	47	255	95	50	235	87	49
61	280	47	265	95	49	242	86	48
66	290	46	273	94	49	246	85	46
70	293	44	278	95	47	247	84	46
74	302	41	285	94	46	253	84	45
78	313	38	290	93	44	253	81	44
82	318	38	298	94	44	261	82	44
87	319	38	302	95	43	262	82	42
91	325	34	301	93	41	263	81	41
96	329	31	304	92	40	264	80	38
100	333	29	304	91	40	265	80	37
103	331	28	301	91	38	263	79	33





FIGURE 3. GROWTH CURVES FOR RATS FED DIETS CONTAINING NITROFURAZONE FOR TWO YEARS



### III. RESULTS: RATS

#### Survival

Estimates of the probabilities of survival for male and female rats fed diets containing nitrofurazone at the concentrations used in these studies and for controls are shown in Table 11 and in the Kaplan and Meier curves in Figure 4. The survival of the high dose group of male rats was significantly lower than that of the controls after week 92. No other significant differences in survival were observed between any groups of either sex.

#### Pathology and Statistical Analyses of Results

This section describes the significant or noteworthy changes in the incidences of rats with neoplastic or nonneoplastic lesions of the mammary gland, joints, tunica vaginalis, skin, preputial gland, testis, and hematopoietic system.

Lesions in male rats are summarized in Appendix A. Histopathologic findings on neoplasms are summarized in Table A1. Table A2 gives the

survival and tumor status for individual male rats. Table A3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table A3 (footnotes). Historical incidences of tumors in control male rats are listed in Table A4. Findings on nonneoplastic lesions are summarized in Table A5.

Lesions in female rats are summarized in Appendix B. Histopathologic findings on neoplasms are summarized in Table B1. Table B2 gives the survival and tumor status for individual female rats. Table B3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table B3 (footnotes). Historical incidences of tumors in control female rats are listed in Table B4. Findings on nonneoplastic lesions are summarized in Table B5.



TABLE 11. SURVIVAL OF RATS IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE

	Control	310 ppm	620 ppm
<b>MALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	17	20	30
Killed at termination	33	30	20
Survival P values (c)	0.005	0.672	0.008
<b>FEMALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	22	13	19
Killed at termination	28	37	31
Survival P values (c)	0.448	0.078	0.496

(a) Terminal-kill period: week 104

(b) Includes animals killed in a moribund condition

(c) The result of the life table trend test is in the control column, and the results of the life table pairwise comparisons with the controls are in the dosed columns.



**FIGURE 4. KAPLAN-MEIER SURVIVAL CURVES FOR RATS FED DIETS CONTAINING NITROFURAZONE FOR TWO YEARS**

### III. RESULTS: RATS

**Mammary Gland:** Fibroadenomas in female rats occurred with a significant positive trend; the incidences in the dosed groups were significantly greater than that in the controls (Table 12). Fibroadenomas consisted of varying proportions of epithelium and fibrous connective tissue. In smaller tumors, the epithelial component was quite prominent, whereas in larger tumors, the fibrous connective component almost completely obliterated the epithelium. Three adenocarcinomas were also observed.

**Joints (Articular Cartilage):** Degenerative changes involving the vertebral and knee (femoro-tibial) joints occurred at increased incidences in dosed rats of each sex relative to those

of controls (Table 13). These lesions were characterized by a spectrum of changes that varied in extent and severity from animal to animal. There was fibrillation of the surface cartilage with degeneration of the cartilage matrix. The articular cartilage was irregularly or focally thickened and contained multiple chondrocyte clones or daughter cell nests. Occasional subchondral cysts and exostoses at the edge of the joint were also noted. Degeneration of the sternal synchondrosis was also increased in high dose female rats and was characterized by granular or fibrillar degeneration of the cartilage matrix with proliferation of the cartilage and formation of chondrocyte clones at the margins of the degenerative changes.

**TABLE 12. ANALYSIS OF MAMMARY GLAND TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (a,b)**

	Control	310 ppm (c)	620 ppm (c)
<b>Fibroadenoma</b>			
Overall Rates	8/49 (16%)	36/50 (72%)	36/50 (72%)
Adjusted Rates	24.8%	81.6%	85.6%
Terminal Rates	5/28 (18%)	29/37 (78%)	25/31 (81%)
Week of First Observation	67	67	60
Life Table Tests	P<0.001	P<0.001	P<0.001
Incidental Tumor Tests	P<0.001	P<0.001	P<0.001
<b>Adenocarcinoma</b>			
Overall Rates	1/49 (2%)	0/50 (0%)	2/50 (4%)

(a) The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix B, Table B3 (footnotes).

(b) Historical incidence at study laboratory (mean  $\pm$  SD): 42/149 (28%  $\pm$  12%); historical incidence in NTP studies: 550/1,984 (28%  $\pm$  11%)

(c) The estimated dose in milligrams per kilograms per day is given in Chapter III (Body Weights, Feed Consumption, and Clinical Signs) and in Appendix G.

**TABLE 13. NUMBER OF RATS WITH DEGENERATION OF JOINT ARTICULAR CARTILAGE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE**

Site	Male			Female		
	Control	310 ppm	620 ppm	Control	310 ppm	620 ppm
No. of rats examined grossly	50	50	50	49	50	50
Vertebral joint	10	31	23	3	39	36
Knee joint	5	32	48	4	30	39
Sternal synchondrosis	24	26	21	15	(a) 1	32

(a) There was incomplete histopathologic sampling of the costochondral junction in low dose female rats.

### III. RESULTS: RATS

*Tunica Vaginalis:* The incidence of mesotheliomas in low dose male rats was significantly greater than that in the controls (Table 14). Mesotheliomas are derived from the mesothelium that lines the body cavities and frequently begin in the tunica vaginalis. The more extensive tumors extend into the peritoneal cavity and involve the mesothelium overlying the gastrointestinal tract, mesentery, and urogenital tract. The mesotheliomas consisted of cuboidal to columnar epithelial cells arranged in complex papillary or pseudoglandular formations with an interspersed collagenous stroma. The tumors sometimes invaded the soft tissues underlying the mesothelium.

*Skin:* The incidence of trichoepitheliomas or sebaceous adenomas (combined) in high dose male rats was significantly greater than that in controls (Table 15). These tumors were observed in 0/50 control, 0/50 low dose, and 2/50 high dose female rats.

Sebaceous adenomas and trichoepitheliomas arise from cells in the epidermis or adnexal structures. Pluripotential cells in the epidermis or adnexa are capable of differentiating into any of several different cell types including sebaceous cells, cells composing hair follicles, and squamous cells. Epithelial tumors of the skin frequently contain varying proportions of basal

TABLE 14. ANALYSIS OF MESOTHELIOMAS IN THE TUNICA VAGINALIS OF MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (a)

	Control	310 ppm	620 ppm
Overall Rates	0/50 (0%)	7/50 (14%)	2/50 (4%)
Adjusted Rates	0.0%	17.4%	6.6%
Terminal Rates	0/33 (0%)	2/30 (7%)	0/20 (0%)
Week of First Observation		67	93
Life Table Tests	P=0.149	P=0.010	P=0.174
Incidental Tumor Tests	P=0.363	P=0.014	P=0.307

(a) Historical incidence of mesotheliomas (all sites) at study laboratory (mean  $\pm$  SD): 5/150 (3%  $\pm$  3%); historical incidence in NTP studies: 52/1,937 (3%  $\pm$  2%)

TABLE 15. ANALYSIS OF SKIN TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Control	310 ppm	620 ppm
<b>Trichoepithelioma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	1/50 (2%)
<b>Sebaceous Adenoma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	4/50 (8%)
Adjusted Rates	0.0%	0.0%	15.2%
Terminal Rates	0/33 (0%)	0/30 (0%)	2/20 (10%)
Week of First Observation			69
Life Table Tests	P=0.006	(a)	P=0.028
Incidental Tumor Tests	P=0.015	(a)	P=0.067
<b>Trichoepithelioma or Sebaceous Adenoma (b)</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates	0.0%	0.0%	17.4%
Terminal Rates	0/33 (0%)	0/30 (0%)	2/20 (10%)
Week of First Observation			69
Life Table Tests	P=0.002	(a)	P=0.014
Incidental Tumor Tests	P=0.009	(a)	P=0.044

(a) No P value recorded because no tumors were observed in the 310-ppm and control groups.

(b) Historical incidence of sebaceous adenomas, basal cell tumors, trichoepitheliomas, or adnexal adenomas (combined) at study laboratory (mean  $\pm$  SD): 2/150 (1%  $\pm$  1%); historical incidence in NTP studies: 32/1,937 (2%  $\pm$  2%)

### III. RESULTS: RATS

cells, sebaceous cells, and hair follicle-like structures; therefore, classification is usually based on the predominant component.

**Preputial Gland:** The incidence of carcinomas in low dose male rats was significantly greater than that in the controls (Table 16). The incidences of adenomas or carcinomas (combined) in dosed rats were not significantly greater than that in the controls. However, the incidence of adenomas or carcinomas (combined) in low dose rats is greater than the highest incidence observed in historical control groups (9/50). Hyperplasia was observed in six low dose male rats in which neither adenomas nor carcinomas were diagnosed. In females, the incidences of adenomas, adenocarcinomas, or carcinomas (combined) in the clitoral gland were not increased in dosed groups (control, 8/49; low dose, 7/50; high dose, 7/50).

Hyperplasia of the preputial gland consisted of expansile foci of enlarged cells with abundant

granular cytoplasm and vesicular nuclei containing prominent nucleoli. The cells retained relatively normal arrangement in small packets or nests separated by a delicate fibrovascular stroma. Ducts present in the hyperplastic foci had increased numbers of cell layers showing variable degrees of squamous differentiation. The adenomas were circumscribed masses exhibiting loss of normal cellular arrangement. The tumor cells were similar to those in foci of hyperplasia but formed large aggregates and solid clusters. Remnants of the duct system were still apparent. Preputial gland carcinomas showed complete effacement of normal architectural features. The tumor cells were arranged in solid clusters or trabecular cords and showed greater pleomorphism and anaplasia than did the adenomas. The carcinomas showed only minimal invasion of adjacent soft tissue. There was a clear morphologic continuum from lesions classified as hyperplasia to those classified as carcinoma.

**TABLE 16. ANALYSIS OF PREPUTIAL GLAND LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

	Control	310 ppm	620 ppm
<b>Hyperplasia</b>			
Overall Rates	0/50 (0%)	6/50 (12%)	1/50 (2%)
<b>Adenoma (a)</b>			
Overall Rates	8/50 (16%)	8/50 (16%)	2/50 (4%)
<b>Carcinoma (b)</b>			
Overall Rates	1/50 (2%)	8/50 (16%)	5/50 (10%)
Adjusted Rates	3.0%	22.2%	16.0%
Terminal Rates	1/33 (3%)	5/30 (17%)	2/20 (10%)
Week of First Observation	104	60	42
Life Table Tests	P=0.041	P=0.016	P=0.053
Incidental Tumor Tests	P=0.171	P=0.018	P=0.166
<b>Adenoma or Carcinoma (c)</b>			
Overall Rates	9/50 (18%)	16/50 (32%)	7/50 (14%)
Adjusted Rates	25.2%	43.6%	22.5%
Terminal Rates	7/33 (21%)	11/30 (37%)	3/20 (15%)
Week of First Observation	95	60	42
Life Table Tests	P=0.356	P=0.062	P=0.496
Incidental Tumor Tests	P=0.366N	P=0.086	P=0.379N

(a) Historical incidence at study laboratory (mean): 2/150 (1%); historical incidence in NTP studies: 57/1,937 (3%)

(b) Historical incidence of carcinomas or adenocarcinomas (combined) at study laboratory (mean): 3/150 (2%); historical incidence in NTP studies: 66/1,937 (3%)

(c) Historical incidence of adenomas, adenocarcinomas, or carcinomas (combined) at study laboratory (mean): 5/150 (3%); historical incidence in NTP studies: 123/1,937 (6%)

### III. RESULTS: RATS

**Testis:** Degeneration was observed at increased incidences in dosed male rats (control, 12/50; low dose, 49/50; high dose, 47/50;  $P < 0.001$ ). The lesion was usually bilateral and diffuse in dosed male rats; the lesion in control rats was often unilateral and associated with interstitial cell tumors. The degeneration was characterized by variable atrophy of the germinal epithelium and lack of spermatogenesis within the seminiferous tubules. Multinucleated giant cells were sometimes present in the lumina of seminiferous tubules.

The administration of nitrofurazone was also associated with a significant decrease in the incidence of testicular interstitial cell tumors (Table 17).

**Hematopoietic System:** Mononuclear cell leukemia in male and female rats occurred with significant negative trends; the incidences of leukemia in high dose males and dosed females were significantly lower than those in controls (Table 18).

TABLE 17. ANALYSIS OF TESTICULAR LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Control	310 ppm	620 ppm
<b>Interstitial Cell Hyperplasia</b>			
Overall Rates	2/50 (4%)	2/50 (4%)	7/50 (14%)
<b>Interstitial Cell Tumor (a)</b>			
Overall Rates	45/50 (90%)	30/50 (60%)	28/50 (56%)
Adjusted Rates	100.0%	74.4%	86.8%
Terminal Rates	33/33 (100%)	20/30 (67%)	16/20 (80%)
Week of First Observation	75	67	75
Life Table Tests	$P = 0.352N$	$P = 0.022N$	$P = 0.495N$
Incidental Tumor Tests	$P = 0.005N$	$P < 0.001N$	$P = 0.007N$

(a) Historical incidence at study laboratory (mean  $\pm$  SD): 133/150 (89%  $\pm$  6%); historical incidence in NTP studies: 1,681/1,909 (88%  $\pm$  7%)

TABLE 18. ANALYSIS OF MONONUCLEAR CELL LEUKEMIA IN RATS IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE

	Control	310 ppm	620 ppm
<b>MALE (a)</b>			
Overall Rates	21/50 (42%)	23/50 (46%)	6/50 (12%)
Adjusted Rates	50.8%	55.5%	21.2%
Terminal Rates	13/33 (39%)	12/30 (40%)	1/20 (5%)
Week of First Observation	88	88	92
Life Table Tests	$P = 0.068N$	$P = 0.334$	$P = 0.041N$
Incidental Tumor Tests	$P = 0.001N$	$P = 0.388$	$P = 0.001N$
<b>FEMALE (b)</b>			
Overall Rates	15/49 (31%)	2/50 (4%)	2/50 (4%)
Adjusted Rates	40.8%	4.5%	6.5%
Terminal Rates	7/28 (25%)	0/37 (0%)	2/31 (6%)
Week of First Observation	87	67	104
Life Table Tests	$P < 0.001N$	$P < 0.001N$	$P < 0.001N$
Incidental Tumor Tests	$P < 0.001N$	$P < 0.001N$	$P < 0.001N$

(a) Historical incidence of leukemia at study laboratory (mean  $\pm$  SD): 71/150 (47%  $\pm$  3%); historical incidence in NTP studies: 586/1,937 (30%  $\pm$  12%)

(b) Historical incidence of leukemia at study laboratory (mean  $\pm$  SD): 41/149 (28%  $\pm$  2%); historical incidence in NTP studies: 378/1,984 (19%  $\pm$  7%)

### III. RESULTS: MICE

#### FOURTEEN-DAY STUDIES

All mice that received 2,500, 5,000, or 10,000 ppm nitrofurazone and 3/5 males that received 1,250 ppm died before the end of the studies (Table 19). All dosed groups except the 630-ppm female group lost weight. Feed consumption

relative to that of the controls was reduced in all but the two lowest dose male groups and the lowest dose female group. All dosed animals had rough hair coats and convulsive seizures. No compound-related histopathologic effects were observed.

**TABLE 19. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF MICE IN THE FOURTEEN-DAY FEED STUDIES OF NITROFURAZONE**

Concentration (ppm)	Survival (a)	Mean Body Weights (grams)			Final Weight Relative to Controls (percent)	Feed Consumption (d)	
		Initial (b)	Final	Change (c)		Week 1	Week 2
<b>MALE</b>							
0	5/5	24.5 ± 0.9	25.4 ± 1.0	+0.9 ± 0.3	--	2.9	3.1
630	5/5	25.9 ± 1.2	24.4 ± 1.1	-1.5 ± 1.1	96.1	3.4	3.0
1,250	(e) 2/5	26.3 ± 1.3	24.9 ± 0.4	-2.5 ± 0.2	98.0	2.9	3.3
2,500	(f) 0/5	25.9 ± 0.9	(g)	(g)	(g)	1.9	1.9
5,000	(h) 0/5	26.3 ± 0.3	(g)	(g)	(g)	0.9	0.9
10,000	(i) 0/5	25.2 ± 0.5	(g)	(g)	(g)	0.6	(g)
<b>FEMALE</b>							
0	5/5	20.7 ± 0.7	21.7 ± 0.7	+1.0 ± 0.1	--	3.1	3.0
630	5/5	21.7 ± 0.6	22.1 ± 0.5	+0.4 ± 0.2	101.8	3.1	2.9
1,250	5/5	20.3 ± 0.4	16.7 ± 1.1	-3.6 ± 0.9	77.0	2.7	1.8
2,500	(j) 0/5	21.0 ± 0.5	(g)	(g)	(g)	1.6	1.4
5,000	(k) 0/5	19.9 ± 0.5	(g)	(g)	(g)	0.8	0.3
10,000	(l) 0/5	20.9 ± 0.4	(g)	(g)	(g)	0.3	(g)

(a) Number surviving/number initially in the group

(b) Initial mean group body weight ± standard error of the mean. Subsequent calculations are based on those animals surviving to the end of the study.

(c) Mean body weight change of the survivors ± standard error of the mean

(d) Grams per animal per day; not corrected for scatter.

(e) Day of death: 8,8,12

(f) Day of death: 10,12,12,12,12

(g) No data are reported due to 100% mortality in this group.

(h) Day of death: 7,7,9,10,10

(i) Day of death: all 5

(j) Day of death: 6,7,10,10,11

(k) Day of death: 6,7,7,8,9

(l) Day of death: all 6

### III. RESULTS: MICE

#### THIRTEEN-WEEK STUDIES

Six of 10 males and 9/10 females that received 1,250 ppm and 3/10 males and 5/10 females that received 620 ppm died before the end of the studies (Table 20). The final mean body weight of the 5/20 surviving mice that received 1,250 ppm was 21% lower than that of the controls. The liver weight to body weight ratio for male mice that received 620 or 1,250 mg/kg was significantly greater than that for the controls (Table 21). The liver weight to body weight ratios for male and female mice that received 70 mg/kg

and for female mice that received 150 mg/kg were significantly lower than those for controls. Hyperexcitability and convulsive seizures were observed for all mice that received at least 620 ppm nitrofurazone. Testicular hypoplasia of mild to moderate severity was observed in 8/10 males that received 1,250 ppm and in 9/10 that received 620 ppm.

*Dose Selection Rationale:* Because of the incidence of deaths, lower weight gain, and seizures at higher concentrations, dietary concentrations of nitrofurazone selected for mice for the 2-year studies were 150 and 310 ppm.

TABLE 20. SURVIVAL, MEAN BODY WEIGHTS, AND FEED CONSUMPTION OF MICE IN THE THIRTEEN-WEEK FEED STUDIES OF NITROFURAZONE

Concentration (ppm)	Survival (a)	Mean Body Weights (grams)			Final Weight Relative to Controls (percent)	Feed Consumption (d)	
		Initial (b)	Final	Change (c)		Week 7	Week 13
<b>MALE</b>							
0	10/10	19.5 ± 0.3	31.7 ± 0.8	+12.2 ± 0.6	--	3.4	2.9
70	10/10	19.2 ± 0.3	30.9 ± 1.0	+11.7 ± 1.0	97.5	3.5	3.1
150	10/10	19.8 ± 0.3	30.9 ± 0.6	+11.1 ± 0.5	97.5	3.5	3.1
310	10/10	19.9 ± 0.3	32.8 ± 1.0	+12.9 ± 0.8	103.5	3.8	3.4
620	(e) 7/10	19.9 ± 0.3	29.9 ± 1.1	+10.1 ± 1.2	94.3	3.3	3.6
1,250	(f) 4/10	19.7 ± 0.3	24.9 ± 1.6	+4.7 ± 1.6	78.5	2.9	2.4
<b>FEMALE</b>							
0	10/10	16.3 ± 0.3	25.3 ± 0.6	+9.0 ± 0.4	--	3.2	3.0
70	10/10	16.8 ± 0.3	25.1 ± 0.6	+8.3 ± 0.6	99.2	3.0	3.1
150	10/10	16.2 ± 0.4	25.2 ± 0.7	+9.0 ± 0.9	99.6	2.9	3.1
310	10/10	16.6 ± 0.3	23.3 ± 0.4	+6.7 ± 0.3	92.1	3.4	3.2
620	(g) 5/10	15.9 ± 0.3	25.1 ± 1.3	+9.1 ± 1.4	99.2	2.6	3.2
1,250	(h) 1/10	16.3 ± 0.5	20.1	+2.6	79.4	3.2	3.2

(a) Number surviving/number initially in the group

(b) Initial mean group body weight ± standard error of the mean. Subsequent calculations are based on those animals surviving to the end of the study.

(c) Mean body weight change of the survivors ± standard error of the mean

(d) Grams per animal per day; not corrected for scatter.

(e) Week of death: 3,11,12

(f) Week of death: 3,3,3,3,4

(g) Week of death: 4,7,9,10,12

(h) Week of death: 2,3,3,4,4,4,4,6,9



TABLE 21. ANALYSIS OF LIVER WEIGHTS OF MICE IN THE THIRTEEN-WEEK FEED STUDIES OF NITROFURAZONE (a)

Concentration (ppm)	No. of Animals Examined	Final Body Weight (grams)	Liver Weight (mg)	Liver Weight/Final Body Weight (mg/g)
<b>MALE</b>				
0	10	31.7 ± 0.8	1,306 ± 74	41.5 ± 2.61
70	10	30.9 ± 1.0	(b) 1,071 ± 34	(b) 34.7 ± 0.61
150	10	30.9 ± 0.6	1,145 ± 28	37.0 ± 0.33
310	10	32.8 ± 1.0	1,488 ± 46	45.4 ± 0.76
620	7	29.9 ± 1.1	(c) 1,647 ± 90	(c) 55.2 ± 2.86
1,250	(d) 4	(c) 24.9 ± 1.6	1,523 ± 29	(c) 57.6 ± 0.44
<b>FEMALE</b>				
0	10	25.3 ± 0.6	1,179 ± 74	46.9 ± 2.97
70	10	25.1 ± 0.6	(c) 891 ± 28	(c) 35.5 ± 1.01
150	10	25.2 ± 0.7	(b) 998 ± 48	(b) 39.5 ± 1.48
310	10	23.3 ± 0.4	1,204 ± 36	51.6 ± 1.25
620	5	25.1 ± 1.3	1,240 ± 50	49.9 ± 2.68
1,250	(e) 1	20.1	1,220	60.7

(a) Mean ± standard error; P values vs. the controls by Dunnett's test (Dunnett, 1955).

(b) P < 0.05

(c) P < 0.01

(d) One liver weight not taken; ratio is based on the remaining three animals.

(e) Not included in statistical analysis

## TWO-YEAR STUDIES

### Body Weights, Feed Consumption, and Clinical Signs



Mean body weights of dosed mice were comparable to or greater than those of the controls throughout most of the studies (Table 22 and Figure 5). The average daily feed consumption by low dose and high dose male mice was 100% and 105% that of the controls and by low dose and high dose female mice, 97% that of the controls (Appendix G, Tables G3 and G4). The average amount of nitrofurazone consumed per day was approximately 16 or 33 mg/kg for low or high dose male mice and 14 or 29 mg/kg for low or high dose female mice.

Stimulus-sensitive seizures of short duration

were seen primarily during the first year, beginning at weeks 4 and 5 for high dose male and female mice and at week 24 for low dose female mice. The seizures were usually initiated by the auditory and tactile stimuli created by cage changing and weighing activities. The episodes were characterized by about 10 seconds of convulsive seizures that began with the animal either sitting or lying down and with eyes partially closed. When animals were in the sitting position, some facial preening motions were noted which faded into a steady, tense stance followed by trembling that became severe enough to cause the animal to fall over. Seizure episodes averaged 10 seconds and lasted up to 34 seconds. Episodes ended as the tremulous activity subsided and righting reflexes began. Postseizure signs usually included a lethargic period followed by a prolonged period of hyperexcitability.

**TABLE 22. MEAN BODY WEIGHTS AND SURVIVAL OF MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE**

Weeks on Study	Control		150 ppm			310 ppm		
	Av. Wt. (grams)	No. of Survivors	Av. Wt. (grams)	Wt. (percent of controls)	No. of Survivors	Av. Wt. (grams)	Wt. (percent of controls)	No. of Survivors
<b>MALE</b>								
1	23.0	50	22.3	97	50	23.2	101	50
2	25.0	50	24.6	98	50	25.1	100	50
3	25.5	50	25.6	100	50	26.1	102	50
4	27.0	50	27.5	102	50	26.9	100	50
5	27.0	50	27.3	101	48	28.2	104	50
6	28.7	50	29.0	101	44	29.2	102	50
7	29.8	50	30.5	102	44	30.9	104	50
8	29.5	50	29.7	101	44	29.8	101	50
9	29.4	50	30.7	104	44	31.0	105	50
10	30.3	49	30.7	101	44	30.8	102	50
11	30.7	49	31.0	101	44	31.5	103	50
12	31.7	49	32.1	101	44	32.3	102	50
13	32.3	49	31.5	98	44	32.1	99	49
20	33.0	49	33.1	100	44	33.1	100	45
23	34.3	49	34.3	100	43	35.2	103	44
28	35.9	49	35.7	99	43	36.8	103	44
33	36.4	49	35.8	98	42	37.0	102	43
37	37.3	49	36.4	98	42	38.2	102	43
42	37.1	49	36.4	98	42	38.3	103	42
46	38.6	49	38.1	99	42	39.6	103	41
49	38.3	49	38.8	101	41	40.4	105	41
54	39.2	49	38.8	99	40	39.5	101	40
58	39.0	49	39.1	100	40	39.9	102	40
64	38.7	49	38.7	100	40	40.0	103	40
68	38.3	47	38.6	101	40	39.1	102	40
72	37.9	47	39.0	103	40	40.2	106	40
77	39.1	47	39.6	101	40	40.2	103	40
80	38.9	46	39.0	100	40	39.2	101	40
84	39.9	45	39.2	98	38	40.0	100	40
89	37.1	45	37.6	101	36	38.0	102	36
93	38.5	44	37.7	98	36	37.6	98	33
98	39.1	42	36.7	94	35	38.2	98	29
102	39.4	40	37.6	95	32	38.6	98	27
104	39.6	39	38.1	96	31	38.6	97	27
<b>FEMALE</b>								
1	17.7	50	17.9	101	50	17.6	99	50
2	19.5	50	19.6	101	50	18.9	97	50
3	19.9	50	19.5	98	50	19.9	100	50
4	20.9	50	20.5	98	50	21.1	101	50
5	21.5	50	21.5	100	50	21.1	98	50
6	22.6	50	22.8	101	50	22.5	100	50
7	23.3	50	23.1	99	50	22.8	98	50
8	23.5	50	23.9	102	50	23.2	99	50
9	23.7	50	24.3	103	50	23.9	101	50
10	23.4	50	24.5	105	50	23.9	102	49
11	24.2	50	24.4	101	50	24.2	100	49
12	24.8	50	25.0	101	50	24.4	98	49
13	25.7	50	25.8	100	50	25.3	98	49
20	27.3	50	27.1	99	50	26.5	97	49
23	28.6	50	28.1	98	50	27.7	97	49
28	31.0	50	29.6	95	50	29.4	95	47
33	31.1	50	29.8	96	50	29.4	95	47
37	32.3	50	30.7	95	50	31.4	97	47
42	33.6	50	32.6	97	50	32.8	98	46
46	34.9	50	32.8	94	49	34.1	98	46
49	35.7	50	34.8	97	49	35.9	101	46
54	37.1	50	35.7	96	49	37.2	100	46
58	37.3	49	36.6	98	49	38.4	103	46
64	37.9	49	37.4	99	49	39.7	105	46
68	38.2	49	38.6	101	49	40.5	106	46
72	39.0	49	39.3	101	49	41.5	106	46
77	39.6	49	41.1	104	49	42.1	106	46
80	39.2	49	41.5	106	49	42.3	108	46
84	40.4	49	42.1	104	48	43.5	108	44
89	39.6	47	41.3	104	48	41.9	106	42
93	40.3	44	41.8	104	45	42.5	105	41
98	41.7	42	42.5	102	42	44.1	106	36
102	42.7	39	43.0	101	40	43.5	102	36
104	42.7	39	42.6	100	40	43.3	101	35



**FIGURE 5. GROWTH CURVES FOR MICE FED DIETS CONTAINING NITROFURAZONE FOR TWO YEARS**

### III. RESULTS: MICE

#### Survival

Estimates of the probabilities of survival for male and female mice fed diets containing nitrofurazone at the concentrations used in these studies and for controls are shown in Table 23 and in the Kaplan and Meier curves in Figure 6.

The survival of the high dose group of male mice was significantly lower than that of the controls after week 88. No other significant differences in survival were observed between any groups of either sex. Three low dose males in each of two separate cages died during weeks 5 and 6, probably as a result of fighting.



TABLE 23. SURVIVAL OF MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE

	Control	150 ppm	310 ppm
<b>MALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	10	19	23
Accidentally killed	1	0	0
Killed at termination	39	31	27
Survival P values (c)	0.008	0.057	0.007
<b>FEMALE (a)</b>			
Animals initially in study	50	50	50
Nonaccidental deaths before termination (b)	11	10	14
Accidentally killed	0	0	1
Killed at termination	39	40	35
Survival P values (c)	0.448	0.974	0.529

(a) Terminal-kill period: week 104

(b) Includes animals killed in a moribund condition

(c) The result of the life table trend test is in the control column, and the results of the life table pairwise comparisons with the controls are in the dosed columns.



**FIGURE 6. KAPLAN-MEIER SURVIVAL CURVES FOR MICE FED DIETS CONTAINING NITROFURAZONE FOR TWO YEARS**

### III. RESULTS: MICE

---

#### Pathology and Statistical Analyses of Results

This section describes the significant or noteworthy changes in the incidences of mice with neoplastic or nonneoplastic lesions of the ovary, circulatory system, integumentary system, liver, anterior pituitary gland, and kidney.

Lesions in male mice are summarized in Appendix C. Histopathologic findings on neoplasms are summarized in Table C1. Table C2 gives the survival and tumor status for individual male mice. Table C3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table C3 (footnotes). Historical incidences of tumors in control male mice are listed in Table C4. Findings on nonneoplastic lesions are summarized in Table C5.

Lesions in female mice are summarized in Appendix D. Histopathologic findings on neoplasms are summarized in Table D1. Table D2 gives the survival and tumor status for individual female mice. Table D3 contains the statistical analyses of those primary tumors that occurred with an incidence of at least 5% in one of the three groups. The statistical analyses used are discussed in Chapter II (Statistical Methods) and Table D3 (footnotes). Historical incidences of tumors in control female mice are listed in Table D4. Findings on nonneoplastic lesions are summarized in Table D5.

*Ovary:* Ovarian atrophy and tubular cell hyperplasia were observed at increased incidences ( $P < 0.001$ ) in dosed female mice (ovarian atrophy: control, 7/47; low dose, 44/50; high dose, 38/50; tubular cell hyperplasia: 1/47; 23/50; 21/50). Benign mixed tumors, granulosa cell tumors, and granulosa cell tumors or luteomas (combined) occurred with significant positive

trends; the incidences of benign mixed tumors in dosed female mice and granulosa cell tumors in high dose female mice were significantly greater than those in the controls (Table 24).

The ovarian atrophy and tubular cell hyperplasia were characterized by variable reduction in size of the ovaries, loss of graafian follicles and associated theca cells, and branching tubular downgrowth of the cuboidal cells lining the surface of the ovary (modified mesothelium).

Tumors classified as benign mixed tumors consisted of variable amounts of cuboidal cells arranged in complex branching tubular structures, apparently arising from the surface mesothelium, and interspersed stroma. The stromal cells had scant cytoplasm and contained fusiform or round nuclei with dense chromatin patterns. In some tumors, the stromal cells contained fine cytoplasmic vacuoles characteristic of lipid accumulation. The few tumors classified as tubular cell adenomas consisted primarily of the branching tubular component seen in the mixed tumors. Mixed tumors and tubular adenomas constitute a morphologic spectrum and are classified according to the extent of stromal proliferation.

The granulosa cell tumors consisted predominantly of granulosa cells arranged in follicular, glandular, or tubular patterns. Enlargement of granulosa cells with the accumulation of pale eosinophilic vacuoles (luteinization) occurred in some tumors. The luteomas were composed primarily of similarly luteinized cells and may be derived from granulosa or theca cells.

*Circulatory System:* Hemangiomas or hemangiosarcomas (combined) in male mice occurred with a significant positive trend (control, 1/50; low dose, 0/50; high dose, 4/50;  $P = 0.049$ , life table test); the incidences in the dosed groups were not significantly greater than that in the controls.

**TABLE 24. ANALYSIS OF OVARIAN LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (a)**

	Control	150 ppm (b)	310 ppm (b)
<b>Granulosa Cell Hyperplasia</b>			
Overall Rates	1/47 (2%)	0/50 (0%)	1/50 (2%)
<b>Granulosa Cell Tumor</b>			
Overall Rates	1/47 (2%)	4/50 (8%)	9/50 (18%)
Adjusted Rates	2.6%	10.0%	23.9%
Terminal Rates	1/39 (3%)	4/40 (10%)	7/35 (20%)
Week of First Observation	104	104	88
Life Table Tests	P=0.003	P=0.187	P=0.007
Incidental Tumor Tests	P=0.004	P=0.187	P=0.009
<b>Luteoma</b>			
Overall Rates	2/47 (4%)	2/50 (4%)	0/50 (0%)
<b>Granulosa Cell Tumor or Luteoma (c)</b>			
Overall Rates	3/47 (6%)	6/50 (12%)	9/50 (18%)
Adjusted Rates	7.7%	14.5%	23.9%
Terminal Rates	3/39 (8%)	5/40 (13%)	7/35 (20%)
Week of First Observation	104	96	88
Life Table Tests	P=0.030	P=0.257	P=0.043
Incidental Tumor Tests	P=0.039	P=0.267	P=0.055
<b>Tubular Cell Hyperplasia</b>			
Overall Rates	1/47 (2%)	23/50 (46%)	21/50 (42%)
<b>Tubular Cell Adenoma</b>			
Overall Rates	0/47 (0%)	2/50 (4%)	0/50 (0%)
<b>Benign Mixed Tumor</b>			
Overall Rates	0/47 (0%)	17/50 (34%)	20/50 (40%)
Adjusted Rates	0.0%	41.4%	55.5%
Terminal Rates	0/39 (0%)	16/40 (40%)	19/35 (54%)
Week of First Observation		96	97
Life Table Tests	P<0.001	P<0.001	P<0.001
Incidental Tumor Tests	P<0.001	P<0.001	P<0.001
<b>Tubular Cell Adenoma or Benign Mixed Tumor (d)</b>			
Overall Rates	0/47 (0%)	18/50 (36%)	20/50 (40%)
Adjusted Rates	0.0%	43.8%	55.5%
Terminal Rates	0/39 (0%)	17/40 (43%)	19/35 (54%)
Week of First Observation		96	97
Life Table Tests	P<0.001	P<0.001	P<0.001
Incidental Tumor Tests	P<0.001	P<0.001	P<0.001

(a) The statistical analyses used are discussed in Chapter II (Statistical Methods) and Appendix D, Table D3 (footnotes).

(b) The estimated dose in milligrams per kilograms per day is given in Chapter III (Body Weights, Feed Consumption, and Clinical Signs) and in Appendix G.

(c) Historical incidence of granulosa cell tumors or luteomas (combined) at study laboratory (mean): 0/134; historical incidence in NTP studies: 8/1,858 (0.4%)

(d) Historical incidence of benign mixed tumors or tubular cell adenomas (combined) at study laboratory (mean): 0/134; historical incidence in NTP studies: 5/1,858 (0.3%)

### III. RESULTS: MICE

*Integumentary System:* Subcutaneous tissue fibromas, sarcomas, fibrosarcomas, and neurofibrosarcomas in male mice occurred with significant positive trends by the life table test (Table 25). The incidence of fibromas, sarcomas, fibrosarcomas, or neurofibrosarcomas (combined) in high dose male mice was significantly greater than that in the controls by the life table test. However, neither of these increases was significant by the incidental tumor test, which is the more appropriate test for these generally nonfatal neoplasms.

*Liver:* The incidence of hepatocellular adenomas or carcinomas (combined) in high dose male mice

was significantly lower than that in the controls by the incidental tumor test (Table 26).

*Anterior Pituitary Gland:* Adenomas and adenomas or carcinomas (combined) in female mice occurred with significant negative trends; the incidences in the high dose group were significantly lower than those in the controls (Table 27).

*Kidney:* Mineralization was observed at increased incidences in dosed male mice (male: control, 1/50; low dose, 3/49; high dose, 8/50; female: 2/50; 0/7; 3/50).

TABLE 25. ANALYSIS OF SUBCUTANEOUS TISSUE TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Control	150 ppm	310 ppm
<b>Fibroma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	1/50 (2%)
<b>Fibrosarcoma</b>			
Overall Rates	2/50 (4%)	3/50 (6%)	5/50 (10%)
<b>Fibroma or Fibrosarcoma</b>			
Overall Rates	2/50 (4%)	3/50 (6%)	6/50 (12%)
Adjusted Rates	4.7%	8.9%	18.5%
Terminal Rates	0/39 (0%)	2/31 (6%)	2/27 (7%)
Week of First Observation	97	88	86
Life Table Tests	P=0.039	P=0.402	P=0.057
Incidental Tumor Tests	P=0.119	P=0.519	P=0.159
<b>Sarcoma</b>			
Overall Rates	1/50 (2%)	0/50 (0%)	1/50 (2%)
<b>Neurofibrosarcoma</b>			
Overall Rates	0/50 (0%)	0/50 (0%)	1/50 (2%)
<b>Sarcoma, Fibrosarcoma, or Neurofibrosarcoma</b>			
Overall Rates	3/50 (6%)	3/50 (6%)	7/50 (14%)
Adjusted Rates	6.9%	8.9%	20.8%
Terminal Rates	0/39 (0%)	2/31 (6%)	1/27 (4%)
Week of First Observation	97	88	86
Life Table Tests	P=0.044	P=0.557	P=0.064
Incidental Tumor Tests	P=0.140	P=0.653N	P=0.172
<b>Fibroma, Sarcoma, Fibrosarcoma, or Neurofibrosarcoma (a)</b>			
Overall Rates	3/50 (6%)	3/50 (6%)	8/50 (16%)
Adjusted Rates	6.9%	8.9%	23.8%
Terminal Rates	0/39 (0%)	2/31 (6%)	2/27 (7%)
Week of First Observation	97	88	86
Life Table Tests	P=0.021	P=0.557	P=0.034
Incidental Tumor Tests	P=0.070	P=0.653N	P=0.084

(a) Historical incidence of fibromas, neurofibromas, sarcomas, fibrosarcomas, or neurofibrosarcomas (combined) at study laboratory (mean ± SD): 16/150 (11% ± 14%); historical incidence in NTP studies: 160/2,040 (8% ± 8%)



**TABLE 26. ANALYSIS OF HEPATOCELLULAR TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

	Control	150 ppm	310 ppm
<b>Adenoma</b>			
Overall Rates	9/50 (18%)	6/49 (12%)	2/50 (4%)
<b>Carcinoma</b>			
Overall Rates	8/50 (16%)	9/49 (18%)	4/50 (8%)
<b>Adenoma or Carcinoma (a)</b>			
Overall Rates	16/50 (32%)	15/49 (31%)	5/50 (10%)
Adjusted Rates	36.8%	43.8%	17.7%
Terminal Rates	12/39 (31%)	12/31 (39%)	4/27 (15%)
Week of First Observation	66	83	97
Life Table Tests	P=0.072N	P=0.380	P=0.062N
Incidental Tumor Tests	P=0.007N	P=0.382	P=0.031N

(a) Historical incidence at study laboratory (mean ± SD): 52/150 (35% ± 4%); historical incidence in NTP studies: 609/2,032 (30% ± 8%)

**TABLE 27. ANALYSIS OF ANTERIOR PITUITARY GLAND TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

	Control	150 ppm	310 ppm
<b>Adenoma</b>			
Overall Rates	9/50 (18%)	5/50 (10%)	2/49 (4%)
Adjusted Rates	22.4%	12.5%	5.7%
Terminal Rates	8/39 (21%)	5/40 (13%)	2/35 (6%)
Week of First Observation	96	104	104
Life Table Tests	P=0.025N	P=0.180N	P=0.041N
Incidental Tumor Tests	P=0.026N	P=0.187N	P=0.043N
<b>Carcinoma</b>			
Overall Rates	1/50 (2%)	2/50 (4%)	0/49 (0%)
<b>Adenoma or Carcinoma (a)</b>			
Overall Rates	10/50 (20%)	7/50 (14%)	2/49 (4%)
Adjusted Rates	24.1%	17.5%	5.7%
Terminal Rates	8/39 (21%)	7/40 (18%)	2/35 (6%)
Week of First Observation	93	104	104
Life Table Tests	P=0.019N	P=0.280N	P=0.026N
Incidental Tumor Tests	P=0.019N	P=0.296N	P=0.027N

(a) Historical incidence at study laboratory (mean ± SD): 26/146 (18% ± 16%); historical incidence in NTP studies: 204/1,764 (12% ± 10%)



## **IV. DISCUSSION AND CONCLUSIONS**

## IV. DISCUSSION AND CONCLUSIONS

---

Studies of the toxicity and carcinogenicity of nitrofurazone were conducted in F344/N rats and B6C3F<sub>1</sub> mice of each sex. For the 2-year studies, nitrofurazone was administered in the diet at concentrations of 0, 310, or 620 ppm to rats and 0, 150, or 310 ppm to mice. The selection of these doses was based on results of 14-day and 13-week studies.

In the 13-week studies, doses for rats of each sex were 0, 150, 310, 620, 1,250, or 2,500 ppm. None of the rats died, all animals gained weight, and decreases in weight gain and feed consumption were evident only at the two doses above 620 ppm. At the two highest doses, nitrofurazone produced hyperexcitability and seizures. Thus, for rats of each sex, nitrofurazone at 620 ppm and below had negligible effects on weight gain and feed intake and, with the exception of moderate testicular degeneration, did not show evidence of overt toxicity. Based on these findings, 310 ppm and 620 ppm were chosen as the dietary concentrations for the 2-year evaluation of nitrofurazone in rats of each sex.

The survival of male rats after 103 weeks of exposure to nitrofurazone at 620 ppm was two-thirds that of controls and low dose animals. Feed consumption in the high dose group decreased throughout most of the study, and this was accompanied by lower body weights. The survival among all groups of female rats was comparable, but there was a dose-related decrease in body weight gain. In retrospect, somewhat lower doses might have been chosen for male rats. However, the doses for the 2-year studies were based primarily on chemical-associated convulsive seizures, weight gain, and survival in the 13-week studies. Furthermore, the depressed weight gain of dosed groups in the 2-year studies did not become evident until after 4 months. Since survival of dosed females was not decreased and since 80% of high dose male rats survived for at least 90 weeks of exposure, these studies were considered to be adequate assessments of the long-term toxicity and carcinogenicity of nitrofurazone in male and female rats.

The long bones of male and female rats were observed for histopathologic effects in both the 13-week and 2-year studies. It is uncertain if the osteoporosis observed in the 13-week studies was

directly related to the administration of nitrofurazone. Since it was not observed in the 2-year studies in which weight gain was not depressed as severely as in the 13-week studies, it is possible that the osteoporosis occurred secondarily to the severe decrease in weight gain of the high dose groups in the 13-week studies.

Degenerative lesions of articular cartilage were also observed in the 2-year studies in rats. These lesions were microscopically evaluated at three sites: the vertebral and knee joints and the sternal synchondrosis. Although the arthropathy was observed in the control groups, increased incidences of the site-specific lesions of the vertebral and knee joints (see Table 13) indicate that these lesions were the result of nitrofurazone administration. Since examinations did not provide neurologic bases for the observed disturbed gait and muscle atrophy, it is likely that these were secondary to the degenerative lesions in the articular cartilage. The etiology of these lesions is unknown. They have been described as occurring in untreated F344 rats, but not as early as 90 days, and they were not severe enough to cause gait or motor disturbances (Yamasaki and Inui, 1985). Similar arthropathies have been described in young dogs after administration of nalidixic, oxolinic, or pipemidic acids. Although structurally unrelated to nitrofurazone, these three chemicals (fused ring *N*-alkyl-4-pyridone-3-carboxylic acids) are also used as antibiotics (Ingham et al., 1977; Gough et al., 1979).

Gonadal degeneration and atrophy were prominent findings in the 13-week and 2-year studies of nitrofurazone in rats. Testicular degeneration was characteristically bilateral and diffuse and accompanied by a lack of spermatogenesis. These lesions were reported previously by other investigators studying the toxicity of nitrofurazone (Montemurro, 1969; Miyaji, 1971; Hagenas et al., 1978), but the mechanism responsible for these findings is unknown.

The range of nitrofurazone doses used in the 13-week studies in B6C3F<sub>1</sub> mice of each sex encompassed a no-apparent-effect level as well as levels that produced overt signs of toxicity, as evidenced by the occurrence of seizures, microscopic evidence of gonadal hypoplasia, and chemically

## IV. DISCUSSION AND CONCLUSIONS

related deaths. Feed consumption for mice was decreased only at the highest dose in males, and decreases in body weight were observed at the 620-ppm (males only) and 1,250-ppm doses. Gross lesions observed at necropsy did not provide evidence of any chemically affected organs. Testicular hypoplasia, judged not to be life threatening, was observed only at doses above 310 ppm. Although clinical signs of hyperexcitability and convulsive seizures were noted in both sexes at doses of 620 ppm and above, no histopathologic lesions were found which would account for this behavior. Thus, in the 13-week studies, the effects of nitrofurazone on mortality rate, clinical signs, feed consumption, and weight gain depression were comparable for male and female mice. Considered together, these observations indicated that doses of nitrofurazone not exceeding 310 ppm would be appropriate and compatible with long-term survival in the 2-year studies in B6C3F<sub>1</sub> mice of each sex.

Throughout most of the 2-year studies in mice, body weights and feed consumption of dosed and control animals were comparable. Convulsive seizures, seen in these studies, were reported in other toxicologic investigations of nitrofurazone in rodents (Krantz and Evans, 1945; Dodd, 1946). Furthermore, peripheral sensorimotor polyneuropathies were observed after administration of nitrofurazone and other nitrofurans to humans and animals (Karol, 1960; Lister and Fisher, 1970; Toole and Parrish, 1973). No histopathologic lesions were found to explain the seizures observed in the studies reported here.

### Neoplastic Lesions

Results from the 2-year study provide substantial evidence that administration of nitrofurazone induces mammary gland fibroadenomas in female rats. Marked increases in incidence were seen in both dosed groups, although chemical exposure did not hasten the time to appearance of this neoplasm. The control incidence in this study (16%) was somewhat lower than the historical laboratory and NTP average (28%), but the incidences in both dosed groups were about 50% greater than the highest incidences observed in untreated historical control groups (Appendix B, Table B4a). This interpretation

that nitrofurazone induced mammary gland neoplasms is consistent with observations reported by other investigators. Erturk et al. (1970) reported mammary gland fibroadenoma incidences of 2/29 and 22/29 in the control and dosed groups, respectively, in a study in which 30 female Sprague Dawley rats were fed diets containing 1,000 ppm of pure nitrofurazone for 46 weeks followed by 20 weeks of a control diet. Concurrent evaluation of equimolar concentrations of 2-furaldehyde semicarbazone revealed no difference in the incidences of mammary gland fibroadenomas in dosed groups compared with that in controls. Except for the absence of the nitro group, 2-furaldehyde is structurally identical to nitrofurazone. Therefore, this observation leads to the speculation that the nitro group is required for the induction of fibroadenomas by nitrofurazone.

Fibroadenomas are benign tumors that can progress to malignant epithelial or mesenchymal tumors. In observations from at least 1,100 rats of each strain, Van Zwieten (1984) reported carcinomas arising in mammary gland fibroadenomas at rates of 2.3% for WAG/Rij rats, 0.5% for BN/BiRij rats, and 2.1% for Sprague Dawley rats. Furthermore, a low incidence of carcinomas arising from fibroadenomas has also been observed in F344/N rats (Boorman et al., unpublished observations). Evidence of malignancy was also observed in mammary tissue from studies reported here. Therefore, these studies provide strong evidence of a marked increase in the incidence of benign tumors that can progress to malignancy.

Cells showing sebaceous differentiation predominated in four skin neoplasms found in high dose male rats and diagnosed as sebaceous adenomas; an additional neoplasm showing differentiation toward hair follicles was diagnosed as a trichoepithelioma. Because of their similar histogenesis, these were combined for evaluation. Since these neoplasms were not observed in the low dose groups (see Table 15), there was not a clear dose response, but the incidence of these neoplasms in the high dose male rats (5/50) exceeds the highest observed incidence in historical controls for studies at this laboratory (1/50) or at all NTP laboratories (4/50).

## IV. DISCUSSION AND CONCLUSIONS

---

The incidence of preputial gland carcinomas in low dose male rats, a group having a survival rate comparable to that of controls, was increased above that of concurrent and historical controls (see Table 16). Furthermore, 3/8 carcinomas were seen in the early-death low dose animals beginning at week 60. In high dose males, 3/5 carcinomas were observed earlier than week 80. In contrast, no preputial gland carcinomas were observed in the 17 early-death control animals. Considered together, these results suggest that nitrofurazone administration may have shortened the time to appearance of this neoplasm. Evidence supporting the conclusion that nitrofurazone caused the preputial gland neoplasms is lessened when the incidence of male rats with adenomas is considered. The combined incidence is the most appropriate value to use when comparing the incidences of preputial gland neoplasms in dosed and control groups because both lesions are derived from the same cell type; adenomas and carcinomas of the preputial gland represent a morphologic continuum, and distinctions between them are not easily quantifiable. The incidence of adenomas in the control group (16%) is well above the mean historical rate (3%) and, when combined with the carcinomas, does not strongly support an association between chemical exposure and these lesions in the dosed groups. Inflammation of the preputial gland was observed at incidences of 75% in all groups (Appendix A, Table A5), but the incidence of hyperplasia was increased above that of controls only in the low dose group. Nitrofurazone administration did not cause a response in the corresponding (clitoral) gland of female rats.

In view of the marginal responses in the sebaceous glands of the skin and preputial glands (modified sebaceous glands) observed in male rats in this study, it is of interest that the toxicologic assessment of a variety of nitrofurans showed an apparent positive correlation between their reported carcinogenicity in rodents (regardless of topography) and their ability to destroy sebaceous glands in mouse skin (Takizawa et al., 1975). Evidence of nitrofurazone-induced neoplasia in sebaceous glands has not been described in the literature.

The incidence of mesotheliomas of the tunica vaginalis in low dose male rats was increased

above the control incidence and exceeded the incidence in historical controls. The incidence of this neoplasm was not increased in the high dose group, possibly because of poor survival.

Results of the 2-year studies also included considerable evidence of nitrofurazone-induced atrophy, hyperplasia, and neoplasia in the ovaries of female mice. The incidences in both dosed groups were dose related and markedly above the historical control rates observed in NTP studies (Appendix D, Table D4a). Except for two neoplasms in the high dose group, all of these lesions were observed at week 104. Overall, the results indicate that nitrofurazone increased the incidence of granulosa cell tumors. No evidence of malignancy was observed in ovarian tissue from studies reported here; however, malignant granulosa cell tumors have been observed in this and other strains of mice (NTP, 1988; Beamer et al., 1985).

The ovaries of mice also exhibited a dose-dependent increase in the incidence of benign mixed tumors. This neoplasm has a low (0.3%) incidence in NTP studies and was absent in control animals, but it was observed at rates of 34% and 40% in the low and high dose groups (see Table 24). Most of these neoplasms were found in animals that lived to the end of the study. Tubular cell hyperplasia was observed in ovaries from almost half of the nitrofurazone-exposed mice but was seen in only one control animal. NTP data and observations of others (Lemon and Gubareva, 1979) support the view that tumors of the ovary are comparatively rare in untreated mice.

The ovarian neoplasms were observed at doses that were also associated with ovarian atrophy. Since the biologic behavior of ovarian tumors is thought to be influenced by pituitary gonadotropic hormones (Biskind and Biskind, 1944), it can be questioned whether the ovarian tumors were caused directly by the nitrofurazone or were influenced indirectly by alterations in hormonal status resulting from diminished follicle production. A negative trend in pituitary gland neoplasms was observed in female mice, and this trend may conceivably be an indication of a chemical-related interaction with the ovary/pituitary gland axis. At present, the role for gonadotropin involvement in the causation of

## IV. DISCUSSION AND CONCLUSIONS

ovarian tumors is unclear. Recent experimental evidence obtained with mice indicates that the presence of gonadotropins is necessary for normal follicular atresia processes including stromal luteinization after oocyte death, but the mere presence of gonadotropins was insufficient to stimulate adenoma formation (Tennent and Beamer, 1986; Beamer and Tennent, 1986).

The incidences of mesenchymal neoplasms (fibromas, fibrosarcomas, sarcomas, or neurofibrosarcomas) of subcutaneous tissue in male mice occurred with a positive trend. These neoplasms are combined for evaluation because of probable similar histogenesis and their common origin from fibroblasts. The incidence in high dose male mice was marginally increased compared with that in concurrent controls, and the incidence was within the range seen in historical controls for studies both at this laboratory and for all NTP studies (Appendix C, Table C4b). For these reasons, the increase in mesenchymal neoplasms of subcutaneous tissue is not considered to be chemical related.

Vascular neoplasms (hemangioma or hemangiosarcoma) in male mice occurred with a positive trend; the lesions were observed at different organ sites (Table C1). The incidence of these neoplasms in the high dose group (4/50) exceeded the highest incidence observed in historical controls from studies conducted by this laboratory but was within the overall range for historical controls at all NTP laboratories (Table C4a). Thus, the increased incidence of vascular neoplasms was not considered to be clearly related to chemical exposure.

The incidences of some neoplasms were decreased in these studies. The incidence of mononuclear cell leukemia was lower in high dose male rats and in dosed female rats than in controls (see Table 18). The decreased incidence in the high dose males is probably not due entirely to the poor survival of this group because a decreased incidence was also observed in high dose females, which had survival rates comparable to control values. The combined incidence of hepatocellular adenomas and carcinomas (10%) in high dose male mice was lower than the concurrent control value (30%) and was below the lowest incidence observed in historical controls (16%). Although the survival rate of the high

dose group at week 104 was lower than that of the controls (78% vs. 54%), hepatocellular neoplasms were first observed in the control group 31 weeks earlier than in the high dose group. These findings suggest that the decreased incidence of hepatocellular neoplasms may be related to chemical exposure. The incidences of testicular interstitial cell tumors were decreased in dosed male rats. Although survival was decreased in the high dose group, it is conceivable that the decreased tumor incidences may be chemically related because a similar decrease was also observed in dosed male rats in a study of the structurally related nitrofurantoin (NTP, 1988). Survival of dosed rats was not decreased in that study.

Nitrofurazone is a gene mutagen in bacteria, requiring metabolism by either a bacterial nitroreductase or a eukaryotic cell enzyme system for expression of this mutagenic activity. In cultured mammalian cells, nitrofurazone is a clastogen as well as a gene mutagen in the absence of exogenous metabolic activation and is, therefore, either direct acting or is activated by enzymes functioning in established cell lines. Nitrofurazone has not been demonstrated to be mutagenic *in vivo*; however, these negative studies are limited to a sex-linked lethal study in *Drosophila*, a test for morphologically abnormal sperm in mice, and micronuclei studies in two rodent species (one rat and one mouse). Both micronuclei studies used doses of 30 mg/kg per day; mice were injected on 5 consecutive days (Bruce and Heddle, 1979), and rats were dosed twice (Goodman et al., 1977). In both studies, bone marrow sampling occurred within 6 hours of the final dosing, which effectively decreased the total dose by 30 mg/kg. The *in vivo* mutagenicity data are insufficient to assess whether the observed carcinogenicity of this chemical is related to its mutagenicity *in vitro*.

The experimental and tabulated data for the NTP Technical Report on nitrofurazone were examined for accuracy, consistency, completeness, and compliance with Good Laboratory Practice regulations. As summarized in Appendix I, the audit revealed no major problems with the conduct of the studies or with collection and documentation of the experimental data. No discrepancies were found that influenced the

## IV. DISCUSSION AND CONCLUSIONS

---

final interpretation of the results of these studies.

*Conclusions:* Under the conditions of these 2-year feed studies, there was *equivocal evidence of carcinogenic activity\** of nitrofurazone for male F344/N rats as shown by the occurrence of sebaceous gland adenomas and trichoepitheliomas of the skin, mesotheliomas of the tunica vaginalis, and preputial gland tumors. There was *clear evidence of carcinogenic activity* of nitrofurazone for female F344/N rats as shown by a markedly increased incidence of fibroadenomas of the mammary gland. There was *no evidence of carcinogenic activity* for male B6C3F<sub>1</sub> mice fed diets containing nitrofurazone at concentrations of

150 or 310 ppm. There was *clear evidence of carcinogenic activity* of nitrofurazone for female B6C3F<sub>1</sub> mice as shown by increased incidences of benign mixed tumors and granulosa cell tumors of the ovary.

Administration of nitrofurazone was associated with decreased incidences of mononuclear cell leukemia in male and female rats, testicular interstitial cell tumors in male rats, and pituitary gland neoplasms in female mice. Convulsive seizures in mice of each sex, ovarian atrophy in female mice, testicular degeneration in rats, and degeneration of articular cartilage in rats were all associated with the administration of nitrofurazone.

---

\*Explanation of Levels of Evidence of Carcinogenic Activity is on page 9.

A summary of the Peer Review comments and the public discussion on this Technical Report appears on pages 12-13.



## V. REFERENCES

## V. REFERENCES

---

1. Armitage, P. (1971) *Statistical Methods in Medical Research*. New York: John Wiley & Sons Inc., pp. 362-365.
2. Baars, A.J.; Blijleven, W.G.H.; Mohn, G.R.; Nataragan, A.T.; Breimer, D.D. (1980) Preliminary studies on the ability of *Drosophila* microsomal preparations to activate mutagens and carcinogens. *Mutat. Res.* 72:257-264.
3. Beamer, W.; Tennent, B. (1986) Gonadotropin uptake in genetic and irradiation models of ovarian tumorigenesis. *Biol. Reprod.* 34:761-770.
4. Beamer, W.G.; Hoppe, P.C.; Whitten, W.K. (1985) Spontaneous malignant granulosa cell tumors in ovaries of young SWR mice. *Cancer Res.* 45:5575-5581.
5. Berenblum, I., Ed. (1969) *Carcinogenicity Testing: A Report of the Panel on Carcinogenicity of the Cancer Research Commission of UICC*, Vol. 2. Geneva: International Union Against Cancer.
6. Beutler, E. (1972) Glucose 6-phosphate dehydrogenase deficiency. Williams, W.; Beutler, E.; Erslev, A.; Rundles, R., Eds.: *Hematology*. New York: McGraw-Hill, pp. 391-399.
7. Biskind, M.; Biskind, G. (1944) Development of tumors in the rat ovary after transplantation into the spleen. *Proc. Soc. Exp. Biol. Med.* 55:176-179.
8. Boorman, G.A.; Montgomery, C.A., Jr.; Eustis, S.L.; Wolfe, M.J.; McConnell, E.E.; Hardisty, J.F. (1985) Quality assurance in pathology for rodent carcinogenicity studies. Milman, H.; Weisburger, E., Eds.: *Handbook of Carcinogen Testing*. Park Ridge, NJ: Noyes Publications, pp. 345-357.
9. Bruce, W.R.; Heddle, J.A. (1979) The mutagenic activity of 61 agents as determined by the micronucleus, *Salmonella*, and sperm abnormality assays. *Can. J. Genet. Cytol.* 21:319-334.
10. Chemical Information Services, Ltd. (1973) *Directory of West European Producers*. Ocean-side, New York.
11. Chin, J.B.; Sheinin, D.M.K.; Rauth, A.M. (1978) Screening for the mutagenicity of nitro-group containing hypoxic cell radiosensitizers using *Salmonella typhimurium* strains TA 100 and TA 98. *Mutat. Res.* 58:1-10.
12. Clive, D.; Johnson, K.O.; Spector, J.F.S.; Batson, A.G.; Brown, M.M.M. (1979) Validation and characterization of the L5178Y/TK<sup>±</sup>-mouse lymphoma mutagen assay system. *Mutat. Res.* 59:61-108.
13. Cox, D.R. (1972) Regression models and life tables. *J. R. Stat. Soc.* B34:187-220.
14. Davis, J.R.; Firlit, C.F. (1965) Effect of glucose uptake of L-lysine-<sup>3</sup>H in cells of the seminiferous epithelium. *Am. J. Physiol.* 209:425.
15. Dodd, M.C. (1946) The chemotherapeutic properties of 5-nitro-2-furaldehyde semicarbazone (Furacin). *J. Pharmacol. Exp. Ther.* 86:311-323.
16. Dodd, M.C.; Stillman, W.B. (1944) The in vitro bacteriostatic action of some simple furan derivatives. *J. Pharmacol. Exp. Ther.* 82:11-18.
17. Dunnett, C.W. (1955) A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* 50:1096-1122.
18. Ebringer, L.; Bencova, M. (1980) Mutagenicity of nitrofurans in bacterial systems. *Folia Microbiol.* 25:388-396.
19. Erturk, E.; Morris, J.E.; Cohen, S.M.; Price, J.M.; Bryan, G.T. (1970) Transplantable rat mammary tumors induced by 5-nitro-2-furaldehyde semicarbazone and by formic acid 2-[4-(5-nitro-2-furyl)-2-thiazolyl]hydrazide. *Cancer Res.* 30:1409-1412.
20. Galloway, S.M.; Bloom, A.D.; Resnick, M.; Margolin, B.H.; Nakamura, F.; Archer, P.; Zeiger, E. (1985) Development of a standard protocol for in vitro cytogenetic testing with Chinese hamster ovary cells: Comparison of results for 22 compounds in two laboratories. *Environ. Mutagen.* 7:1-51.

## V. REFERENCES

21. Gart, J.J.; Chu, K.C.; Tarone, R.E. (1979) Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. *J. Natl. Cancer Inst.* 62:957-974.
22. Goodman, D.R.; Hakkinen, P.J.; Nemenzo, J.H.; Vore, M. (1977) Mutagenicity evaluation of nitrofurantoin derivatives in *Salmonella typhimurium*, by the micronucleus test, and by in vivo cytogenetics. *Mutat. Res.* 48:295-306.
23. Gough, A.; Barsoum, N.J.; Mitchell, L.; McGuire, E.J.; de la Iglesia, F. (1979) Juvenile canine drug-induced arthropathy: Clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. *Toxicol. Appl. Pharmacol.* 51:177-187.
24. Griswold, D.P.; Casey, A.E.; Weisburger, E.K.; Weisburger, J.H. (1968) The carcinogenicity of multiple intragastric doses of aromatic and heterocyclic nitro or amino derivatives in young female Sprague-Dawley rats. *Cancer Res.* 28:924-933.
25. Hagenas, L.; Ploen, L.; Ritzen, E.M. (1978) The effect of nitrofurazone on the endocrine, secretory and spermatogenic functions of the rat testis. *Andrologia* 10:107-126.
26. Haseman, J.K. (1984) Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies. *Environ. Health Perspect.* 58:385-392.
27. Haseman, J.K.; Huff, J.; Boorman, G.A. (1984) Use of historical control data in carcinogenicity studies in rodents. *Toxicol. Pathol.* 12:126-135.
28. Haseman, J.K.; Huff, J.; Rao, G.N.; Arnold, J.; Boorman, G.A.; McConnell, E.E. (1985) Neoplasms observed in untreated and corn oil gavage control groups of F344/N rats and (C57BL/6N × C3H/HeN)F<sub>1</sub> (B6C3F<sub>1</sub>) mice. *J. Natl. Cancer Inst.* 75:975-984.
29. Haveland-Smith, R.B.; Combes, R.D.; Bridges, B.A. (1979) Methodology for the testing of food dyes for genotoxic activity: Experiments with Red 2G (C.I. 18050). *Mutat. Res.* 64:241-248.
30. Hayes, K.J. (1967) Nitrofurans. Kirk, R.E.; Othmer, D.F., Eds.: *Encyclopedia of Chemical Technology*, 2nd ed., Vol. 13. New York: John Wiley & Sons Inc., p. 854.
31. Haworth, S.; Lawlor, T.; Mortelmans, K.; Speck, W.; Zeiger, E. (1983) *Salmonella* mutagenicity test results for 250 chemicals. *Environ. Mutagen. Suppl.* 1:3-142.
32. Hoener, B.-A.; Krueger, T.R. (1984) Disposition of nitrofurantoin and nitrofurazone in the isolated perfused rat kidney. *J. Pharm. Sci.* 73:1669-1671.
33. Hollinger, M.A.; Davis, J.R. (1969) Effect of nitrofurazone on the aerobic metabolism of uniformly labelled [<sup>14</sup>C]glucose in tissue slices of rat testis. *J. Reprod. Fertil.* 19:585-589.
34. IMS (1987) Database search, April 7. IMS America Ltd., Plymouth Meeting, PA 19462.
35. Ingham, B.; Brentall, D.W.; Dale, E.A.; McFadzean, J.A. (1977) Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. *Toxicol. Lett.* 1:21-26.
36. Ishidate, M., Jr.; Odashima, S. (1977) Chromosome tests with 134 compounds on Chinese hamster cells in vitro--a screening for chemical carcinogens. *Mutat. Res.* 48:337-354.
37. Kaplan, E.L.; Meier, P. (1958) Nonparametric estimation from incomplete observations. *J. Am. Stat. Assoc.* 53:457-481.
38. Karol, H.J. (1960) Nitrofurans in treatment of malignant testicular tumors. *J. Urol.* 84:120-122.
39. Klemencic, J.M.; Wang, C.Y. (1978) Mutagenicity of nitrofurans. Bryan, G.T., Ed.: *Carcinogenesis*, Vol. 4: Nitrofurans. New York: Raven Press, pp. 99-130.
40. Koch-Weser, J.; Sidel, V.W.; Dexter, M.; Parish, C.; Finer, D.C.; Kanarek, P. (1971) Adverse reactions to sulfisoxazole, sulfamethoxazole, and nitrofurantoin. *Arch. Intern. Med.* 128:399-404.

## V. REFERENCES

---

41. Kramers, P.G.N. (1982) Studies on the induction of sex-linked recessive lethal mutations in *Drosophila melanogaster* by nitroheterocyclic compounds. *Mutat. Res.* 101:209-236.
42. Krantz, J.C.; Evans, W.E. (1945) A contribution to the pharmacology of 5-nitro-2-furaldehyde semicarbazone. *J. Pharmacol. Exp. Ther.* 85:324-331.
43. Kutcher, W.W.; McCalla, D.R. (1984) Aerobic reduction of 5-nitro-2-furaldehyde semicarbazone by rat liver xanthine dehydrogenase. *Biochem. Pharmacol.* 33:799-805.
44. Lemon, P.S.; Gubareva, A.V. (1979) Tumors of the ovary. *Pathology of Tumours in Laboratory Animals. Vol. II: Tumors of the Mouse.* IARC Scientific Publication No. 23. Lyon: IARC, pp. 385-397.
45. Linhart, M.S.; Cooper, J.; Martin, R.L.; Page, N.; Peters, J. (1974) Carcinogenesis Bioassay Data System. *Comput. Biomed. Res.* 7:230-248.
46. Lister, E.E.; Fisher, L.J. (1970) Establishment of the toxic level of nitrofurazone for young liquid-fed calves. *J. Dairy Sci.* 53:1490-1495.
47. Mantel, N.; Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl. Cancer Inst.* 22:719-748.
48. Maronpot, R.R.; Boorman, G.A. (1982) Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* 10:71-80.
49. Mason, R.P.; Holtzman, J.L. (1975) The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. *Biochemistry* 14:1626-1632.
50. Matsuoka, A.; Hayashi, M.; Ishidate, M., Jr. (1979) Chromosomal aberration tests on 29 chemicals combined with S9 mix in vitro. *Mutat. Res.* 66:277-290.
51. McCalla, D.R. (1983) Mutagenicity of nitro-furan derivatives: Review. *Environ. Mutagen.* 5:745-765.
52. McCalla, D.R.; Voutsinos, D.; Olive, P.L. (1975) Mutagen screening with bacteria: Niridazole and nitrofurans. *Mutat. Res.* 31:31-37.
53. McConnell, E.E. (1983a) Pathology requirements for rodent two-year studies. I. A review of current procedures. *Toxicol. Pathol.* 11:60-64.
54. McConnell, E.E. (1983b) Pathology requirements for rodent two-year studies. II. Alternative approaches. *Toxicol. Pathol.* 11:65-76.
55. McConnell, E.E.; Solleveld, H.A.; Swenberg, J.A.; Boorman, G.A. (1986) Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *J. Natl. Cancer Inst.* 76:283-289.
56. Miyaji, T. (1971) Acute and chronic toxicity of furylfuramide in rats and mice. *Tohoku J. Exp. Med.* 103:331-369.
57. Montemurro, D.G. (1969) The effect of nitrofurazone on the testes and accessory sex organs of normal rats and rats bearing the Walker carcinoma 256. *Br. J. Cancer* 14:319-326.
58. Morris, J.E.; Price, J.M.; Lalich, J.J.; Stein, R.J. (1969) The carcinogenic activity of some 5-nitrofurans in the rat. *Cancer Res.* 29:2145-2156.
59. Myhr, B.; Bowers, L.; Caspary, W.J. (1985) Assays for the induction of gene mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells in culture. *Prog. Mutat. Res.* 5:555-568.
60. National Cancer Institute (NCI) (1976) Guidelines for Carcinogen Bioassay in Small Rodents. NCI Technical Report No. 1. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health.

## V. REFERENCES

61. The National Formulary (1975) 14th ed. Washington, DC: United States Pharmacopeial Convention, Inc., p. 487.
62. National Institutes of Health (NIH) (1978) Open Formula Rat and Mouse Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.
63. National Toxicology Program (NTP) (1988) Toxicology and Carcinogenesis Studies of Nitrofurantoin in F344/N Rats and B6C3F<sub>1</sub> Mice. NTP Technical Report No. 341. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health (in preparation).
64. Nissim, J.A. (1957) Increased pituitary gonadotropin activity after degeneration of seminiferous tubules produced by nitrofurazone. *Lancet* 1:304-305.
65. Olive, P.L. (1979) Inhibition of DNA synthesis by nitroheterocycles. II. Mechanisms of cytotoxicity. *Br. J. Cancer* 40:94-104.
66. Olive, P.L. (1981) Correlation between the half-wave reduction potentials of nitroheterocycles and their mutagenicity in Chinese hamster V79 spheroids. *Mutat. Res.* 82:137-145.
67. Olive, P.L.; Durand, R.E. (1978) Activation of radiosensitizers by hypoxic cells. *Br. J. Cancer* 37(Suppl. III):124-128.
68. Olive, P.L.; McCalla, D.R. (1975) Damage to mammalian cell DNA by nitrofurans. *Cancer Res.* 35:781-784.
69. Paul, H.E.; Ells, V.R.; Kopko, F.; Bender, R.C. (1960) Metabolic degradation of the nitrofurans. *J. Med. Pharm. Chem.* 2:563-584.
70. Peterson, F.J.; Mason, R.P.; Hovsepian, J.; Holtzman, J.L. (1979) Oxygen-sensitive and -insensitive nitroreduction by *Escherichia coli* and rat hepatic microsomes. *J. Biol. Chem.* 254:4009-4014.
71. Physicians' Desk Reference (PDR) (1984) 38th ed. Oradell, NJ: Medical Economics Company Inc.
72. Price, C.; George, J.; Marr, M. (1985) Teratologic Evaluation of Nitrofurazone Administered to CD-1 Mice on Gestational Days 6-15. National Toxicology Program/Research Triangle Institute Report NTP-85-335.
73. Prior, J.T.; Ferguson, J.H. (1950) Cytotoxic effects of a nitrofurantoin on the rat testes. *Cancer* 3:1062-1072.
74. Rosenkranz, H.S.; Speck, W.T. (1976) Activation of nitrofurantoin to a mutagen by rat liver nitroreductase. *Biochem. Pharmacol.* 25:1555-1556.
75. Sadtler Pharmaceutical Spectra, IR No. R448. Philadelphia: Sadtler Research Laboratories.
76. Sadtler Standard Spectra, NMR No. 6416M. Philadelphia: Sadtler Research Laboratories.
77. Shipley, E.R.; Dodd, M.C. (1947) Clinical observations on furacin soluble dressing in the treatment of surface infections. *Surg. Gynecol. Obstet.* 84:366-372.
78. Sugimura, T.; Sato, S.; Nagao, M.; Yahagi, T.; Matsushima, T.; Seino, Y.; Takeuchi, M.; Kawachi, T. (1976) Overlapping of carcinogens and mutagens. Magee, P.N.; et al., Eds.: *Fundamentals in Cancer Prevention*. Tokyo: University of Tokyo Press, pp. 191-215.
79. Takizawa, H.; Hozumi, M.; Sugimura, T.; Bryan, G.T. (1975) Correlation between the carcinogenicities of nitrofurantoin derivatives and their destructive actions on sebaceous glands in mouse skin. *J. Natl. Cancer Inst.* 54:487-489.
80. Tanooka, H. (1977) Development and applications of *Bacillus subtilis* test systems for mutagens, involving DNA-repair deficiency and suppressible auxotrophic mutations. *Mutat. Res.* 42:19-31.
81. Tarone, R.E. (1975) Tests for trend in life table analysis. *Biometrika* 62:679-682.

## V. REFERENCES

---

82. Tatsumi, K.; Ou, T.; Yoshimura, H.; Tsukamoto, H. (1971) Metabolism of drugs. LXXIII. The metabolic fate of nitrofurans derivatives. (1) Studies on the absorption and excretion. *Chem. Pharm. Bull.* 19:330-334.
83. Tatsumi, K.; Yamaguchi, T.; Yoshimura, H. (1973) Metabolism of Drugs. LXXX. The metabolic fate of nitrofurans derivatives. (3). Studies on enzymes in small intestinal mucosa of rat catalyzing degradation of nitrofurans derivatives. *Chem. Pharm. Bull.* 21:622-628.
84. Tatsumi, K.; Kitamura, S.; Yoshimura, H. (1977) Binding of nitrofurans derivatives to nucleic acids and protein. *Chem. Pharm. Bull.* 25:2948-2952.
85. Tennent, B.; Beamer, W. (1986) Ovarian tumors not induced by irradiation and gonadotropins in hypogonadal (hpg) mice. *Biol. Reprod.* 34:751-760.
86. Tonomura, A.; Sasaki, M.S. (1973) Chromosome aberrations and DNA repair synthesis in cultured human cells exposed to nitrofurans. *Jpn. J. Genet.* 48:291-294.
87. Toole, J.F.; Parrish, M.L. (1973) Nitrofurantoin polyneuropathy. *Neurology* 23:554-559.
88. Van Zwieten, M. (1984) The Rat as Animal Model in Breast Cancer Research. The Netherlands: Martinus Nijhoff Publishers, pp. 135-158.
89. Yahagi, T.; Nagao, M.; Hara, K.; Matsushima, T.; Sugimura, T.; Bryan, G.T. (1974) Relationships between the carcinogenic and mutagenic or DNA-modifying effects of nitrofurans derivatives, including 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide, a food additive. *Cancer Res.* 34:2266-2273.
90. Yamasaki, K.; Inui, S. (1985) Lesions of articular, sternal and growth plate cartilage in rats. *Vet. Pathol.* 22:46-50.
91. Yeung, T.-C.; Sudlow, G.; Koch, R.L.; Goldman, P. (1983) Reduction of nitroheterocyclic compounds by mammalian tissues *in vivo*. *Biochem. Pharmacol.* 32:2249-2253.
92. Zeiger, E.; Anderson, B.; Haworth, S.; Lawlor, T.; Mortelmans, K.; Speck, W. (1987) Salmonella mutagenicity tests. III. Results from the testing of 255 chemicals. *Environ. Mutagen.* 9(Suppl. 9):1-110.

## APPENDIX A

### SUMMARY OF LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	PAGE	
TABLE A1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	71
TABLE A2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	74
TABLE A3	ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	80
TABLE A4a	HISTORICAL INCIDENCE OF MESOTHELIOMAS IN MALE F344/N RATS RECEIVING NO TREATMENT	84
TABLE A4b	HISTORICAL INCIDENCE OF INTEGUMENTARY SYSTEM TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT	84
TABLE A4c	HISTORICAL INCIDENCE OF PREPUTIAL GLAND TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT	85
TABLE A4d	HISTORICAL INCIDENCE OF TESTICULAR INTERSTITIAL CELL TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT	85
TABLE A4e	HISTORICAL INCIDENCE OF LEUKEMIA IN MALE F344/N RATS RECEIVING NO TREATMENT	86
TABLE A5	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	87





**TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*Skin	(50)	(50)	(50)
Papilloma, NOS		1 (2%)	
Trichoepithelioma			1 (2%)
Sebaceous adenoma			4 (8%)
*Subcutaneous tissue	(50)	(50)	(50)
Fibroma	3 (6%)	4 (8%)	6 (12%)
Fibrosarcoma	1 (2%)	2 (4%)	1 (2%)
Fibrous histiocytoma, malignant	1 (2%)		
Neurilemoma, malignant			1 (2%)
<b>RESPIRATORY SYSTEM</b>			
#Lung	(50)	(46)	(50)
Alveolar/bronchiolar carcinoma		3 (7%)	
<b>HEMATOPOIETIC SYSTEM</b>			
*Multiple organs	(50)	(50)	(50)
Leukemia, mononuclear cell	21 (42%)	23 (46%)	6 (12%)
#Spleen	(48)	(46)	(50)
Sarcoma, NOS	1 (2%)		
#Thymus	(29)	(28)	(35)
Thymoma, benign			1 (3%)
<b>CIRCULATORY SYSTEM</b>			
#Spleen	(48)	(46)	(50)
Hemangioma	1 (2%)		
Hemangiosarcoma			1 (2%)
<b>DIGESTIVE SYSTEM</b>			
*Intestinal tract	(50)	(50)	(50)
Sarcoma, NOS		1 (2%)	
#Liver	(50)	(49)	(50)
Neoplastic nodule	6 (12%)	4 (8%)	3 (6%)
Hepatocellular carcinoma	1 (2%)		
Fibrosarcoma, metastatic	1 (2%)		
#Pancreas	(48)	(49)	(49)
Adenoma, NOS	1 (2%)		
#Jejunum	(50)	(50)	(49)
Leiomyoma	1 (2%)		
Leiomyosarcoma	1 (2%)		
#Ileum	(50)	(50)	(49)
Mucinous adenocarcinoma	1 (2%)		
<b>URINARY SYSTEM</b>			
#Kidney	(50)	(50)	(50)
Tubular cell adenocarcinoma			1 (2%)
Nephroblastoma			1 (2%)
#Kidney/cortex	(50)	(50)	(50)
Lipoma		1 (2%)	

TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR  
FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>ENDOCRINE SYSTEM</b>			
#Anterior pituitary	(48)	(49)	(45)
Adenoma, NOS	11 (23%)	7 (14%)	8 (18%)
#Adrenal	(50)	(50)	(50)
Cortical adenoma	1 (2%)		
#Adrenal medulla	(50)	(50)	(50)
Pheochromocytoma	12 (24%)	15 (30%)	12 (24%)
Pheochromocytoma, malignant	2 (4%)	1 (2%)	2 (4%)
#Thyroid	(49)	(49)	(50)
Follicular cell carcinoma	1 (2%)	1 (2%)	1 (2%)
C-cell adenoma	11 (22%)	7 (14%)	8 (16%)
#Parathyroid	(38)	(38)	(39)
Adenoma, NOS			1 (3%)
#Pancreatic islets	(48)	(49)	(49)
Islet cell adenoma		1 (2%)	
<b>REPRODUCTIVE SYSTEM</b>			
*Mammary gland	(50)	(50)	(50)
Adenocarcinoma, NOS			2 (4%)
Fibroadenoma	2 (4%)	1 (2%)	1 (2%)
*Preputial gland	(50)	(50)	(50)
Carcinoma, NOS	1 (2%)	8 (16%)	5 (10%)
Adenoma, NOS	8 (16%)	8 (16%)	2 (4%)
#Testis	(50)	(50)	(50)
Interstitial cell tumor	45 (90%)	30 (60%)	28 (56%)
<b>NERVOUS SYSTEM</b>			
#Brain	(50)	(50)	(50)
Astrocytoma		1 (2%)	
<b>SPECIAL SENSE ORGANS</b>			
*Zymbal gland	(50)	(50)	(50)
Squamous cell carcinoma	1 (2%)	2 (4%)	1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>			
*Vertebra	(50)	(50)	(50)
Chordoma		1 (2%)	
<b>BODY CAVITIES</b>			
*Mesentery	(50)	(50)	(50)
Fibrosarcoma	1 (2%)		
*Tunica vaginalis	(50)	(50)	(50)
Mesothelioma, NOS		6 (12%)	
Mesothelioma, malignant		1 (2%)	2 (4%)
<b>ALL OTHER SYSTEMS</b>			
*Multiple organs	(50)	(50)	(50)
Fibrosarcoma			1 (2%)
Fibrous histiocytoma, metastatic	1 (2%)		
Mesothelioma, metastatic		1 (2%)	2 (4%)
Osteosarcoma, metastatic			1 (2%)
Shoulder			
Osteosarcoma			1

**TABLE A1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>ANIMAL DISPOSITION SUMMARY</b>			
Animals initially in study	50	50	50
Natural death	2	1	3
Moribund sacrifice	15	19	27
Terminal sacrifice	33	30	20
<b>TUMOR SUMMARY</b>			
Total animals with primary tumors**	49	47	46
Total primary tumors	135	129	101
Total animals with benign tumors	48	40	40
Total benign tumors	96	75	72
Total animals with malignant tumors	27	34	21
Total malignant tumors	33	44	26
Total animals with secondary tumors##	2	1	3
Total secondary tumors	2	1	3
Total animals with tumors uncertain-- benign or malignant	6	10	3
Total uncertain tumors	6	10	3

\* Number of animals receiving complete necropsy examinations; all gross lesions including masses examined microscopically.

\*\* Primary tumors: all tumors except secondary tumors

# Number of animals examined microscopically at this site

## Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ















TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Control	310 ppm	620 ppm
<b>Skin: Sebaceous Adenoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	4/50 (8%)
Adjusted Rates (b)	0.0%	0.0%	15.2%
Terminal Rates (c)	0/33 (0%)	0/30 (0%)	2/20 (10%)
Week of First Observation			69
Life Table Tests (d)	P=0.006	(e)	P=0.028
Incidental Tumor Tests (d)	P=0.015	(e)	P=0.067
Cochran-Armitage Trend Test (d)	P=0.015		
Fisher Exact Test (d)		(e)	P=0.059
<b>Skin: Trichoepithelioma or Sebaceous Adenoma</b>			
Overall Rates (a)	0/50 (0%)	0/50 (0%)	5/50 (10%)
Adjusted Rates (b)	0.0%	0.0%	17.4%
Terminal Rates (c)	0/33 (0%)	0/30 (0%)	2/20 (10%)
Week of First Observation			69
Life Table Tests (d)	P=0.002	(e)	P=0.014
Incidental Tumor Tests (d)	P=0.009	(e)	P=0.044
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Test (d)		(e)	P=0.028
<b>Subcutaneous Tissue: Fibroma</b>			
Overall Rates (a)	3/50 (6%)	4/50 (8%)	6/50 (12%)
Adjusted Rates (b)	7.4%	12.4%	23.4%
Terminal Rates (c)	1/33 (3%)	3/30 (10%)	3/20 (15%)
Week of First Observation	87	97	87
Life Table Tests (d)	P=0.069	P=0.465	P=0.106
Incidental Tumor Tests (d)	P=0.160	P=0.433	P=0.231
Cochran-Armitage Trend Test (d)	P=0.187		
Fisher Exact Test (d)		P=0.500	P=0.243
<b>Subcutaneous Tissue: Fibroma or Fibrosarcoma</b>			
Overall Rates (a)	4/50 (8%)	6/50 (12%)	7/50 (14%)
Adjusted Rates (b)	9.4%	16.9%	26.1%
Terminal Rates (c)	1/33 (3%)	3/30 (10%)	3/20 (15%)
Week of First Observation	84	78	87
Life Table Tests (d)	P=0.079	P=0.339	P=0.113
Incidental Tumor Tests (d)	P=0.256	P=0.340	P=0.287
Cochran-Armitage Trend Test (d)	P=0.215		
Fisher Exact Test (d)		P=0.370	P=0.262
<b>Lung: Alveolar/Bronchiolar Carcinoma</b>			
Overall Rates (a)	0/50 (0%)	3/46 (7%)	0/50 (0%)
Adjusted Rates (b)	0.0%	11.1%	0.0%
Terminal Rates (c)	0/33 (0%)	3/27 (11%)	0/20 (0%)
Week of First Observation		104	
Life Table Tests (d)	P=0.504	P=0.087	(e)
Incidental Tumor Tests (d)	P=0.504	P=0.087	(e)
Cochran-Armitage Trend Test (d)	P=0.638		
Fisher Exact Test (d)		P=0.106	(e)
<b>Hematopoietic System: Mononuclear Cell Leukemia</b>			
Overall Rates (a)	21/50 (42%)	23/50 (46%)	6/50 (12%)
Adjusted Rates (b)	50.8%	55.5%	21.2%
Terminal Rates (c)	13/33 (39%)	12/30 (40%)	1/20 (5%)
Week of First Observation	88	88	92
Life Table Tests (d)	P=0.068N	P=0.334	P=0.041N
Incidental Tumor Tests (d)	P=0.001N	P=0.388	P=0.001N
Cochran-Armitage Trend Test (d)	P=0.001N		
Fisher Exact Test (d)		P=0.420	P<0.001N

**TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Control	310 ppm	620 ppm
<b>Liver: Neoplastic Nodule</b>			
Overall Rates (a)	6/50 (12%)	4/49 (8%)	3/50 (6%)
Adjusted Rates (b)	15.3%	11.5%	14.3%
Terminal Rates (c)	3/33 (9%)	2/30 (7%)	2/20 (10%)
Week of First Observation	87	94	103
Life Table Tests (d)	P=0.397N	P=0.411N	P=0.481N
Incidental Tumor Tests (d)	P=0.221N	P=0.424N	P=0.299N
Cochran-Armitage Trend Test (d)	P=0.188N		
Fisher Exact Test (d)		P=0.384N	P=0.244N
<b>Liver: Neoplastic Nodule or Hepatocellular Carcinoma</b>			
Overall Rates (a)	7/50 (14%)	4/49 (8%)	3/50 (6%)
Adjusted Rates (b)	18.1%	11.5%	14.3%
Terminal Rates (c)	4/33 (12%)	2/30 (7%)	2/20 (10%)
Week of First Observation	87	94	103
Life Table Tests (d)	P=0.292N	P=0.305N	P=0.383N
Incidental Tumor Tests (d)	P=0.150N	P=0.312N	P=0.224N
Cochran-Armitage Trend Test (d)	P=0.115N		
Fisher Exact Test (d)		P=0.274N	P=0.159N
<b>Anterior Pituitary Gland: Adenoma</b>			
Overall Rates (a)	11/48 (23%)	7/49 (14%)	8/45 (18%)
Adjusted Rates (b)	30.0%	23.3%	28.0%
Terminal Rates (c)	7/32 (22%)	7/30 (23%)	3/19 (16%)
Week of First Observation	96	104	79
Life Table Tests (d)	P=0.472	P=0.266N	P=0.483
Incidental Tumor Tests (d)	P=0.443N	P=0.200N	P=0.443N
Cochran-Armitage Trend Test (d)	P=0.300N		
Fisher Exact Test (d)		P=0.203N	P=0.362N
<b>Adrenal Gland: Pheochromocytoma</b>			
Overall Rates (a)	12/50 (24%)	15/50 (30%)	12/50 (24%)
Adjusted Rates (b)	36.4%	42.0%	52.9%
Terminal Rates (c)	12/33 (36%)	10/30 (33%)	10/20 (50%)
Week of First Observation	104	95	86
Life Table Tests (d)	P=0.094	P=0.236	P=0.110
Incidental Tumor Tests (d)	P=0.175	P=0.299	P=0.142
Cochran-Armitage Trend Test (d)	P=0.545		
Fisher Exact Test (d)		P=0.326	P=0.592N
<b>Adrenal Gland: Pheochromocytoma or Malignant Pheochromocytoma</b>			
Overall Rates (a)	14/50 (28%)	15/50 (30%)	14/50 (28%)
Adjusted Rates (b)	41.1%	42.0%	59.1%
Terminal Rates (c)	13/33 (39%)	10/30 (33%)	11/20 (55%)
Week of First Observation	102	95	86
Life Table Tests (d)	P=0.080	P=0.391	P=0.085
Incidental Tumor Tests (d)	P=0.174	P=0.486	P=0.147
Cochran-Armitage Trend Test (d)	P=0.544		
Fisher Exact Test (d)		P=0.500	P=0.588N
<b>Thyroid Gland: C-Cell Adenoma</b>			
Overall Rates (a)	11/49 (22%)	7/49 (14%)	8/50 (16%)
Adjusted Rates (b)	30.0%	20.0%	29.6%
Terminal Rates (c)	8/33 (24%)	4/30 (13%)	4/20 (20%)
Week of First Observation	95	92	75
Life Table Tests (d)	P=0.486	P=0.281N	P=0.484
Incidental Tumor Tests (d)	P=0.340N	P=0.218N	P=0.434N
Cochran-Armitage Trend Test (d)	P=0.240N		
Fisher Exact Test (d)		P=0.217N	P=0.288N

**TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Control	310 ppm	620 ppm
<b>Preputial Gland: Adenoma</b>			
Overall Rates (a)	8/50 (16%)	8/50 (16%)	2/50 (4%)
Adjusted Rates (b)	22.3%	23.7%	7.3%
Terminal Rates (c)	6/33 (18%)	6/30 (20%)	1/20 (5%)
Week of First Observation	95	67	75
Life Table Tests (d)	P=0.169N	P=0.539	P=0.170N
Incidental Tumor Tests (d)	P=0.075N	P=0.592N	P=0.079N
Cochran-Armitage Trend Test (d)	P=0.045N		
Fisher Exact Test (d)		P=0.607N	P=0.046N
<b>Preputial Gland: Carcinoma</b>			
Overall Rates (a)	1/50 (2%)	8/50 (16%)	5/50 (10%)
Adjusted Rates (b)	3.0%	22.2%	16.0%
Terminal Rates (c)	1/33 (3%)	5/30 (17%)	2/20 (10%)
Week of First Observation	104	60	42
Life Table Tests (d)	P=0.041	P=0.016	P=0.053
Incidental Tumor Tests (d)	P=0.171	P=0.018	P=0.166
Cochran-Armitage Trend Test (d)	P=0.114		
Fisher Exact Test (d)		P=0.015	P=0.102
<b>Preputial Gland: Adenoma or Carcinoma</b>			
Overall Rates (a)	9/50 (18%)	16/50 (32%)	7/50 (14%)
Adjusted Rates (b)	25.2%	43.6%	22.5%
Terminal Rates (c)	7/33 (21%)	11/30 (37%)	3/20 (15%)
Week of First Observation	95	60	42
Life Table Tests (d)	P=0.356	P=0.062	P=0.496
Incidental Tumor Tests (d)	P=0.366N	P=0.086	P=0.379N
Cochran-Armitage Trend Test (d)	P=0.357N		
Fisher Exact Test (d)		P=0.083	P=0.393N
<b>Testis: Interstitial Cell Tumor</b>			
Overall Rates (a)	45/50 (90%)	30/50 (60%)	28/50 (56%)
Adjusted Rates (b)	100.0%	74.4%	86.8%
Terminal Rates (c)	33/33 (100%)	20/30 (67%)	16/20 (80%)
Week of First Observation	75	67	75
Life Table Tests (d)	P=0.352N	P=0.022N	P=0.495N
Incidental Tumor Tests (d)	P=0.005N	P<0.001N	P=0.007N
Cochran-Armitage Trend Test (d)	P<0.001N		
Fisher Exact Test (d)		P<0.001N	P<0.001N
<b>All Sites: Mesothelioma</b>			
Overall Rates (a)	0/50 (0%)	7/50 (14%)	2/50 (4%)
Adjusted Rates (b)	0.0%	17.4%	6.6%
Terminal Rates (c)	0/33 (0%)	2/30 (7%)	0/20 (0%)
Week of First Observation		67	93
Life Table Tests (d)	P=0.149	P=0.010	P=0.174
Incidental Tumor Tests (d)	P=0.363	P=0.014	P=0.307
Cochran-Armitage Trend Test (d)	P=0.264		
Fisher Exact Test (d)		P=0.006	P=0.247
<b>All Sites: Benign Tumors</b>			
Overall Rates (a)	48/50 (96%)	40/50 (80%)	40/50 (80%)
Adjusted Rates (b)	100.0%	95.2%	100.0%
Terminal Rates (c)	33/33 (100%)	28/30 (93%)	20/20 (100%)
Week of First Observation	59	67	69
Life Table Tests (d)	P=0.050	P=0.249N	P=0.054
Incidental Tumor Tests (d)	P=0.262N	P=0.012N	P=0.258N
Cochran-Armitage Trend Test (d)	P=0.017N		
Fisher Exact Test (d)		P=0.014N	P=0.014N

**TABLE A3. ANALYSIS OF PRIMARY TUMORS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Control	310 ppm	620 ppm
<b>All Sites: Malignant Tumors</b>			
Overall Rates (a)	27/50 (54%)	34/50 (68%)	21/50 (42%)
Adjusted Rates (b)	59.6%	73.7%	54.6%
Terminal Rates (c)	15/33 (45%)	18/30 (60%)	5/20 (25%)
Week of First Observation	66	60	42
Life Table Tests (d)	P=0.285	P=0.112	P=0.391
Incidental Tumor Tests (d)	P=0.055N	P=0.138	P=0.057N
Cochran-Armitage Trend Test (d)	P=0.135N		
Fisher Exact Test (d)		P=0.109	P=0.159N
<b>All Sites: All Tumors</b>			
Overall Rates (a)	49/50 (98%)	47/50 (94%)	46/50 (92%)
Adjusted Rates (b)	100.0%	97.9%	100.0%
Terminal Rates (c)	33/33 (100%)	29/30 (97%)	20/20 (100%)
Week of First Observation	59	60	42
Life Table Tests (d)	P=0.008	P=0.469	P=0.010
Incidental Tumor Tests (d)	P=0.390N	P=0.265N	P=0.545N
Cochran-Armitage Trend Test (d)	P=0.133N		
Fisher Exact Test (d)		P=0.309N	P=0.182N

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) No P value is reported because no tumors were observed in the dosed and control groups.

**TABLE A4a. HISTORICAL INCIDENCE OF MESOTHELIOMAS IN MALE F344/N RATS RECEIVING NO TREATMENT (a,b)**

Study	Incidence in Controls	
<b>Historical Incidence at Physiological Research Laboratories</b>		
Ephedrine sulfate		3/50
Phenylephrine hydrochloride		2/50
Oxytetracycline hydrochloride		0/50
TOTAL		5/150 (3.3%)
SD (c)		3.06%
Range (d)		
High		3/50
Low		0/50
<b>Overall Historical Incidence</b>		
TOTAL		52/1,937 (2.7%)
SD (c)		2.39%
Range (d)		
High		5/50
Low		0/50

(a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Includes mesotheliomas designated as NOS, benign, or malignant  
 (c) Standard deviation  
 (d) Range and SD are presented for groups of 35 or more animals.

**TABLE A4b. HISTORICAL INCIDENCE OF INTEGUMENTARY SYSTEM TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls		
	Benign	Malignant	Benign or Malignant
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	1/50	0/50	1/50
Phenylephrine hydrochloride	1/50	0/50	1/50
Oxytetracycline hydrochloride	0/50	0/50	0/50
TOTAL	(b) 2/150 (1.3%)	0/150 (0.0%)	(b) 2/150 (1.3%)
SD (c)	1.15%	0.00%	1.15%
Range (d)			
High	1/50	0/50	1/50
Low	0/50	0/50	0/50
<b>Overall Historical Incidence</b>			
TOTAL	(e) 18/1,937 (0.9%)	(f) 14/1,937 (0.7%)	(e,f) 32/1,937 (1.7%)
SD (c)	1.45%	1.19%	1.90%
Range (d)			
High	3/50	2/50	4/50
Low	0/50	0/50	0/50

(a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Basal cell tumors  
 (c) Standard deviation  
 (d) Range and SD are presented for groups of 35 or more animals.  
 (e) Includes nine basal cell tumors, five trichoepitheliomas, one adnexal adenoma, and three sebaceous adenomas  
 (f) Basal cell carcinomas; no other malignant sebaceous gland tumors have been observed.

**TABLE A4c. HISTORICAL INCIDENCE OF PREPUTIAL GLAND TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

Study	No. Examined	No. of Tumors	Diagnosis
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	50	2	Adenoma, NOS
Phenylephrine hydrochloride	50	2	Carcinoma, NOS
Oxytetracycline hydrochloride	50	1	Adenocarcinoma, NOS
TOTAL	150	5 (3.3%)	
<b>Overall Historical Incidence</b>			
		55	Adenoma, NOS
		1	Papillary adenoma
		1	Cystadenoma
		55	Carcinoma, NOS
		2	Squamous cell carcinoma
		8	Adenocarcinoma, NOS
		1	Sebaceous adenocarcinoma
TOTAL	1,937	123 (6.4%)	

(a) Data as of August 7, 1986, for studies of at least 104 weeks; greatest incidence observed in any untreated control group is 9/50.

**TABLE A4d. HISTORICAL INCIDENCE OF TESTICULAR INTERSTITIAL CELL TUMORS IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls
<b>Historical Incidence at Physiological Research Laboratories</b>	
Ephedrine sulfate	45/50
Phenylephrine hydrochloride	47/50
Oxytetracycline hydrochloride	41/50
TOTAL	133/150 (88.7%)
SD (b)	6.11%
Range (c)	
High	47/50
Low	41/50
<b>Overall Historical Incidence</b>	
TOTAL	1,681/1,909 (88.1%)
SD (b)	7.32%
Range (c)	
High	49/50
Low	35/49

(a) Data as of August 7, 1986, for studies of at least 104 weeks; no malignant tumors have been observed.

(b) Standard deviation

(c) Range and SD are presented for groups of 35 or more animals.

**TABLE A4e. HISTORICAL INCIDENCE OF LEUKEMIA IN MALE F344/N RATS RECEIVING NO TREATMENT (a)**

<b>Study</b>	<b>Incidence in Controls</b>
<b>Historical Incidence at Physiological Research Laboratories</b>	
Ephedrine sulfate	25/50
Phenylephrine hydrochloride	24/50
Oxytetracycline hydrochloride	22/50
TOTAL	71/150 (47.3%)
SD (b)	3.06%
Range (c)	
High	25/50
Low	22/50
<b>Overall Historical Incidence</b>	
TOTAL	586/1,937 (30.3%)
SD (b)	11.97%
Range (c)	
High	30/50
Low	5/50

(a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.



TABLE A5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*Skin	(50)	(50)	(50)
Epidermal inclusion cyst	2 (4%)	3 (6%)	2 (4%)
<b>RESPIRATORY SYSTEM</b>			
*Nasal cavity	(50)	(50)	(50)
Inflammation, NOS	8 (16%)	4 (8%)	14 (28%)
Inflammation, suppurative		1 (2%)	
Infection, fungal		1 (2%)	
Foreign material, NOS		2 (4%)	
*Nasal turbinate	(50)	(50)	(50)
Exostosis			1 (2%)
#Tracheal submucosa	(49)	(49)	(49)
Cyst, NOS			1 (2%)
#Tracheal cartilage	(49)	(49)	(49)
Degeneration, NOS			1 (2%)
#Lung	(50)	(46)	(50)
Congestion, NOS	1 (2%)		1 (2%)
Inflammation, NOS	3 (6%)	1 (2%)	5 (10%)
Hyperplasia, alveolar epithelium		2 (4%)	1 (2%)
#Lung/alveoli	(50)	(46)	(50)
Edema, NOS	1 (2%)		1 (2%)
Histiocytosis	1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>			
#Bone marrow	(50)	(50)	(50)
Hypoplasia, NOS	2 (4%)	1 (2%)	5 (10%)
Hyperplasia, NOS	12 (24%)	18 (36%)	6 (12%)
Hyperplasia, reticulum cell	1 (2%)		1 (2%)
#Spleen	(48)	(46)	(50)
Inflammation, acute	1 (2%)		
Fibrosis	1 (2%)		
Scar	2 (4%)	5 (11%)	5 (10%)
Hematopoiesis	1 (2%)		
#Lymph node	(50)	(50)	(50)
Cyst, NOS		1 (2%)	4 (8%)
Hemorrhage	2 (4%)	2 (4%)	1 (2%)
Granulation tissue	1 (2%)		
Hyperplasia, NOS	2 (4%)		2 (4%)
Histiocytosis			2 (4%)
Plasmacytosis		1 (2%)	
*Intestinal tract	(50)	(50)	(50)
Hyperplasia, lymphoid		1 (2%)	
#Glandular stomach	(50)	(50)	(50)
Hyperplasia, lymphoid	1 (2%)	2 (4%)	
#Thymus	(29)	(28)	(35)
Cyst, NOS	1 (3%)		
Hyperplasia, lymphoid			1 (3%)
<b>CIRCULATORY SYSTEM</b>			
#Heart/atrium	(50)	(50)	(50)
Thrombosis, NOS	1 (2%)		
#Myocardium	(50)	(50)	(50)
Degeneration, NOS	49 (98%)	47 (94%)	50 (100%)

TABLE A5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>CIRCULATORY SYSTEM (Continued)</b>			
*Artery	(50)	(50)	(50)
Periarteritis	1 (2%)	2 (4%)	3 (6%)
<b>DIGESTIVE SYSTEM</b>			
#Salivary gland	(49)	(48)	(48)
Cyst, NOS	1 (2%)		
Nuclear alteration	2 (4%)	3 (6%)	2 (4%)
Atrophy, focal	4 (8%)		3 (6%)
Hyperplasia, focal			1 (2%)
Metaplasia, squamous			1 (2%)
#Liver	(50)	(49)	(50)
Accessory structure	3 (6%)	4 (8%)	3 (6%)
Inflammation, NOS		1 (2%)	2 (4%)
Granuloma, NOS	1 (2%)	1 (2%)	2 (4%)
Cystic degeneration	1 (2%)	1 (2%)	1 (2%)
Necrosis, NOS	1 (2%)	1 (2%)	2 (4%)
Angiectasis			1 (2%)
#Intrahepatic bile duct	(50)	(49)	(50)
Hyperplasia, NOS	47 (94%)	47 (96%)	46 (92%)
#Liver/hepatocytes	(50)	(49)	(50)
Degeneration, NOS	1 (2%)		3 (6%)
Focal cellular change	35 (70%)	34 (69%)	29 (58%)
Nodular regeneration	2 (4%)	1 (2%)	1 (2%)
#Pancreas	(48)	(49)	(49)
Atrophy, focal	30 (63%)	30 (61%)	22 (45%)
Atrophy, diffuse	1 (2%)		1 (2%)
#Glandular stomach	(50)	(50)	(50)
Cyst, NOS	8 (16%)	12 (24%)	6 (12%)
Erosion			1 (2%)
#Forestomach	(50)	(50)	(50)
Ulcer, NOS	1 (2%)		
#Colon	(49)	(50)	(47)
Inflammation, chronic focal			1 (2%)
<b>URINARY SYSTEM</b>			
#Kidney	(50)	(50)	(50)
Nephropathy	48 (96%)	50 (100%)	47 (94%)
#Kidney/cortex	(50)	(50)	(50)
Cyst, NOS		3 (6%)	2 (4%)
#Kidney/tubule	(50)	(50)	(50)
Hyperplasia, focal	1 (2%)		1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#Pituitary intermedia	(48)	(49)	(45)
Hyperplasia, focal	1 (2%)		
#Anterior pituitary	(48)	(49)	(45)
Hemorrhage	1 (2%)		
Hyperplasia, focal	6 (13%)	13 (27%)	10 (22%)
Hyperplasia, cystic	3 (6%)	2 (4%)	
Angiectasis		1 (2%)	
#Adrenal cortex	(50)	(50)	(50)
Accessory structure	1 (2%)	1 (2%)	1 (2%)
Cytoplasmic vacuolization	4 (8%)	7 (14%)	4 (8%)
Hypertrophy, focal	6 (12%)	4 (8%)	3 (6%)
Hyperplasia, focal	16 (32%)	21 (42%)	10 (20%)
#Adrenal medulla	(50)	(50)	(50)
Hyperplasia, NOS	1 (2%)		
Hyperplasia, focal	10 (20%)	9 (18%)	4 (8%)

**TABLE A5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>ENDOCRINE SYSTEM (Continued)</b>			
#Thyroid	(49)	(49)	(50)
Follicular cyst, NOS	2 (4%)		2 (4%)
Hemorrhage			1 (2%)
Inflammation, chronic necrotizing			1 (2%)
Hyperplasia, C-cell	4 (8%)	3 (6%)	5 (10%)
#Thyroid follicle	(49)	(49)	(50)
Mineralization	1 (2%)		
Degeneration, NOS		1 (2%)	1 (2%)
Necrosis, NOS		1 (2%)	
Atrophy, NOS			1 (2%)
Hyperplasia, cystic		1 (2%)	
#Parathyroid	(38)	(38)	(39)
Hyperplasia, NOS		2 (5%)	1 (3%)
#Pancreatic islets	(48)	(49)	(49)
Hypertrophy, NOS	1 (2%)	1 (2%)	
Hyperplasia, NOS	2 (4%)	1 (2%)	
<b>REPRODUCTIVE SYSTEM</b>			
*Mammary gland	(50)	(50)	(50)
Hyperplasia, cystic	7 (14%)	8 (16%)	5 (10%)
*Preputial gland	(50)	(50)	(50)
Inflammation, NOS	37 (74%)	37 (74%)	38 (76%)
Hyperplasia, NOS		6 (12%)	1 (2%)
#Prostate	(49)	(49)	(50)
Cyst, NOS			1 (2%)
Inflammation, NOS	32 (65%)	30 (61%)	30 (60%)
Inflammation, acute/chronic	1 (2%)		
Inflammation, chronic			1 (2%)
Inflammation, chronic suppurative			1 (2%)
Atrophy, NOS	1 (2%)		
Hyperplasia, cystic	1 (2%)		2 (4%)
*Seminal vesicle	(50)	(50)	(50)
Dilatation, NOS	1 (2%)	1 (2%)	
Cyst, NOS	1 (2%)		
Hemorrhage	1 (2%)		
Inflammation, chronic suppurative	1 (2%)		
Atrophy, NOS	8 (16%)		3 (6%)
Hyperplasia, epithelial		4 (8%)	
Hyperplasia, cystic		1 (2%)	
#Testis	(50)	(50)	(50)
Degeneration, NOS	12 (24%)	49 (98%)	47 (94%)
Hyperplasia, interstitial cell	2 (4%)	2 (4%)	7 (14%)
*Epididymis	(50)	(50)	(50)
Dilatation, NOS		1 (2%)	
Inflammation, chronic	1 (2%)		
Basophilic cyto change	1 (2%)		
Atrophy, NOS	15 (30%)	14 (28%)	18 (36%)
<b>NERVOUS SYSTEM</b>			
#Brain/meninges	(50)	(50)	(50)
Hemorrhage	1 (2%)		1 (2%)
#Cerebral cortex	(50)	(50)	(50)
Atrophy, focal			1 (2%)
#Brain stem	(50)	(50)	(50)
Atrophy, pressure	3 (6%)		4 (8%)
*Spinal cord	(50)	(50)	(50)
Cyst, NOS			1 (2%)
Atrophy, pressure	1 (2%)		1 (2%)

TABLE A5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>NERVOUS SYSTEM (Continued)</b>			
*White matter spinal Degeneration, NOS	(50) 3 (6%)	(50) 6 (12%)	(50) 4 (8%)
<b>SPECIAL SENSE ORGANS</b>			
*Eye	(50)	(50)	(50)
Phthisis bulbi		1 (2%)	1 (2%)
*Eye/crystalline lens	(50)	(50)	(50)
Cataract			1 (2%)
*Nasolacrimal duct	(50)	(50)	(50)
Inflammation, NOS			1 (2%)
*Harderian gland	(50)	(50)	(50)
Lymphocytic inflammatory infiltrate		1 (2%)	
*Ear canal	(50)	(50)	(50)
Hemorrhage			1 (2%)
<b>MUSCULOSKELETAL SYSTEM</b>			
*Bone	(50)	(50)	(50)
Deformity, NOS			1 (2%)
Fibrous osteodystrophy		1 (2%)	
*Maxilla	(50)	(50)	(50)
Exostosis		1 (2%)	
*Vertebra	(50)	(50)	(50)
Exostosis	1 (2%)		
*Joint	(50)	(50)	(50)
Degeneration, NOS		1 (2%)	3 (6%)
*Vertebral joint	(50)	(50)	(50)
Degeneration, NOS	10 (20%)	31 (62%)	23 (46%)
*Sternal synchondrosis	(50)	(50)	(50)
Degeneration, NOS	24 (48%)	26 (52%)	21 (42%)
*Knee joint	(50)	(50)	(50)
Degeneration, NOS	5 (10%)	32 (64%)	48 (96%)
*Intervertebral disc	(50)	(50)	(50)
Prolapse	1 (2%)		1 (2%)
<b>BODY CAVITIES</b>			
*Mesentery	(50)	(50)	(50)
Necrosis, fat	5 (10%)	2 (4%)	1 (2%)
*Tunica vaginalis	(50)	(50)	(50)
Hyperplasia, mesothelial	1 (2%)	1 (2%)	
<b>ALL OTHER SYSTEMS</b>			
*Multiple organs	(50)	(50)	(50)
Mineralization			1 (2%)
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
None			

\* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically.

# Number of animals examined microscopically at this site

## APPENDIX B

### SUMMARY OF LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

		PAGE
TABLE B1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	93
TABLE B2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	96
TABLE B3	ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	102
TABLE B4a	HISTORICAL INCIDENCE OF MAMMARY GLAND TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT	105
TABLE B4b	HISTORICAL INCIDENCE OF LEUKEMIA IN FEMALE F344/N RATS RECEIVING NO TREATMENT	105
TABLE B5	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	106



**TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	49	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	49	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*Skin	(49)	(50)	(50)
Trichoepithelioma			2 (4%)
*Subcutaneous tissue	(49)	(50)	(50)
Fibrosarcoma	1 (2%)		
<b>RESPIRATORY SYSTEM</b>			
#Lung	(48)	(15)	(49)
Alveolar/bronchiolar adenoma	1 (2%)		
Alveolar/bronchiolar carcinoma		1 (7%)	1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>			
*Multiple organs	(49)	(50)	(50)
Leukemia, mononuclear cell	15 (31%)	2 (4%)	2 (4%)
<b>CIRCULATORY SYSTEM</b>			
#Heart/atrium	(48)	(11)	(50)
Neurilemoma, malignant	1 (2%)		
<b>DIGESTIVE SYSTEM</b>			
*Tongue	(49)	(50)	(50)
Squamous cell carcinoma			1 (2%)
#Liver	(49)	(50)	(50)
Neoplastic nodule		2 (4%)	2 (4%)
#Forestomach	(49)	(12)	(50)
Squamous cell papilloma		1 (8%)	
#Duodenum	(49)	(10)	(50)
Leiomyosarcoma		1 (10%)	
<b>URINARY SYSTEM</b>			
None			
<b>ENDOCRINE SYSTEM</b>			
#Pituitary intermedia	(48)	(50)	(48)
Adenoma, NOS	1 (2%)		
#Anterior pituitary	(48)	(50)	(48)
Carcinoma, NOS		4 (8%)	
Adenoma, NOS	18 (38%)	17 (34%)	15 (31%)
#Adrenal	(49)	(50)	(49)
Cortical adenoma	2 (4%)		1 (2%)
#Adrenal medulla	(49)	(50)	(49)
Pheochromocytoma	4 (8%)	1 (2%)	4 (8%)
#Thyroid	(48)	(14)	(49)
C-cell adenoma	6 (13%)	1 (7%)	9 (18%)

TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR  
FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>REPRODUCTIVE SYSTEM</b>			
*Mammary gland	(49)	(50)	(50)
Adenocarcinoma, NOS	1 (2%)		2 (4%)
Fibroadenoma	8 (16%)	36 (72%)	36 (72%)
*Clitoral gland	(49)	(50)	(50)
Carcinoma, NOS	5 (10%)	6 (12%)	
Adenoma, NOS	3 (6%)		7 (14%)
Adenocarcinoma, NOS		1 (2%)	
#Uterus	(49)	(20)	(50)
Endometrial stromal polyp	11 (22%)	9 (45%)	15 (30%)
Endometrial stromal sarcoma		1 (5%)	
Neurilemoma, malignant			2 (4%)
#Cervix uteri	(49)	(20)	(50)
Neurilemoma, malignant	1 (2%)		
#Ovary	(49)	(12)	(50)
Granulosa cell tumor		1 (8%)	
Granulosa cell carcinoma	1 (2%)		
<b>NERVOUS SYSTEM</b>			
#Brain	(48)	(9)	(50)
Astrocytoma			1 (2%)
<b>SPECIAL SENSE ORGANS</b>			
*Zymbal gland	(49)	(50)	(50)
Squamous cell carcinoma	1 (2%)	1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
None			
<b>BODY CAVITIES</b>			
*Mesentery	(49)	(50)	(50)
Neurilemoma, invasive			1 (2%)
<b>ALL OTHER SYSTEMS</b>			
*Multiple organs	(49)	(50)	(50)
Granulosa cell carcinoma, metastatic	1 (2%)		
<b>ANIMAL DISPOSITION SUMMARY</b>			
Animals initially in study	50	50	50
Natural death	3	1	2
Moribund sacrifice	19	12	17
Terminal sacrifice	28	37	31



**TABLE B1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>TUMOR SUMMARY</b>			
Total animals with primary tumors**	44	47	46
Total primary tumors	80	85	100
Total animals with benign tumors	37	40	43
Total benign tumors	54	65	89
Total animals with malignant tumors	23	17	9
Total malignant tumors	26	17	9
Total animals with secondary tumors##	1		1
Total secondary tumors	1		1
Total animals with tumors uncertain-- benign or malignant		3	2
Total uncertain tumors		3	2

\* Number of animals receiving complete necropsy examinations; all gross lesions including masses examined microscopically.

\*\* Primary tumors: all tumors except secondary tumors

# Number of animals examined microscopically at this site

## Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ





**TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE: LOW DOSE**

ANIMAL NUMBER	WEEKS ON STUDY																				
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2	3	4	4	1	3	2	1	5	1	0	1	0	0	0	0	0	0	0	0	0
	9	4	9	7	5	0	3	3	0	7	9	4	2	1	3	4	5	6	7	8	0
	6	6	6	7	7	7	8	8	8	9	0	0	0	0	0	0	0	0	0	0	0
	1	7	7	0	5	6	2	7	7	5	0	1	3	4	4	4	4	4	4	4	4
<b>RESPIRATORY SYSTEM</b>																					
Lungs and bronchi	+	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	
Alveolar/bronchiolar carcinoma																			X		
Trachea	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	-
<b>HEMATOPOIETIC SYSTEM</b>																					
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph nodes	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Thymus	+	+	+	+	-	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
<b>CIRCULATORY SYSTEM</b>																					
Heart	+	+	+	+	+	+	+	+	+	-	-	-	+	-	-	-	-	-	-	-	-
<b>DIGESTIVE SYSTEM</b>																					
Salivary gland	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Neoplastic nodule																				X	
Bile duct	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pancreas	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Esophagus	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	+	+	-
Stomach	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Squamous cell papilloma																					
Small intestine	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Leiomyosarcoma																					
Large intestine	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
<b>URINARY SYSTEM</b>																					
Kidney	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Urinary bladder	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
<b>ENDOCRINE SYSTEM</b>																					
Pituitary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Carcinoma, NOS																			X		
Adenoma, NOS						X						X	X		X	X	X	X	X	X	X
Adrenal	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pheochromocytoma												X									
Thyroid	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	+	+	-
C-cell adenoma																					
Parathyroid	+	+	-	-	-	-	+	+	+	-	-	-	-	-	-	-	-	-	+	+	-
<b>REPRODUCTIVE SYSTEM</b>																					
Mammary gland	+	+	+	+	+	+	+	+	+	N	+	+	N	+	+	+	+	+	+	+	N
Fibroadenoma		X	X			X		X	X												
Preputial/clitoral gland	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Carcinoma, NOS							X					X	X								
Adenocarcinoma, NOS																			X		X
Uterus	+	+	+	+	+	+	+	+	+	-	+	-	-	-	-	-	-	-	+	-	-
Endometrial stromal polyp											X										
Endometrial stromal sarcoma						X															
Ovary	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
Granulosa cell tumor																					
<b>NERVOUS SYSTEM</b>																					
Brain	+	+	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-
<b>SPECIAL SENSE ORGANS</b>																					
Zymbal gland	+	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Squamous cell carcinoma	X																				
<b>ALL OTHER SYSTEMS</b>																					
Multiple organs, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Leukemia, mononuclear cell		X									X										



**TABLE B2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE: HIGH DOSE**

ANIMAL NUMBER	069	057	077	079	088	086	088	088	097	088	052	063	058	081	092	005	077	079	093	051	053	054	055	056	059	061
WEEKS ON STUDY	26	06	04	04	02	06	04	04	08	01	02	03	07	01	01	02	02	03	03	04	04	04	04	04	04	04
<b>INTEGUMENTARY SYSTEM</b>																										
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Trichoepithelioma																										X
<b>RESPIRATORY SYSTEM</b>																										
Lungs and bronchi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Alveolar/bronchiolar carcinoma																										
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>HEMATOPOIETIC SYSTEM</b>																										
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Lymph nodes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+	-	+	+	+	-
<b>CIRCULATORY SYSTEM</b>																										
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>DIGESTIVE SYSTEM</b>																										
Oral cavity	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Squamous cell carcinoma																										
Salivary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Neoplastic nodule																										
Bile duct	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Small intestine	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Large intestine	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>URINARY SYSTEM</b>																										
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>ENDOCRINE SYSTEM</b>																										
Pituitary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenoma, NOS																										
Adrenal	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Cortical adenoma																										
Pheochromocytoma																										
Thyroid	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
C-cell adenoma																										
Parathyroid	-	+	-	+	+	+	+	-	+	-	-	-	-	-	+	-	+	+	+	+	+	+	+	+	+	X
<b>REPRODUCTIVE SYSTEM</b>																										
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Adenocarcinoma, NOS																										
Fibroadenoma		X																								
Preputial/clitoral gland	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Adenoma, NOS																										
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Endometrial stromal polyp																										
Neurilemoma, malignant																										
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
<b>NERVOUS SYSTEM</b>																										
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Astrocytoma																										
<b>BODY CAVITIES</b>																										
Mesentery	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Neurilemoma, invasive																										
<b>ALL OTHER SYSTEMS</b>																										
Multiple organs, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
Leukemia, mononuclear cell																										X



**TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

	Control	310 ppm	620 ppm
<b>Hematopoietic System: Mononuclear Cell Leukemia</b>			
Overall Rates (a)	15/49 (31%)	2/50 (4%)	2/50 (4%)
Adjusted Rates (b)	40.8%	4.5%	6.5%
Terminal Rates (c)	7/28 (25%)	0/37 (0%)	2/31 (6%)
Week of First Observation	87	67	104
Life Table Tests (d)	P<0.001N	P<0.001N	P<0.001N
Incidental Tumor Tests (d)	P<0.001N	P<0.001N	P<0.001N
Cochran-Armitage Trend Test (d)	P<0.001N		
Fisher Exact Test (d)		P<0.001N	P<0.001N
<b>Anterior Pituitary Gland: Adenoma</b>			
Overall Rates (a)	18/48 (38%)	17/50 (34%)	15/48 (31%)
Adjusted Rates (b)	51.2%	43.4%	42.4%
Terminal Rates (c)	11/27 (41%)	15/37 (41%)	10/30 (33%)
Week of First Observation	54	76	97
Life Table Tests (d)	P=0.180N	P=0.165N	P=0.212N
Incidental Tumor Tests (d)	P=0.219N	P=0.310N	P=0.253N
Cochran-Armitage Trend Test (d)	P=0.295N		
Fisher Exact Test (d)		P=0.440N	P=0.334N
<b>Anterior Pituitary Gland: Carcinoma</b>			
Overall Rates (a)	0/48 (0%)	4/50 (8%)	0/48 (0%)
Adjusted Rates (b)	0.0%	10.8%	0.0%
Terminal Rates (c)	0/27 (0%)	4/37 (11%)	0/30 (0%)
Week of First Observation		104	
Life Table Tests (d)	P=0.596N	P=0.109	(e)
Incidental Tumor Tests (d)	P=0.596N	P=0.109	(e)
Cochran-Armitage Trend Test (d)	P=0.623		
Fisher Exact Test (d)		P=0.064	(e)
<b>Anterior Pituitary Gland: Adenoma or Carcinoma</b>			
Overall Rates (a)	18/48 (38%)	21/50 (42%)	15/48 (31%)
Adjusted Rates (b)	51.2%	53.7%	42.4%
Terminal Rates (c)	11/27 (41%)	19/37 (51%)	10/30 (33%)
Week of First Observation	54	76	97
Life Table Tests (d)	P=0.176N	P=0.388N	P=0.212N
Incidental Tumor Tests (d)	P=0.214N	P=0.579	P=0.253N
Cochran-Armitage Trend Test (d)	P=0.299N		
Fisher Exact Test (d)		P=0.402	P=0.334N
<b>Adrenal Gland: Pheochromocytoma</b>			
Overall Rates (a)	4/49 (8%)	1/50 (2%)	4/49 (8%)
Adjusted Rates (b)	12.5%	2.6%	12.9%
Terminal Rates (c)	2/28 (7%)	0/37 (0%)	4/31 (13%)
Week of First Observation	90	103	104
Life Table Tests (d)	P=0.529N	P=0.118N	P=0.579N
Incidental Tumor Tests (d)	P=0.519N	P=0.210N	P=0.574N
Cochran-Armitage Trend Test (d)	P=0.584		
Fisher Exact Test (d)		P=0.175N	P=0.643
<b>Thyroid Gland: C-Cell Adenoma</b>			
Overall Rates (a)	6/48 (13%)	(f) 1/14 (7%)	9/49 (18%)
Adjusted Rates (b)	19.6%		26.2%
Terminal Rates (c)	5/28 (18%)		7/31 (23%)
Week of First Observation	64		64
Life Table Test (d)			P=0.363
Incidental Tumor Test (d)			P=0.314
Fisher Exact Test (d)			P=0.303



TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Control	310 ppm	620 ppm
<b>Mammary Gland: Fibroadenoma</b>			
Overall Rates (a)	8/49 (16%)	36/50 (72%)	36/50 (72%)
Adjusted Rates (b)	24.8%	81.6%	85.6%
Terminal Rates (c)	5/28 (18%)	29/37 (78%)	25/31 (81%)
Week of First Observation	67	67	60
Life Table Tests (d)	P<0.001	P<0.001	P<0.001
Incidental Tumor Tests (d)	P<0.001	P<0.001	P<0.001
Cochran-Armitage Trend Test (d)	P<0.001		
Fisher Exact Test (d)		P<0.001	P<0.001
<b>Uterus: Endometrial Stromal Polyp</b>			
Overall Rates (a)	11/49 (22%)	9/21 (43%)	15/50 (30%)
Adjusted Rates (b)	30.9%	73.4%	41.8%
Terminal Rates (c)	6/28 (21%)	8/11 (73%)	11/31 (35%)
Week of First Observation	47	87	64
Life Table Tests (d)	P=0.320	P=0.225	P=0.359
Incidental Tumor Tests (d)	P=0.279	P=0.034	P=0.275
Cochran-Armitage Trend Test (d)	P=0.239		
Fisher Exact Test (d)		P=0.076	P=0.266
<b>Clitoral Gland: Adenoma</b>			
Overall Rates (a)	3/49 (6%)	0/50 (0%)	7/50 (14%)
Adjusted Rates (b)	10.7%	0.0%	21.5%
Terminal Rates (c)	3/28 (11%)	0/37 (0%)	6/31 (19%)
Week of First Observation	104		101
Life Table Tests (d)	P=0.094	P=0.076N	P=0.206
Incidental Tumor Tests (d)	P=0.099	P=0.076N	P=0.208
Cochran-Armitage Trend Test (d)	P=0.084		
Fisher Exact Test (d)		P=0.117N	P=0.167
<b>Clitoral Gland: Carcinoma</b>			
Overall Rates (a)	5/49 (10%)	6/50 (12%)	0/50 (0%)
Adjusted Rates (b)	14.6%	14.8%	0.0%
Terminal Rates (c)	3/28 (11%)	3/37 (8%)	0/31 (0%)
Week of First Observation	54	82	
Life Table Tests (d)	P=0.029N	P=0.591N	P=0.029N
Incidental Tumor Tests (d)	P=0.040N	P=0.486	P=0.047N
Cochran-Armitage Trend Test (d)	P=0.039N		
Fisher Exact Test (d)		P=0.514	P=0.027N
<b>Clitoral Gland: Adenocarcinoma or Carcinoma</b>			
Overall Rates (a)	5/49 (10%)	7/50 (14%)	0/50 (0%)
Adjusted Rates (b)	14.6%	17.3%	0.0%
Terminal Rates (c)	3/28 (11%)	4/37 (11%)	0/31 (0%)
Week of First Observation	54	82	
Life Table Tests (d)	P=0.034N	P=0.547	P=0.029N
Incidental Tumor Tests (d)	P=0.045N	P=0.383	P=0.047N
Cochran-Armitage Trend Test (d)	P=0.045N		
Fisher Exact Test (d)		P=0.394	P=0.027N
<b>Clitoral Gland: Adenoma, Adenocarcinoma, or Carcinoma</b>			
Overall Rates (a)	8/49 (16%)	7/50 (14%)	7/50 (14%)
Adjusted Rates (b)	24.9%	17.3%	21.5%
Terminal Rates (c)	6/28 (21%)	4/37 (11%)	6/31 (19%)
Week of First Observation	54	82	101
Life Table Tests (d)	P=0.357N	P=0.310N	P=0.415N
Incidental Tumor Tests (d)	P=0.386N	P=0.451N	P=0.479N
Cochran-Armitage Trend Test (d)	P=0.427N		
Fisher Exact Test (d)		P=0.483N	P=0.483N

**TABLE B3. ANALYSIS OF PRIMARY TUMORS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Control	310 ppm	620 ppm
<b>All Sites: Malignant Tumors</b>			
Overall Rates (a)	23/49 (47%)	17/50 (34%)	9/50 (18%)
Adjusted Rates (b)	55.2%	38.0%	23.7%
Terminal Rates (c)	10/28 (36%)	10/37 (27%)	5/31 (16%)
Week of First Observation	52	61	76
Life Table Tests (d)	P=0.002N	P=0.053N	P=0.003N
Incidental Tumor Tests (d)	P=0.001N	P=0.238N	P=0.001N
Cochran-Armitage Trend Test (d)	P=0.002N		
Fisher Exact Test (d)		P=0.134N	P=0.002N
<b>All Sites: All Tumors</b>			
Overall Rates (a)	44/49 (90%)	47/50 (94%)	46/50 (92%)
Adjusted Rates (b)	91.6%	95.9%	95.8%
Terminal Rates (c)	24/28 (86%)	35/37 (95%)	29/31 (94%)
Week of First Observation	47	61	60
Life Table Tests (d)	P=0.365N	P=0.150N	P=0.386N
Incidental Tumor Tests (d)	P=0.441	P=0.299	P=0.528
Cochran-Armitage Trend Test (d)	P=0.415		
Fisher Exact Test (d)		P=0.346	P=0.487

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) No P value is reported because no tumors were observed in the 620-ppm and control groups.

(f) Incomplete sampling of tissues

**TABLE B4a. HISTORICAL INCIDENCE OF MAMMARY GLAND TUMORS IN FEMALE F344/N RATS RECEIVING NO TREATMENT (a)**

Study	Incidence of Fibroadenomas in Controls
<b>Historical Incidence at Physiological Research Laboratories</b>	
Ephedrine sulfate	10/49
Phenylephrine hydrochloride	11/50
Oxytetracycline hydrochloride	21/50
TOTAL	42/149 (28.2%)
SD (c)	12.03%
Range (d)	
High	21/50
Low	10/49
<b>Overall Historical Incidence</b>	
TOTAL	(d) 550/1,984 (27.7%)
SD (c)	11.07%
Range (d)	
High	24/49
Low	5/50

- (a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.  
 (d) Four cystfibroadenomas were also observed.

**TABLE B4b. HISTORICAL INCIDENCE OF LEUKEMIA IN FEMALE F344/N RATS RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls
<b>Historical Incidence at Physiological Research Laboratories</b>	
Ephedrine sulfate	13/49
Phenylephrine hydrochloride	15/50
Oxytetracycline hydrochloride	13/50
TOTAL	41/149 (27.5%)
SD (b)	2.17%
Range (c)	
High	15/50
Low	13/50
<b>Overall Historical Incidence</b>	
TOTAL	378/1,984 (19.1%)
SD (b)	6.94%
Range (c)	
High	19/50
Low	3/50

- (a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.

TABLE B5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	49	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	49	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*Skin	(49)	(50)	(50)
Epidermal inclusion cyst	1 (2%)		
<b>RESPIRATORY SYSTEM</b>			
*Nasal cavity	(49)	(50)	(50)
Inflammation, NOS	12 (24%)		8 (16%)
Inflammation, suppurative			1 (2%)
Parasitism	1 (2%)		
Infection, fungal	1 (2%)		
#Lung	(48)	(15)	(49)
Edema, NOS			1 (2%)
Hemorrhage		1 (7%)	
Inflammation, NOS	5 (10%)	2 (13%)	1 (2%)
Inflammation, focal		1 (7%)	
Inflammation, chronic focal	1 (2%)		
Infection, protozoan		1 (7%)	
Hyperplasia, alveolar epithelium	3 (6%)		2 (4%)
#Lung/alveoli	(48)	(15)	(49)
Histiocytosis	1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>			
#Bone marrow	(48)	(50)	(50)
Fibrosis, diffuse	1 (2%)		
Hypoplasia, NOS	1 (2%)		6 (12%)
Hyperplasia, NOS	12 (25%)	8 (16%)	4 (8%)
Histiocytosis		1 (2%)	
Hyperplasia, reticulum cell	2 (4%)	6 (12%)	5 (10%)
#Megakaryocytes	(48)	(50)	(50)
Hyperplasia, NOS	1 (2%)		
#Spleen	(49)	(50)	(50)
Scar	1 (2%)	1 (2%)	2 (4%)
Metamorphosis, fatty	1 (2%)		
#Lymph node	(49)	(10)	(50)
Cyst, NOS	1 (2%)		
Hemorrhage	1 (2%)		
Inflammation, acute	1 (2%)		
Hyperplasia, NOS			3 (6%)
#Mandibular lymph node	(49)	(10)	(50)
Hemorrhagic cyst			1 (2%)
#Mesenteric lymph node	(49)	(10)	(50)
Inflammation, granulomatous			1 (2%)
Histiocytosis	1 (2%)	2 (20%)	
*Bone	(49)	(50)	(50)
Myelofibrosis		1 (2%)	
#Ileum	(49)	(10)	(50)
Hyperplasia, lymphoid	1 (2%)		
#Thymus	(36)	(8)	(36)
Hyperplasia, epithelial	2 (6%)		
Hyperplasia, lymphoid			1 (3%)

TABLE B5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>CIRCULATORY SYSTEM</b>			
#Heart/ventricle	(48)	(11)	(50)
Dilatation, NOS			1 (2%)
#Myocardium	(48)	(11)	(50)
Degeneration, NOS	35 (73%)	10 (91%)	37 (74%)
#Mitral valve	(48)	(11)	(50)
Degeneration, mucoid			1 (2%)
*Artery	(49)	(50)	(50)
Inflammation, chronic			1 (2%)
<b>DIGESTIVE SYSTEM</b>			
*Tongue	(49)	(50)	(50)
Hyperplasia, epithelial		1 (2%)	
#Salivary gland	(47)	(10)	(48)
Inflammation, NOS	1 (2%)	1 (10%)	1 (2%)
Atrophy, focal	1 (2%)		2 (4%)
#Liver	(49)	(50)	(50)
Accessory structure	6 (12%)	7 (14%)	4 (8%)
Inflammation, NOS	2 (4%)	1 (2%)	1 (2%)
Granuloma, NOS	13 (27%)	23 (46%)	21 (42%)
Necrosis, NOS	1 (2%)		1 (2%)
Necrosis, coagulative	1 (2%)		
Angiectasis		1 (2%)	
#Intrahepatic bile duct	(49)	(50)	(50)
Hyperplasia, NOS	27 (55%)	34 (68%)	25 (50%)
#Liver/hepatocytes	(49)	(50)	(50)
Cytoplasmic vacuolization	1 (2%)	1 (2%)	1 (2%)
Focal cellular change	38 (78%)	47 (94%)	41 (82%)
#Pancreas	(48)	(10)	(49)
Inflammation, NOS	1 (2%)	1 (10%)	1 (2%)
Atrophy, focal	14 (29%)	1 (10%)	15 (31%)
Atrophy, diffuse	2 (4%)		
Hypertrophy, focal			1 (2%)
#Glandular stomach	(49)	(12)	(50)
Cyst, NOS	14 (29%)	2 (17%)	16 (32%)
Hyperplasia, epithelial		1 (8%)	
#Stomach wall	(49)	(12)	(50)
Granuloma, NOS	1 (2%)		
#Forestomach	(49)	(12)	(50)
Inflammation, chronic			1 (2%)
Hyperkeratosis	1 (2%)		2 (4%)
<b>URINARY SYSTEM</b>			
#Kidney	(49)	(10)	(50)
Mineralization			4 (8%)
Cyst, NOS			1 (2%)
Nephropathy	33 (67%)	9 (90%)	24 (48%)
#Kidney/cortex	(49)	(10)	(50)
Inflammation, chronic focal	1 (2%)		
#Urinary bladder	(48)	(9)	(50)
Hyperplasia, epithelial	1 (2%)		

**TABLE B5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>ENDOCRINE SYSTEM</b>			
#Anterior pituitary	(48)	(50)	(48)
Cyst, NOS	1 (2%)		
Multiple cysts	2 (4%)		1 (2%)
Hyperplasia, NOS	1 (2%)		
Hyperplasia, focal	7 (15%)	7 (14%)	6 (13%)
Hyperplasia, cystic	16 (33%)	17 (34%)	16 (33%)
#Adrenal/capsule	(49)	(50)	(49)
Accessory structure			2 (4%)
#Adrenal cortex	(49)	(50)	(49)
Accessory structure		1 (2%)	
Cyst, NOS		1 (2%)	
Necrosis, focal	1 (2%)		
Cytoplasmic vacuolization	4 (8%)	5 (10%)	3 (6%)
Hypertrophy, focal	14 (29%)	8 (16%)	1 (2%)
Hyperplasia, focal	15 (31%)	21 (42%)	10 (20%)
Angiectasis	1 (2%)	2 (4%)	
#Adrenal medulla	(49)	(50)	(49)
Hyperplasia, focal		1 (2%)	1 (2%)
#Thyroid	(48)	(14)	(49)
Hyperplasia, C-cell	8 (17%)	1 (7%)	8 (16%)
#Thyroid follicle	(48)	(14)	(49)
Degeneration, NOS			1 (2%)
#Pancreatic islets	(48)	(10)	(49)
Hypertrophy, NOS	2 (4%)		
<b>REPRODUCTIVE SYSTEM</b>			
*Mammary gland	(49)	(50)	(50)
Inflammation, NOS	1 (2%)		
Inflammation, chronic	1 (2%)		1 (2%)
Atrophy, NOS		1 (2%)	1 (2%)
Hyperplasia, cystic	21 (43%)	11 (22%)	20 (40%)
*Clitoral gland	(49)	(50)	(50)
Inflammation, NOS	3 (6%)	3 (6%)	7 (14%)
*Vagina	(49)	(50)	(50)
Cyst, NOS	1 (2%)		
Inflammation, chronic suppurative	1 (2%)		
#Uterus	(49)	(21)	(50)
Hydrometra	2 (4%)	4 (19%)	1 (2%)
Inflammation, NOS		2 (10%)	3 (6%)
#Cervix uteri	(49)	(21)	(50)
Cyst, NOS			1 (2%)
Inflammation, NOS			1 (2%)
Fibrosis	1 (2%)		
#Endometrial gland	(49)	(21)	(50)
Cyst, NOS	4 (8%)	2 (10%)	4 (8%)
Hyperplasia, NOS	2 (4%)	1 (5%)	2 (4%)
#Ovary	(49)	(12)	(50)
Cyst, NOS	3 (6%)	2 (17%)	4 (8%)
Parovarian cyst	1 (2%)	1 (8%)	
<b>NERVOUS SYSTEM</b>			
#Brain/meninges	(48)	(9)	(50)
Congestion, NOS	1 (2%)		
Inflammation, acute			1 (2%)
#Cerebral ventricle	(48)	(9)	(50)
Dilatation, NOS		1 (11%)	
#Brain	(48)	(9)	(50)
Gliosis		1 (11%)	2 (4%)

**TABLE B5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>NERVOUS SYSTEM (Continued)</b>			
#Brain stem	(48)	(9)	(50)
Atrophy, pressure	8 (17%)		7 (14%)
*White matter spinal Cyst, NOS	(49) 1 (2%)	(50)	(50)
<b>SPECIAL SENSE ORGANS</b>			
*Eye/iris	(49)	(50)	(50)
Synechia, anterior	1 (2%)		
Synechia, posterior	1 (2%)	1 (2%)	
*Eye/crystalline lens	(49)	(50)	(50)
Cataract	1 (2%)	5 (10%)	
*Nasolacrimal duct	(49)	(50)	(50)
Foreign body, NOS	1 (2%)		
Inflammation, NOS			1 (2%)
*Harderian gland	(49)	(50)	(50)
Inflammation, focal	1 (2%)	1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
*Joint	(49)	(50)	(50)
Degeneration, NOS			4 (8%)
*Synovial tissue	(49)	(50)	(50)
Inflammation, chronic			1 (2%)
*Vertebral joint	(49)	(50)	(50)
Degeneration, NOS	3 (6%)	39 (78%)	36 (72%)
*Sternal synchondrosis	(49)	(50)	(50)
Degeneration, NOS	15 (31%)	1 (2%)	32 (64%)
*Knee joint	(49)	(50)	(50)
Degeneration, NOS	4 (8%)	30 (60%)	39 (78%)
*Skeletal muscle	(49)	(50)	(50)
Mineralization			1 (2%)
Hemorrhage		1 (2%)	
*Cartilage, NOS	(49)	(50)	(50)
Necrosis, focal	1 (2%)		
<b>BODY CAVITIES</b>			
*Mesentery	(49)	(50)	(50)
Steatitis	1 (2%)		
Inflammation, chronic			1 (2%)
Necrosis, fat	4 (8%)	6 (12%)	2 (4%)
<b>ALL OTHER SYSTEMS</b>			
*Multiple organs	(49)	(50)	(50)
Inflammation, granulomatous		1 (2%)	
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
No necropsy performed	1		

\* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically.  
# Number of animals examined microscopically at this site





## APPENDIX C

### SUMMARY OF LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	PAGE	
TABLE C1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	113
TABLE C2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	116
TABLE C3	ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	122
TABLE C4a	HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN MALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT	125
TABLE C4b	HISTORICAL INCIDENCE OF INTEGUMENTARY SYSTEM TUMORS IN MALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT	125
TABLE C4c	HISTORICAL INCIDENCE OF HEPATOCELLULAR TUMORS IN MALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT	126
TABLE C5	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	127



TABLE C1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	49	50
<b>INTEGUMENTARY SYSTEM</b>			
*Subcutaneous tissue	(50)	(50)	(50)
Sarcoma, NOS	1 (2%)		1 (2%)
Fibroma			1 (2%)
Fibrosarcoma	2 (4%)	3 (6%)	† 5 (10%)
Neurofibrosarcoma			1 (2%)
Neurilemoma			2 (4%)
Neurilemoma, malignant		† 1 (2%)	
<b>RESPIRATORY SYSTEM</b>			
#Lung	(50)	(49)	(50)
Hepatocellular carcinoma, metastatic			1 (2%)
Alveolar/bronchiolar adenoma	6 (12%)	5 (10%)	4 (8%)
Alveolar/bronchiolar carcinoma	1 (2%)	2 (4%)	2 (4%)
Sarcoma, NOS, metastatic		1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>			
*Multiple organs	(50)	(50)	(50)
Malignant lymphoma, undifferentiated type		2 (4%)	
Malignant lymphoma, lymphocytic type		1 (2%)	
Malignant lymphoma, mixed type	4 (8%)	1 (2%)	1 (2%)
#Spleen	(49)	(48)	(50)
Malignant lymphoma, undifferentiated type		1 (2%)	
Malignant lymphoma, mixed type		1 (2%)	
#Peyer's patch	(47)	(44)	(45)
Malignant lymphoma, mixed type			1 (2%)
<b>CIRCULATORY SYSTEM</b>			
*Multiple organs	(50)	(50)	(50)
Hemangiosarcoma			2 (4%)
*Subcutaneous tissue	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)		
#Liver	(50)	(49)	(50)
Hemangioma			1 (2%)
*Preputial gland	(50)	(50)	(50)
Hemangioma			1 (2%)
<b>DIGESTIVE SYSTEM</b>			
#Liver	(50)	(49)	(50)
Hepatocellular adenoma	9 (18%)	6 (12%)	2 (4%)
Hepatocellular carcinoma	8 (16%)	9 (18%)	4 (8%)
#Forestomach	(49)	(46)	(48)
Squamous cell papilloma	2 (4%)		
Squamous cell carcinoma			1 (2%)
#Duodenum	(47)	(44)	(45)
Carcinoma, NOS	1 (2%)		
#Jejunum	(47)	(44)	(45)
Carcinoma, NOS			1 (2%)
Papillary carcinoma			1 (2%)
<b>URINARY SYSTEM</b>			
None			

TABLE C1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>ENDOCRINE SYSTEM</b>			
#Pituitary intermedia Adenoma, NOS	(44) 1 (2%)	(48)	(49)
#Adrenal Cortical adenoma	(48) 3 (6%)	(49) 1 (2%)	(49) 1 (2%)
#Adrenal medulla Pheochromocytoma	(48) 2 (4%)	(49)	(49) 1 (2%)
#Thyroid Follicular cell adenoma	(49) 1 (2%)	(48)	(50)
Follicular cell carcinoma			1 (2%)
#Pancreatic islets Islet cell adenoma	(49) 1 (2%)	(48) 1 (2%)	(48) 1 (2%)
<b>REPRODUCTIVE SYSTEM</b>			
*Preputial gland Squamous cell carcinoma	(50)	(50) 1 (2%)	(50)
<b>NERVOUS SYSTEM</b>			
None			
<b>SPECIAL SENSE ORGANS</b>			
*Eye/lacrimal gland Carcinoma, NOS	(50)	(50) 1 (2%)	(50)
*Harderian gland Carcinoma, NOS	(50)	(50) 2 (4%)	(50)
Adenoma, NOS			2 (4%)
<b>MUSCULOSKELETAL SYSTEM</b>			
None			
<b>BODY CAVITIES</b>			
None			
<b>ALL OTHER SYSTEMS</b>			
*Multiple organs Sarcoma, NOS	(50) 1 (2%)	(50)	(50)
<b>ANIMAL DISPOSITION SUMMARY</b>			
Animals initially in study	50	50	50
Natural death	4	12	10
Moribund sacrifice	6	7	13
Terminal sacrifice	39	31	27
Accidentally killed, nda	1		

**TABLE C1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>TUMOR SUMMARY</b>			
Total animals with primary tumors**	28	25	26
Total primary tumors	45	39	38
Total animals with benign tumors	17	12	14
Total benign tumors	25	13	16
Total animals with malignant tumors	16	21	17
Total malignant tumors	20	26	22
Total animals with secondary tumors##		1	1
Total secondary tumors		1	1

\* Number of animals receiving complete necropsy examinations; all gross lesions including masses examined microscopically.

\*\*Primary tumors: all tumors except secondary tumors

# Number of animals examined microscopically at this site

## Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ

† Multiple occurrence of morphology in same organ; tissue counted only once.











**TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE: HIGH DOSE**

ANIMAL NUMBER	0513	0968	0875	0758	0666	0565	0464	0363	0261	0177	0074	0088	0095	0100	0109	0117	0128	0137	0148	0159	0168	0179	0189	0198	0209	0218	0229	0238	0249	0258	0269	0278	0289	0298	0309	0318	0329	0338	0349	0358	0369	0378	0389	0398	0409	0418	0429	0438	0449	0458	0469	0478	0489	0498	0509	0518	0529	0538	0549	0558	0569	0578	0589	0598	0609	0618	0629	0638	0649	0658	0669	0678	0689	0698	0709	0718	0729	0738	0749	0758	0769	0778	0789	0798	0809	0818	0829	0838	0849	0858	0869	0878	0889	0898	0909	0918	0929	0938	0949	0958	0969	0978	0989	0998	1009	1018	1029	1038	1049	1058	1069	1078	1089	1098	1109	1118	1129	1138	1149	1158	1169	1178	1189	1198	1209	1218	1229	1238	1249	1258	1269	1278	1289	1298	1309	1318	1329	1338	1349	1358	1369	1378	1389	1398	1409	1418	1429	1438	1449	1458	1469	1478	1489	1498	1509	1518	1529	1538	1549	1558	1569	1578	1589	1598	1609	1618	1629	1638	1649	1658	1669	1678	1689	1698	1709	1718	1729	1738	1749	1758	1769	1778	1789	1798	1809	1818	1829	1838	1849	1858	1869	1878	1889	1898	1909	1918	1929	1938	1949	1958	1969	1978	1989	1998	2009	2018	2029	2038	2049	2058	2069	2078	2089	2098	2109	2118	2129	2138	2149	2158	2169	2178	2189	2198	2209	2218	2229	2238	2249	2258	2269	2278	2289	2298	2309	2318	2329	2338	2349	2358	2369	2378	2389	2398	2409	2418	2429	2438	2449	2458	2469	2478	2489	2498	2509	2518	2529	2538	2549	2558	2569	2578	2589	2598	2609	2618	2629	2638	2649	2658	2669	2678	2689	2698	2709	2718	2729	2738	2749	2758	2769	2778	2789	2798	2809	2818	2829	2838	2849	2858	2869	2878	2889	2898	2909	2918	2929	2938	2949	2958	2969	2978	2989	2998	3009	3018	3029	3038	3049	3058	3069	3078	3089	3098	3109	3118	3129	3138	3149	3158	3169	3178	3189	3198	3209	3218	3229	3238	3249	3258	3269	3278	3289	3298	3309	3318	3329	3338	3349	3358	3369	3378	3389	3398	3409	3418	3429	3438	3449	3458	3469	3478	3489	3498	3509	3518	3529	3538	3549	3558	3569	3578	3589	3598	3609	3618	3629	3638	3649	3658	3669	3678	3689	3698	3709	3718	3729	3738	3749	3758	3769	3778	3789	3798	3809	3818	3829	3838	3849	3858	3869	3878	3889	3898	3909	3918	3929	3938	3949	3958	3969	3978	3989	3998	4009	4018	4029	4038	4049	4058	4069	4078	4089	4098	4109	4118	4129	4138	4149	4158	4169	4178	4189	4198	4209	4218	4229	4238	4249	4258	4269	4278	4289	4298	4309	4318	4329	4338	4349	4358	4369	4378	4389	4398	4409	4418	4429	4438	4449	4458	4469	4478	4489	4498	4509	4518	4529	4538	4549	4558	4569	4578	4589	4598	4609	4618	4629	4638	4649	4658	4669	4678	4689	4698	4709	4718	4729	4738	4749	4758	4769	4778	4789	4798	4809	4818	4829	4838	4849	4858	4869	4878	4889	4898	4909	4918	4929	4938	4949	4958	4969	4978	4989	4998	5009	5018	5029	5038	5049	5058	5069	5078	5089	5098	5109	5118	5129	5138	5149	5158	5169	5178	5189	5198	5209	5218	5229	5238	5249	5258	5269	5278	5289	5298	5309	5318	5329	5338	5349	5358	5369	5378	5389	5398	5409	5418	5429	5438	5449	5458	5469	5478	5489	5498	5509	5518	5529	5538	5549	5558	5569	5578	5589	5598	5609	5618	5629	5638	5649	5658	5669	5678	5689	5698	5709	5718	5729	5738	5749	5758	5769	5778	5789	5798	5809	5818	5829	5838	5849	5858	5869	5878	5889	5898	5909	5918	5929	5938	5949	5958	5969	5978	5989	5998	6009	6018	6029	6038	6049	6058	6069	6078	6089	6098	6109	6118	6129	6138	6149	6158	6169	6178	6189	6198	6209	6218	6229	6238	6249	6258	6269	6278	6289	6298	6309	6318	6329	6338	6349	6358	6369	6378	6389	6398	6409	6418	6429	6438	6449	6458	6469	6478	6489	6498	6509	6518	6529	6538	6549	6558	6569	6578	6589	6598	6609	6618	6629	6638	6649	6658	6669	6678	6689	6698	6709	6718	6729	6738	6749	6758	6769	6778	6789	6798	6809	6818	6829	6838	6849	6858	6869	6878	6889	6898	6909	6918	6929	6938	6949	6958	6969	6978	6989	6998	7009	7018	7029	7038	7049	7058	7069	7078	7089	7098	7109	7118	7129	7138	7149	7158	7169	7178	7189	7198	7209	7218	7229	7238	7249	7258	7269	7278	7289	7298	7309	7318	7329	7338	7349	7358	7369	7378	7389	7398	7409	7418	7429	7438	7449	7458	7469	7478	7489	7498	7509	7518	7529	7538	7549	7558	7569	7578	7589	7598	7609	7618	7629	7638	7649	7658	7669	7678	7689	7698	7709	7718	7729	7738	7749	7758	7769	7778	7789	7798	7809	7818	7829	7838	7849	7858	7869	7878	7889	7898	7909	7918	7929	7938	7949	7958	7969	7978	7989	7998	8009	8018	8029	8038	8049	8058	8069	8078	8089	8098	8109	8118	8129	8138	8149	8158	8169	8178	8189	8198	8209	8218	8229	8238	8249	8258	8269	8278	8289	8298	8309	8318	8329	8338	8349	8358	8369	8378	8389	8398	8409	8418	8429	8438	8449	8458	8469	8478	8489	8498	8509	8518	8529	8538	8549	8558	8569	8578	8589	8598	8609	8618	8629	8638	8649	8658	8669	8678	8689	8698	8709	8718	8729	8738	8749	8758	8769	8778	8789	8798	8809	8818	8829	8838	8849	8858	8869	8878	8889	8898	8909	8918	8929	8938	8949	8958	8969	8978	8989	8998	9009	9018	9029	9038	9049	9058	9069	9078	9089	9098	9109	9118	9129	9138	9149	9158	9169	9178	9189	9198	9209	9218	9229	9238	9249	9258	9269	9278	9289	9298	9309	9318	9329	9338	9349	9358	9369	9378	9389	9398	9409	9418	9429	9438	9449	9458	9469	9478	9489	9498	9509	9518	9529	9538	9549	9558	9569	9578	9589	9598	9609	9618	9629	9638	9649	9658	9669	9678	9689	9698	9709	9718	9729	9738	9749	9758	9769	9778	9789	9798	9809	9818	9829	9838	9849	9858	9869	9878	9889	9898	9909	9918	9929	9938	9949	9958	9969	9978	9989	9998	10009	10018	10029	10038	10049	10058	10069	10078	10089	10098	10109	10118	10129	10138	10149	10158	10169	10178	10189	10198	10209	10218	10229	10238	10249	10258	10269	10278	10289	10298	10309	10318	10329	10338	10349	10358	10369	10378	10389	10398	10409	10418	10429	10438	10449	10458	10469	10478	10489	10498	10509	10518	10529	10538	10549	10558	10569	10578	10589	10598	10609	10618	10629	10638	10649	10658	10669	10678	10689	10698	10709	10718	10729	10738	10749	10758	10769	10778	10789	10798	10809	10818	10829	10838	10849	10858	10869	10878	10889	10898	10909	10918	10929	10938	10949	10958	10969	10978	10989	10998	11009	11018	11029	11038	11049	11058	11069	11078	11089	11098	11109	11118	11129	11138	11149	11158	11169	11178	11189	11198	11209	11218	11229	11238	11249	11258	11269	11278	11289	11298	11309	11318	11329	11338	11349	11358	11369	11378	11389	11398	11409	11418	11429	11438	11449	11458	11469	11478	11489	11498	11509	11518	11529	11538	11549	11558	11569	11578	11589	11598	11609	11618	11629	11638	11649	11658	11669	11678	11689	11698	11709	11718	11729	11738	11749	11758	11769	11778	11789	11798	11809	11818	11829	11838	11849	11858	11869	11878	11889	11898	11909	11918	11929	11938	11949	11958	11969	11978	11989	11998	12009
---------------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------

**TABLE C2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF MALE MICE: HIGH DOSE**  
(Continued)

ANIMAL NUMBER	057	080	061	063	064	066	070	071	072	075	076	080	082	083	084	085	088	089	091	092	093	096	097	098	099	TOTAL TISSUES TUMORS	
WEEKS ON STUDY	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104	104		
<b>INTEGUMENTARY SYSTEM</b>																											
Subcutaneous tissue	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	*50
Sarcoma, NOS																											1
Fibroma	X																										5
Fibrosarcoma																											1
Neurofibrosarcoma																											2
Neurilemoma																											
<b>RESPIRATORY SYSTEM</b>																											
Lungs and bronchi	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular carcinoma, metastatic																											1
Alveolar/bronchiolar adenoma	X																										3
Alveolar/bronchiolar carcinoma																										X	2
Trachea	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
<b>HEMATOPOIETIC SYSTEM</b>																											
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Lymph nodes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Thymus	-	-	+	+	+	+	-	+	+	+	+	-	+	+	+	+	+	+	+	+	+	+	-	-	-	+	33
<b>CIRCULATORY SYSTEM</b>																											
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
<b>DIGESTIVE SYSTEM</b>																											
Salivary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hepatocellular adenoma																											2
Hepatocellular carcinoma																											4
Hemangioma	X																										1
Bile duct	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder & common bile duct	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Stomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Squamous cell carcinoma																											1
Small intestine	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
Carcinoma, NOS																											1
Papillary carcinoma																											1
Malignant lymphoma, mixed type																											1
Large intestine	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
<b>URINARY SYSTEM</b>																											
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	45
<b>ENDOCRINE SYSTEM</b>																											
Pituitary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Adrenal	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Cortical adenoma																											1
Pheochromocytoma																											1
Thyroid	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Follicular cell carcinoma																											1
Parathyroid	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	37
Pancreatic islets	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Islet cell adenoma																											1
<b>REPRODUCTIVE SYSTEM</b>																											
Mammary gland	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50
Testis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Preputial/clitoral gland	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50
Hemangioma																											1
<b>NERVOUS SYSTEM</b>																											
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
<b>SPECIAL SENSE ORGANS</b>																											
Harderian gland	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50
Adenoma, NOS																											2
<b>ALL OTHER SYSTEMS</b>																											
Multiple organs, NOS	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	*50
Hemangiosarcoma																											2
Malignant lymphoma, mixed type																											1

\* Animals necropsied

TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Control	150 ppm	310 ppm
<b>Subcutaneous Tissue: Fibrosarcoma</b>			
Overall Rates (a)	2/50 (4%)	3/50 (6%)	5/50 (10%)
Adjusted Rates (b)	4.7%	8.9%	15.3%
Terminal Rates (c)	0/39 (0%)	2/31 (6%)	1/27 (4%)
Week of First Observation	97	88	86
Life Table Tests (d)	P=0.080	P=0.402	P=0.109
Incidental Tumor Tests (d)	P=0.224	P=0.519	P=0.293
Cochran-Armitage Trend Test (d)	P=0.159		
Fisher Exact Test (d)		P=0.500	P=0.218
<b>Subcutaneous Tissue: Sarcoma, Fibrosarcoma, or Neurofibrosarcoma</b>			
Overall Rates (a)	3/50 (6%)	3/50 (6%)	7/50 (14%)
Adjusted Rates (b)	6.9%	8.9%	20.8%
Terminal Rates (c)	0/39 (0%)	2/31 (6%)	1/27 (4%)
Week of First Observation	97	88	86
Life Table Tests (d)	P=0.044	P=0.557	P=0.064
Incidental Tumor Tests (d)	P=0.140	P=0.653N	P=0.172
Cochran-Armitage Trend Test (d)	P=0.105		
Fisher Exact Test (d)		P=0.661	P=0.159
<b>Subcutaneous Tissue: Fibroma or Fibrosarcoma</b>			
Overall Rates (a)	2/50 (4%)	3/50 (6%)	6/50 (12%)
Adjusted Rates (b)	4.7%	8.9%	18.5%
Terminal Rates (c)	0/39 (0%)	2/31 (6%)	2/27 (7%)
Week of First Observation	97	88	86
Life Table Tests (d)	P=0.039	P=0.402	P=0.057
Incidental Tumor Tests (d)	P=0.119	P=0.519	P=0.159
Cochran-Armitage Trend Test (d)	P=0.089		
Fisher Exact Test (d)		P=0.500	P=0.134
<b>Subcutaneous Tissue: Fibroma, Sarcoma, Fibrosarcoma, or Neurofibrosarcoma</b>			
Overall Rates (a)	3/50 (6%)	3/50 (6%)	8/50 (16%)
Adjusted Rates (b)	6.9%	8.9%	23.8%
Terminal Rates (c)	0/39 (0%)	2/31 (6%)	2/27 (7%)
Week of First Observation	97	88	86
Life Table Tests (d)	P=0.021	P=0.557	P=0.034
Incidental Tumor Tests (d)	P=0.070	P=0.653N	P=0.084
Cochran-Armitage Trend Test (d)	P=0.059		
Fisher Exact Test (d)		P=0.661	P=0.100
<b>Lung: Alveolar/Bronchiolar Adenoma</b>			
Overall Rates (a)	6/50 (12%)	5/49 (10%)	4/50 (8%)
Adjusted Rates (b)	15.4%	14.8%	13.5%
Terminal Rates (c)	6/39 (15%)	3/31 (10%)	3/27 (11%)
Week of First Observation	104	98	88
Life Table Tests (d)	P=0.542N	P=0.596	P=0.597N
Incidental Tumor Tests (d)	P=0.427N	P=0.623	P=0.511N
Cochran-Armitage Trend Test (d)	P=0.311N		
Fisher Exact Test (d)		P=0.514N	P=0.371N
<b>Lung: Alveolar/Bronchiolar Adenoma or Carcinoma</b>			
Overall Rates (a)	8/50 (16%)	7/49 (14%)	6/50 (12%)
Adjusted Rates (b)	20.5%	20.9%	20.0%
Terminal Rates (c)	8/39 (21%)	5/31 (16%)	4/27 (15%)
Week of First Observation	104	98	88
Life Table Tests (d)	P=0.497	P=0.534	P=0.564
Incidental Tumor Tests (d)	P=0.500N	P=0.558	P=0.563N
Cochran-Armitage Trend Test (d)	P=0.335N		
Fisher Exact Test (d)		P=0.517N	P=0.387N

TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Control	150 ppm	310 ppm
<b>Hematopoietic System: Malignant Lymphoma, Undifferentiated Type</b>			
Overall Rates (a)	0/50 (0%)	3/50 (6%)	0/50 (0%)
Adjusted Rates (b)	0.0%	9.1%	0.0%
Terminal Rates (c)	0/39 (0%)	2/31 (6%)	0/27 (0%)
Week of First Observation		94	
Life Table Tests (d)	P=0.561	P=0.087	(e)
Incidental Tumor Tests (d)	P=0.611	P=0.097	(e)
Cochran-Armitage Trend Test (d)	P=0.626N		
Fisher Exact Test (d)		P=0.121	(e)
<b>Hematopoietic System: Malignant Lymphoma, Mixed Type</b>			
Overall Rates (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)
Adjusted Rates (b)	9.9%	6.5%	7.4%
Terminal Rates (c)	3/39 (8%)	2/31 (6%)	2/27 (7%)
Week of First Observation	99	104	104
Life Table Tests (d)	P=0.418N	P=0.446N	P=0.519N
Incidental Tumor Tests (d)	P=0.384N	P=0.428N	P=0.469N
Cochran-Armitage Trend Test (d)	P=0.258N		
Fisher Exact Test (d)		P=0.339N	P=0.339N
<b>Hematopoietic System: Lymphoma, All Malignant</b>			
Overall Rates (a)	4/50 (8%)	6/50 (12%)	2/50 (4%)
Adjusted Rates (b)	9.9%	17.8%	7.4%
Terminal Rates (c)	3/39 (8%)	4/31 (13%)	2/27 (7%)
Week of First Observation	99	94	104
Life Table Tests (d)	P=0.492N	P=0.244	P=0.519N
Incidental Tumor Tests (d)	P=0.408N	P=0.270	P=0.469N
Cochran-Armitage Trend Test (d)	P=0.284N		
Fisher Exact Test (d)		P=0.370	P=0.339N
<b>Circulatory System: Hemangioma or Hemangiosarcoma</b>			
Overall Rates (a)	1/50 (2%)	0/50 (0%)	4/50 (8%)
Adjusted Rates (b)	2.6%	0.0%	12.2%
Terminal Rates (c)	1/39 (3%)	0/31 (0%)	2/27 (7%)
Week of First Observation	104		86
Life Table Tests (d)	P=0.049	P=0.546N	P=0.109
Incidental Tumor Tests (d)	P=0.107	P=0.546N	P=0.237
Cochran-Armitage Trend Test (d)	P=0.079		
Fisher Exact Test (d)		P=0.500N	P=0.181
<b>Liver: Hepatocellular Adenoma</b>			
Overall Rates (a)	9/50 (18%)	6/49 (12%)	2/50 (4%)
Adjusted Rates (b)	22.3%	19.4%	7.4%
Terminal Rates (c)	8/39 (21%)	6/31 (19%)	2/27 (7%)
Week of First Observation	97	104	104
Life Table Tests (d)	P=0.078N	P=0.467N	P=0.095N
Incidental Tumor Tests (d)	P=0.070N	P=0.454N	P=0.081N
Cochran-Armitage Trend Test (d)	P=0.021N		
Fisher Exact Test (d)		P=0.303N	P=0.026N
<b>Liver: Hepatocellular Carcinoma</b>			
Overall Rates (a)	8/50 (16%)	9/49 (18%)	4/50 (8%)
Adjusted Rates (b)	18.6%	26.1%	14.1%
Terminal Rates (c)	5/39 (13%)	6/31 (19%)	3/27 (11%)
Week of First Observation	66	83	97
Life Table Tests (d)	P=0.376N	P=0.317	P=0.386N
Incidental Tumor Tests (d)	P=0.242N	P=0.304	P=0.288N
Cochran-Armitage Trend Test (d)	P=0.154N		
Fisher Exact Test (d)		P=0.482	P=0.178N

**TABLE C3. ANALYSIS OF PRIMARY TUMORS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Control	150 ppm	310 ppm
<b>Liver: Hepatocellular Adenoma or Carcinoma</b>			
Overall Rates (a)	16/50 (32%)	15/49 (31%)	5/50 (10%)
Adjusted Rates (b)	36.8%	43.8%	17.7%
Terminal Rates (c)	12/39 (31%)	12/31 (39%)	4/27 (15%)
Week of First Observation	66	83	97
Life Table Tests (d)	P=0.072N	P=0.380	P=0.062N
Incidental Tumor Tests (d)	P=0.032N	P=0.382	P=0.031N
Cochran-Armitage Trend Test (d)	P=0.007N		
Fisher Exact Test (d)		P=0.527N	P=0.007N
<b>Adrenal Gland: Cortical Adenoma</b>			
Overall Rates (a)	3/48 (6%)	1/49 (2%)	1/49 (2%)
Adjusted Rates (b)	7.9%	3.0%	3.7%
Terminal Rates (c)	3/38 (8%)	0/31 (0%)	1/27 (4%)
Week of First Observation	104	101	104
Life Table Tests (d)	P=0.314N	P=0.383N	P=0.433N
Incidental Tumor Tests (d)	P=0.263N	P=0.341N	P=0.433N
Cochran-Armitage Trend Test (d)	P=0.202N		
Fisher Exact Test (d)		P=0.301N	P=0.301N
<b>All Sites: Benign Tumors</b>			
Overall Rates (a)	17/50 (34%)	12/50 (24%)	14/50 (28%)
Adjusted Rates (b)	42.4%	35.1%	45.9%
Terminal Rates (c)	16/39 (41%)	9/31 (29%)	11/27 (41%)
Week of First Observation	97	98	88
Life Table Tests (d)	P=0.343	P=0.437N	P=0.368
Incidental Tumor Tests (d)	P=0.508	P=0.396N	P=0.535
Cochran-Armitage Trend Test (d)	P=0.297N		
Fisher Exact Test (d)		P=0.189N	P=0.333N
<b>All Sites: Malignant Tumors</b>			
Overall Rates (a)	16/50 (32%)	21/50 (42%)	17/50 (34%)
Adjusted Rates (b)	34.5%	55.2%	49.6%
Terminal Rates (c)	9/39 (23%)	14/31 (45%)	10/27 (37%)
Week of First Observation	66	83	86
Life Table Tests (d)	P=0.107	P=0.070	P=0.142
Incidental Tumor Tests (d)	P=0.342	P=0.068	P=0.414
Cochran-Armitage Trend Test (d)	P=0.468		
Fisher Exact Test (d)		P=0.204	P=0.500
<b>All Sites: All Tumors</b>			
Overall Rates (a)	28/50 (56%)	25/50 (50%)	26/50 (52%)
Adjusted Rates (b)	60.7%	65.7%	72.0%
Terminal Rates (c)	21/39 (54%)	18/31 (58%)	17/27 (63%)
Week of First Observation	66	83	86
Life Table Tests (d)	P=0.114	P=0.371	P=0.134
Incidental Tumor Tests (d)	P=0.415	P=0.489	P=0.477
Cochran-Armitage Trend Test (d)	P=0.386N		
Fisher Exact Test (d)		P=0.345N	P=0.421N

(a) Number of tumor-bearing animals/number of animals examined at the site

(b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality

(c) Observed tumor incidence at terminal kill

(d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).

(e) No P value is reported because no tumors were observed in the 310-ppm and control groups.

**TABLE C4a. HISTORICAL INCIDENCE OF CIRCULATORY SYSTEM TUMORS IN MALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls		
	Hemangioma	Hemangiosarcoma	Hemangioma or Hemangiosarcoma
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	0/50	2/50	2/50
Phenylephrine hydrochloride	0/50	0/50	0/50
Oxytetracycline hydrochloride	1/50	2/50	3/50
TOTAL	1/150 (0.7%)	4/150 (2.7%)	5/150 (3.3%)
SD (b)	1.15%	2.31%	3.06%
Range (c)			
High	1/50	2/50	3/50
Low	0/50	0/50	0/50
<b>Overall Historical Incidence</b>			
TOTAL	26/2,040 (1.3%)	(d) 69/2,040 (3.4%)	(d) 94/2,040 (4.6%)
SD (b)	2.64%	2.58%	4.03%
Range (c)			
High	7/50	5/49	10/50
Low	0/50	0/50	0/50

(a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.  
 (d) Includes 12 angiosarcomas

**TABLE C4b. HISTORICAL INCIDENCE OF INTEGUMENTARY SYSTEM TUMORS IN MALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls		
	Fibroma (b)	Fibrosarcoma (c)	Fibroma or Fibrosarcoma (b,c)
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	0/50	0/50	0/50
Phenylephrine hydrochloride	2/50	1/50	3/50
Oxytetracycline hydrochloride	2/50	11/50	13/50
TOTAL	4/150 (2.7%)	12/150 (8.0%)	16/150 (10.7%)
SD (d)	2.31%	12.17%	13.61%
Range (e)			
High	2/50	11/50	13/50
Low	0/50	0/50	0/50
<b>Overall Historical Incidence</b>			
TOTAL	39/2,040 (1.9%)	127/2,040 (6.2%)	160/2,040 (7.8%)
SD (d)	2.79%	6.66%	7.80%
Range (e)			
High	6/50	15/50	19/50
Low	0/50	0/50	0/50

(a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Includes neurofibromas  
 (c) Includes sarcomas, NOS, and neurofibrosarcomas  
 (d) Standard deviation  
 (e) Range and SD are presented for groups of 35 or more animals.

**TABLE C4c. HISTORICAL INCIDENCE OF HEPATOCELLULAR TUMORS IN MALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls		
	Adenoma	Carcinoma	Adenoma or Carcinoma
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	10/50	13/50	19/50
Phenylephrine hydrochloride	12/50	4/50	15/50
Oxytetracycline hydrochloride	7/50	11/50	18/50
TOTAL	29/150 (19.3%)	28/150 (18.7%)	52/150 (34.7%)
SD (b)	5.03%	9.45%	4.16%
Range (c)			
High	12/50	13/50	19/50
Low	7/50	4/50	15/50
<b>Overall Historical Incidence</b>			
TOTAL	242/2,032 (11.9%)	394/2,032 (19.4%)	609/2,032 (30.0%)
SD (b)	7.44%	6.84%	7.90%
Range (c)			
High	(d) 22/50	16/50	(e) 29/50
Low	0/49	4/50	8/50

- (a) Data as of August 7, 1986, for studies of at least 104 weeks  
 (b) Standard deviation  
 (c) Range and SD are presented for groups of 35 or more animals.  
 (d) Second highest: 12/50  
 (e) Second highest: 20/50



TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	49	50
<b>INTEGUMENTARY SYSTEM</b>			
*Skin	(50)	(50)	(50)
Ectopia	7 (14%)	4 (8%)	
Ulcer, NOS	1 (2%)		
Inflammation, acute focal		1 (2%)	1 (2%)
Inflammation, granulomatous			1 (2%)
Necrosis, NOS		3 (6%)	1 (2%)
Hyperkeratosis			1 (2%)
*Subcutaneous tissue	(50)	(50)	(50)
Hematoma, NOS	1 (2%)		
Lymphocytic inflammatory infiltrate		1 (2%)	
Inflammation, acute		1 (2%)	1 (2%)
Inflammation, acute/chronic			1 (2%)
Inflammation, chronic	1 (2%)		
Perivascular cuffing			1 (2%)
<b>RESPIRATORY SYSTEM</b>			
*Nasal cavity	(50)	(50)	(50)
Foreign body, NOS		1 (2%)	
Hemorrhage		1 (2%)	2 (4%)
Inflammation, pyogranulomatous		1 (2%)	
*Nasal mucosa	(50)	(50)	(50)
Degeneration, hyaline	1 (2%)	1 (2%)	
#Peritracheal tissue	(50)	(49)	(50)
Multiple cysts	1 (2%)		
#Lung/bronchus	(50)	(49)	(50)
Cyst, NOS			1 (2%)
#Lung/bronchiole	(50)	(49)	(50)
Hyperplasia, epithelial			2 (4%)
#Lung	(50)	(49)	(50)
Congestion, NOS	8 (16%)	11 (22%)	6 (12%)
Hemorrhage	3 (6%)	1 (2%)	4 (8%)
Inflammation, chronic focal	10 (20%)	9 (18%)	8 (16%)
Perivascular cuffing	5 (10%)		
Necrosis, NOS	1 (2%)		
Hemosiderosis		1 (2%)	
Alveolar macrophages	1 (2%)		3 (6%)
Hyperplasia, adenomatous	1 (2%)	1 (2%)	2 (4%)
#Lung/alveoli	(50)	(49)	(50)
Edema, NOS		1 (2%)	
Crystals, NOS		1 (2%)	1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>			
*Multiple organs	(50)	(50)	(50)
Hyperplasia, lymphoid	4 (8%)	1 (2%)	2 (4%)
*Anterior mediastinum	(50)	(50)	(50)
Hyperplasia, lymphoid	1 (2%)		
*Blood	(50)	(50)	(50)
Leukocytosis, NOS		1 (2%)	1 (2%)
*Subcutaneous tissue	(50)	(50)	(50)
Mastocytosis	1 (2%)		

TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
HEMATOPOIETIC SYSTEM (Continued)			
#Bone marrow	(50)	(49)	(50)
Congestion, NOS		1 (2%)	
Fibrosis			1 (2%)
Necrosis, NOS	1 (2%)		
Atrophy, NOS			1 (2%)
Hyperplasia, NOS	8 (16%)	1 (2%)	7 (14%)
Angiectasis	1 (2%)	1 (2%)	1 (2%)
Hyperplasia, granulocytic	12 (24%)	12 (24%)	18 (36%)
Hyperplasia, lymphoid		1 (2%)	1 (2%)
#Spleen	(49)	(48)	(50)
Inflammation, suppurative	1 (2%)		
Necrosis, NOS		1 (2%)	
Atrophy, diffuse		1 (2%)	
Angiectasis	5 (10%)	3 (6%)	
Hyperplasia, granulocytic		1 (2%)	
Hyperplasia, reticulum cell	2 (4%)	3 (6%)	7 (14%)
Hyperplasia, lymphoid	25 (51%)	11 (23%)	16 (32%)
Hematopoiesis	9 (18%)	8 (17%)	13 (26%)
#Splenic follicles	(49)	(48)	(50)
Necrosis, NOS		1 (2%)	
#Lymph node	(49)	(47)	(48)
Hemosiderosis			1 (2%)
#Mandibular lymph node	(49)	(47)	(48)
Hemosiderosis			1 (2%)
Plasmacytosis			1 (2%)
Hyperplasia, lymphoid	1 (2%)	2 (4%)	1 (2%)
Mastocytosis		1 (2%)	
#Mesenteric lymph node	(49)	(47)	(48)
Hemorrhage	1 (2%)		
Inflammation, acute			2 (4%)
Cytomegaly	1 (2%)	1 (2%)	2 (4%)
Angiectasis	18 (37%)	11 (23%)	13 (27%)
Hyperplasia, lymphoid	4 (8%)	1 (2%)	4 (8%)
#Lung	(50)	(49)	(50)
Leukocytosis, NOS	1 (2%)	3 (6%)	
Leukocytosis, neutrophilic			1 (2%)
Hyperplasia, lymphoid		1 (2%)	
#Salivary gland	(50)	(47)	(50)
Hyperplasia, lymphoid	4 (8%)	2 (4%)	2 (4%)
#Liver	(50)	(49)	(50)
Hematopoiesis	1 (2%)	3 (6%)	1 (2%)
#Pancreas	(49)	(48)	(48)
Hyperplasia, lymphoid	1 (2%)		1 (2%)
#Peyer's patch	(47)	(44)	(45)
Hyperplasia, lymphoid	2 (4%)		
#Duodenum	(47)	(44)	(45)
Hyperplasia, lymphoid	1 (2%)		
#Ileum	(47)	(44)	(45)
Hyperplasia, lymphoid	1 (2%)	1 (2%)	
#Cecum	(48)	(46)	(45)
Hyperplasia, lymphoid	3 (6%)	2 (4%)	2 (4%)
#Kidney	(50)	(49)	(50)
Hyperplasia, lymphoid	3 (6%)	2 (4%)	1 (2%)
#Urinary bladder	(48)	(45)	(45)
Hyperplasia, lymphoid	2 (4%)	1 (2%)	3 (7%)
#Prostate	(49)	(46)	(49)
Hyperplasia, lymphoid	3 (6%)		3 (6%)
#Testis	(50)	(49)	(50)
Hyperplasia, lymphoid			1 (2%)
#Thyroid	(49)	(48)	(50)
Hyperplasia, lymphoid	1 (2%)	1 (2%)	

TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>HEMATOPOIETIC SYSTEM (Continued)</b>			
#Thymus	(30)	(29)	(33)
Cyst, NOS	2 (7%)		2 (6%)
Multiple cysts	4 (13%)	2 (7%)	6 (18%)
Necrosis, NOS	1 (3%)	4 (14%)	1 (3%)
Atrophy, NOS	1 (3%)	6 (21%)	6 (18%)
Hyperplasia, epithelial	2 (7%)		1 (3%)
Hyperplasia, lymphoid	1 (3%)		
<b>CIRCULATORY SYSTEM</b>			
#Lymph node	(49)	(47)	(48)
Lymphangiectasis		1 (2%)	
#Mandibular lymph node	(49)	(47)	(48)
Lymphangiectasis		1 (2%)	
#Lung	(50)	(49)	(50)
Thrombosis, NOS		1 (2%)	1 (2%)
#Heart	(50)	(49)	(50)
Inflammation, pyogranulomatous	1 (2%)		
#Myocardium	(50)	(49)	(50)
Inflammation, chronic focal	2 (4%)		
Inflammation with fibrosis		1 (2%)	
Necrosis, focal		1 (2%)	
Calcification, NOS	1 (2%)		
Cytomegaly	1 (2%)		
*Artery	(50)	(50)	(50)
Inflammation, chronic			1 (2%)
<b>DIGESTIVE SYSTEM</b>			
*Hard palate	(50)	(50)	(50)
Inflammation, acute/chronic			1 (2%)
*Tongue	(50)	(50)	(50)
Hemoglobin pigment	1 (2%)		
*Tooth	(50)	(50)	(50)
Dysplasia, NOS	4 (8%)	2 (4%)	3 (6%)
*Pulp of tooth	(50)	(50)	(50)
Inflammation, acute	1 (2%)	1 (2%)	
Inflammation, granulomatous			1 (2%)
*Periodontal tissues	(50)	(50)	(50)
Inflammation, acute/chronic			1 (2%)
Granuloma, foreign body	1 (2%)		
Inflammation with fibrosis		2 (4%)	
Fibrosis	2 (4%)		
#Salivary gland	(50)	(47)	(50)
Dilatation/ducts		1 (2%)	
Fibrosis		1 (2%)	
Degeneration, NOS			1 (2%)
Calcification, focal		1 (2%)	
#Liver	(50)	(49)	(50)
Inflammation, chronic focal			1 (2%)
Degeneration, granular			1 (2%)
Necrosis, NOS	1 (2%)		1 (2%)
Necrosis, focal	4 (8%)	4 (8%)	3 (6%)
Necrosis, coagulative	1 (2%)		1 (2%)
Metamorphosis, fatty			1 (2%)
Basophilic cyto change			1 (2%)
Focal cellular change		1 (2%)	
Hepatocytomegaly			1 (2%)
Multinucleate giant cell			1 (2%)
Syncytial alteration			1 (2%)
Hyperplasia, focal			1 (2%)
Angiectasis	1 (2%)	1 (2%)	1 (2%)

TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>DIGESTIVE SYSTEM (Continued)</b>			
#Liver/centrilobular Congestion, NOS	(50)	(49)	(50) 1 (2%)
#Liver/hepatocytes Inclusion, nuclear	(50)	(49)	(50) 2 (4%)
*Gallbladder	(50)	(50)	(50)
Calculus, gross observation only			1 (2%)
Cyst, NOS		1 (2%)	
Inflammation, acute/chronic			1 (2%)
Hyperplasia, papillary		1 (2%)	2 (4%)
*Gallbladder/mucosa	(50)	(50)	(50)
Degeneration, hyaline		1 (2%)	
#Bile duct	(50)	(49)	(50)
Multiple cysts		1 (2%)	
#Pancreas	(49)	(48)	(48)
Cyst, NOS			1 (2%)
Multiple cysts		1 (2%)	
Inflammation, chronic		1 (2%)	
Inflammation, granulomatous			1 (2%)
Atrophy, focal	1 (2%)	1 (2%)	
#Pancreatic acinus	(49)	(48)	(48)
Degeneration, NOS		1 (2%)	1 (2%)
Cytoplasmic vacuolization	4 (8%)	2 (4%)	1 (2%)
*Esophageal lumen	(50)	(50)	(50)
Inflammation, suppurative		1 (2%)	
#Glandular stomach	(49)	(46)	(48)
Cyst, NOS	1 (2%)		2 (4%)
Multiple cysts			2 (4%)
Inflammation, acute	2 (4%)		
Inflammation, acute/chronic	2 (4%)		
Degeneration, hyaline			1 (2%)
Dysplasia, NOS		2 (4%)	
#Forestomach	(49)	(46)	(48)
Cyst, NOS	1 (2%)		
Inflammation, acute		1 (2%)	
Inflammation, acute/chronic			2 (4%)
Inflammation, chronic focal		1 (2%)	
Hyperplasia, epithelial	1 (2%)		1 (2%)
Hyperkeratosis		1 (2%)	1 (2%)
#Peyer's patch	(47)	(44)	(45)
Inflammation, acute	1 (2%)		
<b>URINARY SYSTEM</b>			
#Kidney	(50)	(49)	(50)
Mineralization	1 (2%)	3 (6%)	8 (16%)
Cyst, NOS	1 (2%)	3 (6%)	4 (8%)
Multiple cysts	2 (4%)		
Congestion, NOS	2 (4%)		2 (4%)
Hemorrhage	1 (2%)		
Inflammation, acute necrotizing		1 (2%)	
Nephropathy	8 (16%)	8 (16%)	13 (26%)
Nephrosis, NOS			1 (2%)
Infarct, NOS	1 (2%)		
Amyloidosis			2 (4%)
Atrophy, NOS	1 (2%)		
Metaplasia, osseous	3 (6%)		1 (2%)
#Kidney/cortex	(50)	(49)	(50)
Necrosis, NOS		1 (2%)	
#Renal papilla	(50)	(49)	(50)
Necrosis, NOS		2 (4%)	

TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>URINARY SYSTEM (Continued)</b>			
#Perirenal tissue	(50)	(49)	(50)
Inflammation, acute			1 (2%)
Calcification, NOS		1 (2%)	
#Kidney/tubule	(50)	(49)	(50)
Dilatation, NOS			1 (2%)
Degeneration, NOS			1 (2%)
#Convolutated tubules	(50)	(49)	(50)
Dilatation, NOS		1 (2%)	
Metamorphosis, fatty			1 (2%)
*Ureter	(50)	(50)	(50)
Inflammation, acute			1 (2%)
#Urinary bladder	(48)	(45)	(45)
Calculus, gross observation only	1 (2%)		1 (2%)
Edema, NOS	1 (2%)		
Hemorrhage		1 (2%)	
Inflammation, acute		1 (2%)	1 (2%)
Calcification, NOS		1 (2%)	
Hyperplasia, epithelial	1 (2%)	1 (2%)	1 (2%)
Angiectasis			2 (4%)
<b>ENDOCRINE SYSTEM</b>			
#Pituitary	(44)	(48)	(49)
Congestion, NOS		3 (6%)	1 (2%)
#Anterior pituitary	(44)	(48)	(49)
Cyst, NOS	2 (5%)	1 (2%)	2 (4%)
Multiple cysts		2 (4%)	1 (2%)
Angiectasis			1 (2%)
#Adrenal/capsule	(48)	(49)	(49)
Hyperplasia, stromal	24 (50%)	16 (33%)	17 (35%)
#Adrenal cortex	(48)	(49)	(49)
Ectopia	1 (2%)	1 (2%)	
Cyst, NOS	1 (2%)	1 (2%)	
Degeneration, lipoid		1 (2%)	
Necrosis, focal			1 (2%)
Metamorphosis, fatty			1 (2%)
Focal cellular change	3 (6%)	3 (6%)	
Hypertrophy, focal	9 (19%)	9 (18%)	8 (16%)
Hyperplasia, focal	2 (4%)	1 (2%)	6 (12%)
#Adrenal medulla	(48)	(49)	(49)
Hyperplasia, focal	3 (6%)	4 (8%)	4 (8%)
#Thyroid	(49)	(48)	(50)
Follicular cyst, NOS	1 (2%)	2 (4%)	
Lymphocytic inflammatory infiltrate		1 (2%)	
Inflammation, granulomatous		1 (2%)	
Inflammation with fibrosis		1 (2%)	
Cholesterol deposit		1 (2%)	
Calcification, NOS		1 (2%)	
Hyperplasia, follicular cell	2 (4%)	1 (2%)	1 (2%)
#Thyroid follicle	(49)	(48)	(50)
Crystals, NOS		1 (2%)	
#Parathyroid	(43)	(38)	(37)
Cyst, NOS		2 (5%)	1 (3%)
#Pancreatic islets	(49)	(48)	(48)
Hypertrophy, NOS	1 (2%)		
Hyperplasia, NOS	1 (2%)		

TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>REPRODUCTIVE SYSTEM</b>			
*Penis	(50)	(50)	(50)
Inflammation, acute/chronic			1 (2%)
*Prepuce	(50)	(50)	(50)
Ulcer, NOS	1 (2%)		1 (2%)
Inflammation, suppurative		2 (4%)	
Abscess, NOS			1 (2%)
Inflammation, acute/chronic			1 (2%)
Necrosis, NOS		1 (2%)	
*Preputial gland	(50)	(50)	(50)
Dilatation, NOS		1 (2%)	
Inflammation, acute	1 (2%)		
Abscess, NOS		1 (2%)	
Inflammation, acute/chronic	5 (10%)	2 (4%)	5 (10%)
Inflammation, chronic	3 (6%)	1 (2%)	2 (4%)
Inflammation, pyogranulomatous			1 (2%)
Inflammation with fibrosis	1 (2%)		
Metaplasia, squamous	9 (18%)	9 (18%)	9 (18%)
#Prostate	(49)	(46)	(49)
Cyst, NOS	1 (2%)		
Inflammation, suppurative		2 (4%)	1 (2%)
Inflammation, acute			1 (2%)
Amyloidosis		1 (2%)	
*Seminal vesicle	(50)	(50)	(50)
Dilatation, NOS		1 (2%)	
Inflammation, suppurative			1 (2%)
#Testis	(50)	(49)	(50)
Degeneration, NOS		1 (2%)	1 (2%)
Necrosis, NOS		1 (2%)	
Calcification, NOS	4 (8%)		2 (4%)
Atrophy, NOS	3 (6%)	1 (2%)	4 (8%)
Atrophy, focal	2 (4%)		
Hyperplasia, interstitial cell	1 (2%)		
*Epididymis	(50)	(50)	(50)
Inflammation, acute/chronic		1 (2%)	
Inflammation, chronic focal	1 (2%)		1 (2%)
Perivascular cuffing	1 (2%)		1 (2%)
Calcification, NOS	1 (2%)		1 (2%)
<b>NERVOUS SYSTEM</b>			
#Brain	(48)	(49)	(50)
Congestion, NOS		5 (10%)	2 (4%)
Hemorrhage	1 (2%)		1 (2%)
#Brain/thalamus	(48)	(49)	(50)
Calcification, NOS	28 (58%)	26 (53%)	27 (54%)
*Spinal cord	(50)	(50)	(50)
Epidermal inclusion cyst			1 (2%)
Perivascular cuffing			1 (2%)
Demyelination	1 (2%)		
<b>SPECIAL SENSE ORGANS</b>			
*Nasolacrimal duct	(50)	(50)	(50)
Hemorrhage	1 (2%)		
Inflammation, suppurative	1 (2%)		
Inflammation, chronic	1 (2%)		

TABLE C5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>MUSCULOSKELETAL SYSTEM</b>			
*Bone	(50)	(50)	(50)
Dyschondroplasia	1 (2%)	1 (2%)	1 (2%)
Atrophy, NOS			1 (2%)
Osteosclerosis	1 (2%)		
*Mandible	(50)	(50)	(50)
Osteosclerosis			1 (2%)
*Ankle joint	(50)	(50)	(50)
Ankylosis	15 (30%)	4 (8%)	4 (8%)
Fibrosis		1 (2%)	
*Skeletal muscle	(50)	(50)	(50)
Fibrosis			1 (2%)
<b>BODY CAVITIES</b>			
*Pericardial cavity	(50)	(50)	(50)
Hemorrhage			1 (2%)
<b>ALL OTHER SYSTEMS</b>			
Periorbital region			
Inflammation, pyogranulomatous		1	
Knee			
Dyschondroplasia	16	9	10
Ankle			
Dyschondroplasia	1		
Adipose tissue			
Necrosis, fat	5	3	1
Renal pelvic cavity			
Inflammation, suppurative			1
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
Auto/necropsy/no histo		1	

\* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically.

# Number of animals examined microscopically at this site





## APPENDIX D

### SUMMARY OF LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	PAGE	
TABLE D1	SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	137
TABLE D2	INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	140
TABLE D3	ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	146
TABLE D4a	HISTORICAL INCIDENCE OF OVARIAN TUMORS IN FEMALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT	150
TABLE D4b	HISTORICAL INCIDENCE OF PITUITARY GLAND TUMORS IN FEMALE B6C3F <sub>1</sub> MICE RECEIVING NO TREATMENT	151
TABLE D5	SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	152



TABLE D1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR  
FEED STUDY OF NITROFURAZONE

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*Subcutaneous tissue	(50)	(50)	(50)
Fibrosarcoma	1 (2%)	1 (2%)	
Neurilemoma, malignant			1 (2%)
<b>RESPIRATORY SYSTEM</b>			
#Lung	(50)	(49)	(49)
Alveolar/bronchiolar adenoma	2 (4%)	6 (12%)	6 (12%)
Alveolar/bronchiolar carcinoma	1 (2%)	1 (2%)	
Osteosarcoma, metastatic	1 (2%)		
<b>HEMATOPOIETIC SYSTEM</b>			
*Multiple organs	(50)	(50)	(50)
Malignant lymphoma, NOS	2 (4%)		1 (2%)
Malignant lymphoma, undifferentiated type			1 (2%)
Malignant lymphoma, lymphocytic type	1 (2%)		2 (4%)
Malignant lymphoma, histiocytic type		3 (6%)	
Malignant lymphoma, mixed type	16 (32%)	13 (26%)	9 (18%)
Plasma cell tumor		1 (2%)	
#Spleen	(49)	(50)	(50)
Malignant lymphoma, lymphocytic type	1 (2%)		
Malignant lymphoma, mixed type	2 (4%)	3 (6%)	
#Mandibular lymph node	(49)	(12)	(49)
Squamous cell carcinoma, metastatic		1 (8%)	
#Peyer's patch	(48)	(8)	(44)
Malignant lymphoma, mixed type		1 (13%)	
#Duodenum	(48)	(8)	(44)
Malignant lymphoma, mixed type			1 (2%)
#Jejunum	(48)	(8)	(44)
Malignant lymphoma, mixed type		1 (13%)	
#Uterus	(50)	(40)	(50)
Malignant lymphoma, histiocytic type		1 (3%)	
<b>CIRCULATORY SYSTEM</b>			
*Abdominal cavity	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)	
#Liver	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)
*Mesentery	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)		
#Urinary bladder	(48)	(3)	(47)
Hemangioma	1 (2%)		
#Ovary	(47)	(50)	(50)
Hemangioma	1 (2%)		
<b>DIGESTIVE SYSTEM</b>			
#Liver	(50)	(50)	(50)
Hepatocellular adenoma	2 (4%)	1 (2%)	1 (2%)
Hepatocellular carcinoma	1 (2%)	2 (4%)	
#Glandular stomach	(48)	(9)	(47)
Adenomatous polyp, NOS			1 (2%)

**TABLE D1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>DIGESTIVE SYSTEM (Continued)</b>			
#Forestomach	(48)	(9)	(47)
Papilloma, NOS		1 (11%)	2 (4%)
Squamous cell carcinoma		1 (11%)	
<b>URINARY SYSTEM</b>			
#Kidney	(50)	(7)	(50)
Tubular cell adenoma	1 (2%)		
Tubular cell adenocarcinoma			1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#Anterior pituitary	(50)	(50)	(49)
Carcinoma, NOS	1 (2%)	2 (4%)	
Adenoma, NOS	9 (18%)	5 (10%)	2 (4%)
Sarcoma, NOS	1 (2%)		
#Adrenal	(49)	(6)	(48)
Sarcoma, NOS		1 (17%)	
#Adrenal/capsule	(49)	(6)	(48)
Adenoma, NOS			2 (4%)
#Adrenal medulla	(49)	(6)	(48)
Pheochromocytoma	1 (2%)		2 (4%)
#Thyroid	(50)	(4)	(50)
Follicular cell adenoma			2 (4%)
Fibrosarcoma, metastatic		1 (25%)	
<b>REPRODUCTIVE SYSTEM</b>			
*Mammary gland	(50)	(50)	(50)
Adenocarcinoma, NOS		1 (2%)	2 (4%)
#Uterus	(50)	(42)	(50)
Adenocarcinoma, NOS			1 (2%)
Endometrial stromal polyp	3 (6%)	3 (7%)	
#Ovary	(47)	(50)	(50)
Cystadenoma, NOS	2 (4%)	2 (4%)	2 (4%)
Luteoma	2 (4%)	2 (4%)	
Granulosa cell tumor	1 (2%)	4 (8%)	9 (18%)
Tubular adenoma		2 (4%)	
Mixed tumor, benign		17 (34%)	20 (40%)
Teratoma, NOS			1 (2%)
<b>NERVOUS SYSTEM</b>			
None			
<b>SPECIAL SENSE ORGANS</b>			
*Eyelid	(50)	(50)	(50)
Papilloma, NOS			1 (2%)
*Harderian gland	(50)	(50)	(50)
Carcinoma, NOS	1 (2%)	3 (6%)	1 (2%)
*Ear	(50)	(50)	(50)
Squamous cell carcinoma		1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>			
None			

TABLE D1. SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE IN THE TWO-YEAR  
FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>BODY CAVITIES</b>			
*Pleura	(50)	(50)	(50)
Osteosarcoma	1 (2%)		
<b>ALL OTHER SYSTEMS</b>			
None			
<b>ANIMAL DISPOSITION SUMMARY</b>			
Animals initially in study	50	50	50
Natural death	4	3	6
Moribund sacrifice	7	7	8
Terminal sacrifice	39	40	35
Accidentally killed, nda			1
<b>TUMOR SUMMARY</b>			
Total animals with primary tumors**	36	43	42
Total primary tumors	55	80	72
Total animals with benign tumors	20	29	33
Total benign tumors	24	39	41
Total animals with malignant tumors	24	30	19
Total malignant tumors	30	36	21
Total animals with secondary tumors##	1	2	
Total secondary tumors	1	2	
Total animals with tumors uncertain--			
benign or malignant	1	5	10
Total uncertain tumors	1	5	10

\* Number of animals receiving complete necropsy examinations; all gross lesions including masses examined microscopically.

\*\* Primary tumors: all tumors except secondary tumors

# Number of animals examined microscopically at this site

## Secondary tumors: metastatic tumors or tumors invasive into an adjacent organ













**TABLE D2. INDIVIDUAL ANIMAL TUMOR PATHOLOGY OF FEMALE MICE: HIGH DOSE**  
(Continued)

ANIMAL NUMBER	063	065	066	067	068	069	070	071	072	073	074	075	076	077	078	079	080	081	082	083	084	085	086	087	088	089	090	091	092	093	094	095	096	097	098	099	100	TOTAL TISSUES TUMORS	
WEEKS ON STUDY	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	14	
<b>INTEGUMENTARY SYSTEM</b>																																							
Subcutaneous tissue																																							
Neurilemoma, malignant																																					*50 1		
<b>RESPIRATORY SYSTEM</b>																																							
Lungs and bronchi																																					49		
Alveolar/bronchiolar adenoma																																					6		
Trachea																																					50		
<b>HEMATOPOIETIC SYSTEM</b>																																							
Bone marrow																																					49		
Spleen																																					50		
Lymph nodes																																					49		
Thymus																																					33		
<b>CIRCULATORY SYSTEM</b>																																							
Heart																																					50		
<b>DIGESTIVE SYSTEM</b>																																							
Salivary gland																																					49		
Liver																																					50		
Hepatocellular adenoma																																					1		
Hemangiosarcoma																																					1		
Bile duct																																					50		
Gallbladder & common bile duct																																					*50		
Pancreas																																					48		
Esophagus																																					50		
Stomach																																					47		
Papilloma, NOS																																					2		
Adematous polyp, NOS																																					1		
Small intestine																																					44		
Malignant lymphoma, mixed type																																					1		
Large intestine																																					44		
<b>URINARY SYSTEM</b>																																							
Kidney																																					50		
Tubular cell adenocarcinoma																																					1		
Urinary bladder																																					47		
<b>ENDOCRINE SYSTEM</b>																																							
Pituitary																																					49		
Adenoma, NOS																																					2		
Adrenal																																					48		
Adenoma, NOS																																					2		
Pheochromocytoma																																					2		
Thyroid																																					50		
Follicular cell adenoma																																					2		
Parathyroid																																					40		
<b>REPRODUCTIVE SYSTEM</b>																																							
Mammary gland																																					*50		
Adenocarcinoma, NOS																																					2		
Uterus																																					50		
Adenocarcinoma, NOS																																					1		
Ovary																																					50		
Cystadenoma, NOS																																					2		
Granulosa cell tumor																																					9		
Mixed tumor, benign																																					20		
Teratoma, NOS																																					1		
<b>NERVOUS SYSTEM</b>																																							
Brain																																					50		
<b>SPECIAL SENSE ORGANS</b>																																							
Eye appendages																																					*50		
Papilloma, NOS																																					1		
Harderian gland																																					*50		
Carcinoma, NOS																																					1		
<b>ALL OTHER SYSTEMS</b>																																							
Multiple organs, NOS																																					*50		
Malignant lymphoma, NOS																																					1		
Malignant lymphoma, undiffer type																																					2		
Malignant lymphoma, lymphocytic type																																					9		
Malignant lymphoma, mixed type																																							

\* Animals necropsied

TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Control	150 ppm	310 ppm
<b>Lung: Alveolar/Bronchiolar Adenoma</b>			
Overall Rates (a)	2/50 (4%)	6/49 (12%)	6/49 (12%)
Adjusted Rates (b)	5.1%	14.7%	17.1%
Terminal Rates (c)	2/39 (5%)	5/39 (13%)	5/34 (15%)
Week of First Observation	104	91	103
Life Table Tests (d)	P=0.056	P=0.137N	P=0.098
Incidental Tumor Tests (d)	P=0.064	P=0.136	P=0.100
Cochran-Armitage Trend Test (d)	P=0.075		
Fisher Exact Test (d)		P=0.128	P=0.128
<b>Lung: Alveolar/Bronchiolar Adenoma or Carcinoma</b>			
Overall Rates (a)	3/50 (6%)	7/49 (14%)	6/49 (12%)
Adjusted Rates (b)	7.2%	17.2%	17.1%
Terminal Rates (c)	2/39 (5%)	6/39 (15%)	5/34 (15%)
Week of First Observation	93	91	103
Life Table Tests (d)	P=0.133	P=0.163N	P=0.188
Incidental Tumor Tests (d)	P=0.149	P=0.155	P=0.193
Cochran-Armitage Trend Test (d)	P=0.170		
Fisher Exact Test (d)		P=0.151	P=0.233
<b>Hematopoietic System: Malignant Lymphoma, Histiocytic Type</b>			
Overall Rates (a)	0/50 (0%)	4/50 (8%)	0/50 (0%)
Adjusted Rates (b)	0.0%	9.8%	0.0%
Terminal Rates (c)	0/39 (0%)	3/40 (7%)	0/35 (0%)
Week of First Observation		101	
Life Table Tests (d)	P=0.613	P=0.068	(e)
Incidental Tumor Tests (d)	P=0.621	P=0.061	(e)
Cochran-Armitage Trend Test (d)	P=0.605N		
Fisher Exact Test (d)		P=0.059	(e)
<b>Hematopoietic System: Malignant Lymphoma, Mixed Type</b>			
Overall Rates (a)	18/50 (36%)	18/50 (36%)	10/50 (20%)
Adjusted Rates (b)	40.6%	41.7%	26.5%
Terminal Rates (c)	13/39 (33%)	15/40 (38%)	8/35 (23%)
Week of First Observation	86	95	86
Life Table Tests (d)	P=0.106N	P=0.545N	P=0.123N
Incidental Tumor Tests (d)	P=0.077N	P=0.567	P=0.085N
Cochran-Armitage Trend Test (d)	P=0.050N		
Fisher Exact Test (d)		P=0.583N	P=0.059N
<b>Hematopoietic System: Lymphoma, All Malignant</b>			
Overall Rates (a)	22/50 (44%)	22/50 (44%)	14/50 (28%)
Adjusted Rates (b)	47.4%	49.9%	33.7%
Terminal Rates (c)	15/39 (38%)	18/40 (45%)	8/35 (23%)
Week of First Observation	56	95	40
Life Table Tests (d)	P=0.148N	P=0.537N	P=0.172N
Incidental Tumor Tests (d)	P=0.093N	P=0.475	P=0.093N
Cochran-Armitage Trend Test (d)	P=0.060N		
Fisher Exact Test (d)		P=0.580N	P=0.072N
<b>Circulatory System: Hemangioma or Hemangiosarcoma</b>			
Overall Rates (a)	3/50 (6%)	1/50 (2%)	1/50 (2%)
Adjusted Rates (b)	7.1%	2.2%	2.9%
Terminal Rates (c)	2/39 (5%)	0/40 (0%)	1/35 (3%)
Week of First Observation	90	92	104
Life Table Tests (d)	P=0.237N	P=0.300N	P=0.348N
Incidental Tumor Tests (d)	P=0.198N	P=0.297N	P=0.315N
Cochran-Armitage Trend Test (d)	P=0.208N		
Fisher Exact Test (d)		P=0.309N	P=0.309N

TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Control	150 ppm	310 ppm
<b>Liver: Hepatocellular Adenoma or Carcinoma</b>			
Overall Rates (a)	3/50 (6%)	3/50 (6%)	1/50 (2%)
Adjusted Rates (b)	7.7%	7.5%	2.4%
Terminal Rates (c)	3/39 (8%)	3/40 (7%)	0/35 (0%)
Week of First Observation	104	104	89
Life Table Tests (d)	P=0.274N	P=0.652N	P=0.346N
Incidental Tumor Tests (d)	P=0.257N	P=0.652N	P=0.315N
Cochran-Armitage Trend Test (d)	P=0.238N		
Fisher Exact Test (d)		P=0.661	P=0.309N
<b>Anterior Pituitary Gland: Adenoma</b>			
Overall Rates (a)	9/50 (18%)	5/50 (10%)	2/49 (4%)
Adjusted Rates (b)	22.4%	12.5%	5.7%
Terminal Rates (c)	8/39 (21%)	5/40 (13%)	2/35 (6%)
Week of First Observation	96	104	104
Life Table Tests (d)	P=0.025N	P=0.180N	P=0.041N
Incidental Tumor Tests (d)	P=0.026N	P=0.187N	P=0.043N
Cochran-Armitage Trend Test (d)	P=0.019N		
Fisher Exact Test (d)		P=0.194N	P=0.028N
<b>Anterior Pituitary Gland: Adenoma or Carcinoma</b>			
Overall Rates (a)	10/50 (20%)	7/50 (14%)	2/49 (4%)
Adjusted Rates (b)	24.1%	17.5%	5.7%
Terminal Rates (c)	8/39 (21%)	7/40 (18%)	2/35 (6%)
Week of First Observation	93	104	104
Life Table Tests (d)	P=0.019N	P=0.280N	P=0.026N
Incidental Tumor Tests (d)	P=0.019N	P=0.296N	P=0.027N
Cochran-Armitage Trend Test (d)	P=0.013N		
Fisher Exact Test (d)		P=0.298N	P=0.015N
<b>Uterus: Endometrial Stromal Polyp</b>			
Overall Rates (a)	3/50 (6%)	3/42 (7%)	0/50 (0%)
Adjusted Rates (b)	7.7%	7.8%	0.0%
Terminal Rates (c)	3/39 (8%)	2/34 (6%)	0/35 (0%)
Week of First Observation	104	90	
Life Table Tests (d)	P=0.124N	P=0.610	P=0.141N
Incidental Tumor Tests (d)	P=0.114N	P=0.585	P=0.141N
Cochran-Armitage Trend Test (d)	P=0.105N		
Fisher Exact Test (d)		P=0.575	P=0.121N
<b>Ovary: Granulosa Cell Tumor</b>			
Overall Rates (a)	1/47 (2%)	4/50 (8%)	9/50 (18%)
Adjusted Rates (b)	2.6%	10.0%	23.9%
Terminal Rates (c)	1/39 (3%)	4/40 (10%)	7/35 (20%)
Week of First Observation	104	104	88
Life Table Tests (d)	P=0.003	P=0.187	P=0.007
Incidental Tumor Tests (d)	P=0.004	P=0.187	P=0.009
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Test (d)		P=0.201	P=0.010
<b>Ovary: Granulosa Cell Tumor or Luteoma</b>			
Overall Rates (a)	3/47 (6%)	6/50 (12%)	9/50 (18%)
Adjusted Rates (b)	7.7%	14.5%	23.9%
Terminal Rates (c)	3/39 (8%)	5/40 (13%)	7/35 (20%)
Week of First Observation	104	96	88
Life Table Tests (d)	P=0.030	P=0.257	P=0.043
Incidental Tumor Tests (d)	P=0.039	P=0.267	P=0.055
Cochran-Armitage Trend Test (d)	P=0.056		
Fisher Exact Test (d)		P=0.275	P=0.075

TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Control	150 ppm	310 ppm
<b>Ovary: Mixed Tumor, Benign</b>			
Overall Rates (a)	0/47 (0%)	17/50 (34%)	20/50 (40%)
Adjusted Rates (b)	0.0%	41.4%	55.5%
Terminal Rates (c)	0/39 (0%)	16/40 (40%)	19/35 (54%)
Week of First Observation		96	97
Life Table Tests (d)	P<0.001	P<0.001	P<0.001
Incidental Tumor Tests (d)	P<0.001	P<0.001	P<0.001
Cochran-Armitage Trend Test (d)	P<0.001		
Fisher Exact Test (d)		P<0.001	P<0.001
<b>Ovary: Tubular Cell Adenoma or Mixed Tumor, Benign</b>			
Overall Rates (a)	0/47 (0%)	18/50 (36%)	20/50 (40%)
Adjusted Rates (b)	0.0%	43.8%	55.5%
Terminal Rates (c)	0/39 (0%)	17/40 (43%)	19/35 (54%)
Week of First Observation		96	97
Life Table Tests (d)	P<0.001	P<0.001	P<0.001
Incidental Tumor Tests (d)	P<0.001	P<0.001	P<0.001
Cochran-Armitage Trend Test (d)	P<0.001		
Fisher Exact Test (d)		P<0.001	P<0.001
<b>Harderian Gland: Carcinoma</b>			
Overall Rates (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)
Adjusted Rates (b)	2.6%	7.5%	2.9%
Terminal Rates (c)	1/39 (3%)	3/40 (7%)	1/35 (3%)
Week of First Observation	104	104	104
Life Table Tests (d)	P=0.585	P=0.314	P=0.738
Incidental Tumor Tests (d)	P=0.585	P=0.314	P=0.738
Cochran-Armitage Trend Test (d)	P=0.604N		
Fisher Exact Test (d)		P=0.309	P=0.753
<b>All Sites: Benign Tumors</b>			
Overall Rates (a)	20/50 (40%)	29/50 (58%)	33/50 (66%)
Adjusted Rates (b)	47.3%	67.2%	84.5%
Terminal Rates (c)	17/39 (44%)	26/40 (65%)	29/35 (83%)
Week of First Observation	90	90	86
Life Table Tests (d)	P<0.001	P=0.073	P=0.001
Incidental Tumor Tests (d)	P<0.001	P=0.059	P=0.001
Cochran-Armitage Trend Test (d)	P=0.006		
Fisher Exact Test (d)		P=0.055	P=0.008
<b>All Sites: Malignant Tumors</b>			
Overall Rates (a)	24/50 (48%)	30/50 (60%)	19/50 (38%)
Adjusted Rates (b)	50.7%	63.8%	43.7%
Terminal Rates (c)	16/39 (41%)	23/40 (58%)	11/35 (31%)
Week of First Observation	56	91	40
Life Table Tests (d)	P=0.355N	P=0.229	P=0.381N
Incidental Tumor Tests (d)	P=0.247N	P=0.098	P=0.256N
Cochran-Armitage Trend Test (d)	P=0.175N		
Fisher Exact Test (d)		P=0.158	P=0.210N
<b>All Sites: All Tumors</b>			
Overall Rates (a)	36/50 (72%)	43/50 (86%)	42/50 (84%)
Adjusted Rates (b)	74.9%	87.8%	91.3%
Terminal Rates (c)	27/39 (69%)	34/40 (85%)	31/35 (89%)
Week of First Observation	56	45	40
Life Table Tests (d)	P=0.040	P=0.184	P=0.055
Incidental Tumor Tests (d)	P=0.027	P=0.067	P=0.030
Cochran-Armitage Trend Test (d)	P=0.086		
Fisher Exact Test (d)		P=0.070	P=0.113

**TABLE D3. ANALYSIS OF PRIMARY TUMORS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

---

- (a) Number of tumor-bearing animals/number of animals examined at the site
- (b) Kaplan-Meier estimated tumor incidences at the end of the study after adjusting for intercurrent mortality
- (c) Observed tumor incidence at terminal kill
- (d) Beneath the control incidence are the P values associated with the trend test. Beneath the dosed group incidence are the P values corresponding to pairwise comparisons between that dosed group and the controls. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The incidental tumor test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. A negative trend or lower incidence in a dosed group is indicated by (N).
- (e) No P value is reported because no tumors were observed in the 310-ppm and control groups

**TABLE D4a. HISTORICAL INCIDENCE OF OVARIAN TUMORS IN FEMALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

Study	No. Examined	No. of Tumors	Diagnosis
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	41	0	
Phenylephrine hydrochloride	49	0	
Oxytetracycline hydrochloride	44	2	Cystadenoma, NOS
<b>TOTAL</b>	<b>134</b>	<b>2 (1.5%)</b>	
<b>Overall Historical Incidence</b>			
		1	Adenoma, NOS
		2	Papillary adenoma
		3	Cystadenoma, NOS
		8	Papillary cystadenoma, NOS
		1	Luteoma
		4	Tubular adenoma
		1	Mixed tumor, benign
		6	Granulosa cell tumor
		1	Carcinoma, NOS
		1	Adenocarcinoma, NOS
		1	Cystadenocarcinoma, NOS
		1	Papillary cystadenocarcinoma, NOS
		1	Mucinous adenocarcinoma
		1	Granulosa cell carcinoma
<b>TOTAL</b>	<b>1,858</b>	<b>8 (0.4%)</b>	<b>Granulosa cell tumor or luteoma</b>
		<b>1 (&lt;0.1%)</b>	<b>Mixed tumor, benign</b>
		<b>4 (0.2%)</b>	<b>Tubular cell adenoma</b>
		<b>32 (1.7%)</b>	<b>All tumors</b>

(a) Data as of August 7, 1986, for studies of at least 104 weeks



**TABLE D4b. HISTORICAL INCIDENCE OF PITUITARY GLAND TUMORS IN FEMALE B6C3F<sub>1</sub> MICE RECEIVING NO TREATMENT (a)**

Study	Incidence in Controls		
	Adenoma (b)	Carcinoma (c)	Adenoma or Carcinoma (b,c)
<b>Historical Incidence at Physiological Research Laboratories</b>			
Ephedrine sulfate	8/48	2/48	10/48
Phenylephrine hydrochloride	0/48	0/48	0/48
Oxytetracycline hydrochloride	13/50	3/50	16/50
<b>TOTAL</b>	<b>21/146 (14.4%)</b>	<b>5/146 (3.4%)</b>	<b>26/146 (17.8%)</b>
SD (d)	13.17%	3.07%	16.24%
<b>Range (e)</b>			
High	13/50	3/50	16/50
Low	0/48	0/48	0/48
<b>Overall Historical Incidence</b>			
<b>TOTAL</b>	<b>192/1,764 (10.9%)</b>	<b>12/1,764 (0.7%)</b>	<b>204/1,764 (11.6%)</b>
SD (d)	9.47%	1.44%	9.67%
<b>Range (e)</b>			
High	12/40	3/50	16/50
Low	0/48	0/49	0/48

(a) Data as of August 7, 1986, for studies of at least 104 weeks

(b) Includes adenomas, NOS, and chromophobe adenomas

(c) Includes carcinomas, NOS, adenocarcinomas, NOS, and chromophobe carcinomas

(d) Standard deviation

(e) Range and SD are presented for groups of 35 or more animals.

TABLE D5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

	Untreated Control	Low Dose	High Dose
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
<b>INTEGUMENTARY SYSTEM</b>			
*Skin	(50)	(50)	(50)
Ectopia	2 (4%)		2 (4%)
Epidermal inclusion cyst	1 (2%)		
Ulcer, NOS	1 (2%)		
*Subcutaneous tissue	(50)	(50)	(50)
Inflammation, acute		1 (2%)	
Necrosis, fat		1 (2%)	
<b>RESPIRATORY SYSTEM</b>			
*Nasal cavity	(50)	(50)	(50)
Dermal inclusion cyst	1 (2%)		
Hemorrhage	2 (4%)		1 (2%)
Inflammation, acute			1 (2%)
*Nasal mucosa	(50)	(50)	(50)
Cyst, NOS	1 (2%)		
Multiple cysts	1 (2%)		
Degeneration, hyaline	29 (58%)		16 (32%)
#Lung/bronchus	(50)	(49)	(49)
Hyperplasia, epithelial			1 (2%)
#Lung/bronchiole	(50)	(49)	(49)
Crystals, NOS			1 (2%)
#Lung	(50)	(49)	(49)
Mineralization	2 (4%)		1 (2%)
Congestion, NOS	4 (8%)		2 (4%)
Hemorrhage	3 (6%)	2 (4%)	2 (4%)
Pneumonia, aspiration			1 (2%)
Inflammation, chronic focal	6 (12%)	8 (16%)	6 (12%)
Perivascular cuffing	5 (10%)	2 (4%)	1 (2%)
Calcification, NOS	1 (2%)		
Crystals, NOS		1 (2%)	
Alveolar macrophages	1 (2%)	3 (6%)	3 (6%)
Hyperplasia, adenomatous			1 (2%)
<b>HEMATOPOIETIC SYSTEM</b>			
#Brain/thalamus	(49)	(4)	(50)
Hyperplasia, lymphoid			1 (2%)
*Multiple organs	(50)	(50)	(50)
Hyperplasia, lymphoid	9 (18%)		5 (10%)
*Blood	(50)	(50)	(50)
Leukocytosis, NOS	1 (2%)		1 (2%)
#Bone marrow	(50)	(4)	(49)
Fibrosis, focal	1 (2%)		1 (2%)
Atrophy, NOS			1 (2%)
Hyperplasia, NOS	4 (8%)		
Hyperplasia, granulocytic	4 (8%)	2 (50%)	3 (6%)

TABLE D5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>HEMATOPOIETIC SYSTEM (Continued)</b>			
#Spleen	(49)	(50)	(50)
Dilatation, NOS		1 (2%)	
Infarct, healed			1 (2%)
Amyloidosis	1 (2%)		
Hemosiderosis			4 (8%)
Hyperplasia, reticulum cell	3 (6%)	5 (10%)	3 (6%)
Hyperplasia, lymphoid	16 (33%)	24 (48%)	19 (38%)
Hematopoiesis	5 (10%)	7 (14%)	4 (8%)
#Mandibular lymph node	(49)	(12)	(49)
Hyperplasia, lymphoid	2 (4%)		1 (2%)
#Mesenteric lymph node	(49)	(12)	(49)
Angiectasis	2 (4%)	1 (8%)	1 (2%)
Hyperplasia, lymphoid	2 (4%)		1 (2%)
#Renal lymph node	(49)	(12)	(49)
Hyperplasia, lymphoid	1 (2%)		
#Lung	(50)	(49)	(49)
Leukocytosis, NOS			1 (2%)
Hyperplasia, lymphoid	1 (2%)	1 (2%)	1 (2%)
#Salivary gland	(49)	(5)	(49)
Hyperplasia, lymphoid	3 (6%)		
#Liver	(50)	(50)	(50)
Hyperplasia, lymphoid	2 (4%)	1 (2%)	6 (12%)
Hematopoiesis	1 (2%)	3 (6%)	
#Pancreas	(48)	(4)	(48)
Hyperplasia, lymphoid			1 (2%)
#Stomach	(48)	(9)	(47)
Hyperplasia, lymphoid		1 (11%)	
#Cecum	(49)	(6)	(44)
Hyperplasia, lymphoid	1 (2%)		1 (2%)
#Kidney	(50)	(7)	(50)
Hyperplasia, lymphoid	2 (4%)	1 (14%)	9 (18%)
#Urinary bladder	(48)	(3)	(47)
Hyperplasia, lymphoid	3 (6%)		7 (15%)
#Thymus	(37)	(5)	(33)
Cyst, NOS	2 (5%)		1 (3%)
Multiple cysts	2 (5%)		1 (3%)
Hemorrhage	1 (3%)		
Atrophy, NOS	2 (5%)		
Angiectasis	1 (3%)		
Hyperplasia, lymphoid	4 (11%)		1 (3%)
<b>CIRCULATORY SYSTEM</b>			
*Skeletal muscle	(50)	(50)	(50)
Perivasculitis			1 (2%)
#Heart	(50)	(4)	(50)
Lymphocytic inflammatory infiltrate	1 (2%)		
#Myocardium	(50)	(4)	(50)
Fibrosis, focal	1 (2%)		
Calcification, NOS	3 (6%)		1 (2%)
*Pulmonary vein	(50)	(50)	(50)
Mineralization	1 (2%)		

TABLE D5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>DIGESTIVE SYSTEM</b>			
*Tooth	(50)	(50)	(50)
Dysplasia, NOS			1 (2%)
#Salivary gland	(49)	(5)	(49)
Degeneration, NOS	1 (2%)		
#Liver	(50)	(50)	(50)
Hemorrhage	1 (2%)		2 (4%)
Fibrosis, focal	1 (2%)		
Necrosis, focal	5 (10%)	11 (22%)	12 (24%)
Necrosis, cytodegenerative			1 (2%)
Necrosis, coagulative	2 (4%)	1 (2%)	1 (2%)
Metamorphosis, fatty	1 (2%)	2 (4%)	3 (6%)
Basophilic cyto change	1 (2%)	1 (2%)	1 (2%)
Clear cell change			1 (2%)
Hepatocytomegaly			1 (2%)
Angiectasis	1 (2%)		1 (2%)
#Hepatic capsule	(50)	(50)	(50)
Calcification, NOS		1 (2%)	1 (2%)
#Liver/centrilobular	(50)	(50)	(50)
Pigmentation, NOS		1 (2%)	
Cytoplasmic vacuolization	1 (2%)		
#Liver/Kupffer cell	(50)	(50)	(50)
Hyperplasia, NOS	1 (2%)		2 (4%)
*Gallbladder	(50)	(50)	(50)
Cyst, NOS	1 (2%)		
Degeneration, hyaline			1 (2%)
#Pancreas	(48)	(4)	(48)
Cyst, NOS	1 (2%)		1 (2%)
Inflammation, acute		1 (25%)	
Inflammation, chronic focal	2 (4%)		
Fibrosis, focal	1 (2%)		
Atrophy, NOS	2 (4%)		4 (8%)
#Pancreatic duct	(48)	(4)	(48)
Multiple cysts			1 (2%)
#Pancreatic acinus	(48)	(4)	(48)
Cytoplasmic vacuolization	3 (6%)		6 (13%)
#Esophageal submucosa	(50)	(4)	(50)
Inflammation, chronic focal	1 (2%)		
#Stomach	(48)	(9)	(47)
Inflammation, acute		1 (11%)	
#Gastric mucosa	(48)	(9)	(47)
Calcification, NOS			1 (2%)
#Glandular stomach	(48)	(9)	(47)
Cyst, NOS	1 (2%)		
Multiple cysts	3 (6%)		5 (11%)
Inflammation, acute/chronic	2 (4%)		
Inflammation, chronic focal	2 (4%)		
Calcification, NOS	3 (6%)		
Hyperplasia, epithelial	1 (2%)		
Dysplasia, NOS	1 (2%)		
#Forestomach	(48)	(9)	(47)
Mineralization			1 (2%)
Inflammation, acute/chronic		2 (22%)	1 (2%)
Hyperplasia, epithelial	1 (2%)	2 (22%)	
Hyperkeratosis		1 (11%)	

TABLE D5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>URINARY SYSTEM</b>			
#Kidney	(50)	(7)	(50)
Mineralization	2 (4%)		3 (6%)
Cyst, NOS	1 (2%)		1 (2%)
Inflammation, suppurative			1 (2%)
Glomerulonephritis, chronic	1 (2%)		
Nephropathy	7 (14%)		10 (20%)
Nephrosis, NOS		1 (14%)	
Nephrosis, toxic		1 (14%)	
Amyloidosis			1 (2%)
#Perirenal tissue	(50)	(7)	(50)
Hemorrhage	1 (2%)		
#Kidney/glomerulus	(50)	(7)	(50)
Amyloidosis			1 (2%)
#Convoluted tubules	(50)	(7)	(50)
Dilatation, NOS		1 (14%)	1 (2%)
Degeneration, hyaline	1 (2%)	1 (14%)	
Necrosis, focal			1 (2%)
Metamorphosis, fatty		1 (14%)	
#Kidney/pelvis	(50)	(7)	(50)
Mineralization			1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#Pituitary	(50)	(50)	(49)
Hemorrhage			1 (2%)
#Pituitary intermedia	(50)	(50)	(49)
Hyperplasia, focal	1 (2%)		
#Anterior pituitary	(50)	(50)	(49)
Cyst, NOS			1 (2%)
Multiple cysts	2 (4%)		
Focal cellular change			1 (2%)
Hyperplasia, focal	8 (16%)	4 (8%)	8 (16%)
Angiectasis		1 (2%)	
#Adrenal/capsule	(49)	(6)	(48)
Hyperplasia, stromal	46 (94%)	5 (83%)	42 (88%)
#Adrenal cortex	(49)	(6)	(48)
Ectopia	1 (2%)		2 (4%)
Degeneration, lipid	1 (2%)		
Hypertrophy, focal	1 (2%)	1 (17%)	2 (4%)
Hyperplasia, focal	1 (2%)		1 (2%)
Angiectasis	1 (2%)		
#Adrenal medulla	(49)	(6)	(48)
Hyperplasia, focal	3 (6%)		1 (2%)
#Thyroid	(50)	(4)	(50)
Multiple cysts			1 (2%)
Granuloma, NOS	1 (2%)		
Inflammation, pyogranulomatous			1 (2%)
Hyperplasia, follicular cell	2 (4%)		1 (2%)
#Parathyroid	(36)	(2)	(40)
Multiple cysts			1 (3%)
#Pancreatic islets	(48)	(4)	(48)
Hyperplasia, focal	1 (2%)		

TABLE D5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)

	Untreated Control	Low Dose	High Dose
<b>REPRODUCTIVE SYSTEM</b>			
*Mammary gland	(50)	(50)	(50)
Dilatation/ducts	1 (2%)	1 (2%)	2 (4%)
Cyst, NOS			1 (2%)
*Clitoral gland	(50)	(50)	(50)
Inflammation, acute/chronic		1 (2%)	
Metaplasia, squamous		1 (2%)	
#Uterus	(50)	(42)	(50)
Dilatation, NOS	1 (2%)	2 (5%)	2 (4%)
#Uterus/endometrium	(50)	(42)	(50)
Multiple cysts	3 (6%)	1 (2%)	1 (2%)
Inflammation, suppurative			1 (2%)
Inflammation, acute/chronic			1 (2%)
Hyperplasia, cystic	44 (88%)	36 (86%)	44 (88%)
Hyperplasia, stromal	1 (2%)		
Angiectasis		2 (5%)	2 (4%)
Metaplasia, squamous	1 (2%)		
#Fallopian tube	(50)	(40)	(50)
Multiple cysts			1 (2%)
#Ovary	(47)	(50)	(50)
Cyst, NOS	13 (28%)	11 (22%)	7 (14%)
Multiple cysts	3 (6%)	3 (6%)	3 (6%)
Hemorrhagic cyst	10 (21%)	1 (2%)	
Inflammation, acute		1 (2%)	
Abscess, NOS	1 (2%)	1 (2%)	
Calcification, NOS	6 (13%)	4 (8%)	3 (6%)
Atrophy, NOS	7 (15%)	44 (88%)	38 (76%)
Hyperplasia, tubular cell	1 (2%)	23 (46%)	21 (42%)
Hyperplasia, granulosa cell	1 (2%)		1 (2%)
Angiectasis		2 (4%)	1 (2%)
#Germinal epithelium	(47)	(50)	(50)
Hyperplasia, NOS		3 (6%)	
#Mesovarium	(47)	(50)	(50)
Necrosis, fat		1 (2%)	
<b>NERVOUS SYSTEM</b>			
*Nerve tract	(50)	(50)	(50)
Demyelination		1 (2%)	
*Choroid plexus	(50)	(50)	(50)
Calcification, NOS			1 (2%)
#Brain	(49)	(4)	(50)
Hemorrhage			2 (4%)
Perivascular cuffing	1 (2%)		
#Brain/thalamus	(49)	(4)	(50)
Calcification, NOS	25 (51%)	1 (25%)	25 (50%)
Cell shape alteration	1 (2%)		
#Cerebellum	(49)	(4)	(50)
Hemorrhage	1 (2%)		
<b>SPECIAL SENSE ORGANS</b>			
*Nasolacrimal duct	(50)	(50)	(50)
Cyst, NOS	1 (2%)		

**TABLE D5. SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE (Continued)**

	Untreated Control	Low Dose	High Dose
<b>MUSCULOSKELETAL SYSTEM</b>			
*Bone	(50)	(50)	(50)
Malocclusion	1 (2%)		
Fibrous osteodystrophy	1 (2%)		
Osteosclerosis	13 (26%)		17 (34%)
<b>BODY CAVITIES</b>			
*Pericardium	(50)	(50)	(50)
Mineralization	1 (2%)		
*Epicardium	(50)	(50)	(50)
Mineralization			1 (2%)
*Mesentery	(50)	(50)	(50)
Cyst, NOS			1 (2%)
Perivascular cuffing	1 (2%)		
Necrosis, fat		1 (2%)	
<b>ALL OTHER SYSTEMS</b>			
Knee			
Dyschondroplasia	6		6
Adipose tissue			
Inflammation, acute		1	
Necrosis, fat	1	3	2
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
None			

\* Number of animals receiving complete necropsy examination; all gross lesions including masses examined microscopically.

# Number of animals examined microscopically at this site





**APPENDIX E**

**GENETIC TOXICOLOGY OF**

**NITROFURAZONE**

	PAGE
TABLE E1	MUTAGENICITY OF NITROFURAZONE IN <i>SALMONELLA TYPHIMURIUM</i> 160
TABLE E2	MUTAGENICITY OF NITROFURAZONE IN MOUSE L5178Y LYMPHOMA CELLS 162
TABLE E3	INDUCTION OF SISTER CHROMATID EXCHANGES IN CHINESE HAMSTER OVARY CELLS BY NITROFURAZONE 163
TABLE E4	INDUCTION OF CHROMOSOMAL ABERRATIONS IN CHINESE HAMSTER OVARY CELLS BY NITROFURAZONE 164

TABLE E1. MUTAGENICITY OF NITROFURAZONE IN *SALMONELLA TYPHIMURIUM* (a)

Strain	Dose (µg/plate)	Revertants/plate (b)					
		-S9		+S9 (hamster)		+S9 (rat)	
		Trial 1	Trial 2	Trial 1	Trial 2	Trial 1	Trial 2
TA100	0	85 ± 3.7	150 ± 0.3	99 ± 13.0	133 ± 5.0	110 ± 9.9	128 ± 3.5
	0.03	--	171 ± 8.5	--	--	--	--
	0.10	163 ± 12.2	212 ± 5.0	--	175 ± 5.5	--	164 ± 6.9
	0.30	383 ± 20.1	344 ± 34.1	--	241 ± 16.2	--	204 ± 16.1
	1	1,091 ± 43.2	902 ± 28.8	302 ± 16.1	406 ± 6.6	253 ± 9.1	297 ± 3.8
	3	1,791 ± 26.0	1,650 ± 85.8	650 ± 103.5	787 ± 51.1	419 ± 7.5	555 ± 37.1
	10	(c) 257 ± 53.7	--	1,239 ± 106.0	1,418 ± 38.5	868 ± 30.9	1,008 ± 19.6
	33	--	--	(c) 58 ± 21.8	--	1,242 ± 71.3	--
	100	--	--	Toxic	--	(c) 101 ± 27.2	--
	Trial summary Positive control (d)	Positive	Positive	Positive	Positive	Positive	Positive
	233 ± 6.2	507 ± 0.3	2,649 ± 40.4	1,901 ± 61.3	1,938 ± 66.0	820 ± 32.1	
TA1535	0	5 ± 0.3	24 ± 1.5	5 ± 0.0	8 ± 2.0	9 ± 2.3	10 ± 2.2
	0.10	10 ± 2.8	--	--	--	--	--
	0.30	11 ± 3.4	18 ± 3.1	--	--	--	--
	1	16 ± 1.9	19 ± 0.3	6 ± 1.2	14 ± 0.9	8 ± 0.6	--
	1.6	--	23 ± 4.0	--	--	--	--
	3	34 ± 2.4	29 ± 2.2	9 ± 3.0	17 ± 2.2	10 ± 3.0	13 ± 2.3
	6	--	37 ± 3.5	--	23 ± 2.7	--	--
	10	(c) 24 ± 3.2	--	25 ± 4.4	31 ± 1.9	13 ± 2.7	17 ± 1.2
	16	--	--	--	38 ± 11.1	--	20 ± 4.7
	33	--	--	(c) 3 ± 3.0	--	23 ± 3.8	26 ± 2.8
66	--	--	--	--	--	45 ± 4.4	
100	--	--	Toxic	--	(c) 24 ± 2.2	--	
Trial summary Positive control (d)	Positive	Negative	Equivocal	Positive	Equivocal	Positive	
	154 ± 2.8	407 ± 1.2	530 ± 29.1	464 ± 22.8	542 ± 39.0	506 ± 17.9	
TA1537	0	3 ± 0.6	6 ± 1.0	5 ± 1.2	7 ± 0.9	4 ± 0.6	5 ± 0.7
	0.10	5 ± 1.9	--	--	--	--	--
	0.30	5 ± 1.2	8 ± 1.9	--	--	--	--
	1	6 ± 2.4	4 ± 0.3	5 ± 1.2	6 ± 1.2	5 ± 0.9	--
	1.6	--	8 ± 3.2	--	--	--	--
	3	17 ± 2.4	7 ± 0.6	4 ± 0.3	13 ± 2.6	3 ± 0.3	6 ± 0.6
	6	--	16 ± 0.6	--	11 ± 1.5	--	--
	10	(c) 3 ± 0.0	--	12 ± 2.6	10 ± 2.0	6 ± 1.0	15 ± 3.8
	16	--	--	--	22 ± 3.1	--	11 ± 2.5
	33	--	--	(c) 5 ± 4.0	--	20 ± 0.9	11 ± 2.2
66	--	--	--	--	--	9 ± 2.3	
100	--	--	Toxic	--	(c) 3 ± 0.9	--	
Trial summary Positive control (d)	Equivocal	Negative	Negative	Equivocal	Negative	Negative	
	216 ± 54.9	106 ± 16.8	89 ± 8.9	479 ± 40.9	231 ± 3.2	356 ± 8.3	
TA98	0	25 ± 4.2	22 ± 2.1	29 ± 3.5	28 ± 2.1	25 ± 2.6	29 ± 2.3
	0.10	21 ± 3.4	--	--	--	--	--
	0.30	23 ± 4.3	24 ± 4.0	--	--	--	--
	1	35 ± 2.7	24 ± 4.0	27 ± 6.0	32 ± 7.8	25 ± 2.0	--
	1.6	--	32 ± 4.7	--	--	--	--
	3	80 ± 2.3	58 ± 2.3	34 ± 2.9	46 ± 3.0	24 ± 1.7	31 ± 3.5
	6	--	126 ± 10.1	--	53 ± 5.2	--	--
	10	96 ± 14.0	--	63 ± 5.5	76 ± 2.6	40 ± 5.6	42 ± 5.5
	16	--	--	--	104 ± 1.3	--	64 ± 0.3
	33	--	--	(c) 20 ± 7.5	--	83 ± 7.2	103 ± 7.8
66	--	--	--	--	--	131 ± 2.1	
100	--	--	Toxic	--	(c) 17 ± 4.6	--	
Trial summary Positive control (d)	Positive	Positive	Positive	Positive	Positive	Positive	
	619 ± 20.5	943 ± 78.7	2,152 ± 45.1	1,551 ± 162.2	1,465 ± 18.5	612 ± 9.1	

**TABLE E1. MUTAGENICITY OF NITROFURAZONE IN *SALMONELLA TYPHIMURIUM* (Continued)**

---

(a) Study performed at SRI International. The detailed protocol is presented in Haworth et al. (1983). Cells and study compound or solvent (dimethyl sulfoxide) were incubated in the absence of exogenous metabolic activation (-S9) or with Aroclor 1254-induced S9 from male Syrian hamster liver or male Sprague Dawley rat liver. High dose was limited by toxicity or solubility but did not exceed 10 mg/plate; 0 µg/plate dose is the solvent control.

(b) Revertants are presented as mean  $\pm$  standard error from three plates.

(c) Slight toxicity

(d) Positive control; 2-aminoanthracene was used on all strains in the presence of S9. In the absence of metabolic activation, 4-nitro-*o*-phenylenediamine was used with TA98, sodium azide was used with TA100 and TA1535, and 9-aminoacridine was used with TA1537.

TABLE E2. MUTAGENICITY OF NITROFURAZONE IN MOUSE L5178Y LYMPHOMA CELLS (a,b)

Compound	Concentration (µg/ml)	Cloning Efficiency (percent)	Relative Total Growth (percent)	Mutant Count	Mutant Fraction (c)
<b>Trial 1</b>					
Dimethyl sulfoxide (d)	--	86.5 ± 3.9	99.8 ± 6.1	136.0 ± 7.1	52.8 ± 3.6
Nitrofurazone	25	61.3 ± 4.1	61.0 ± 8.1	62.3 ± 2.7	34.0 ± 3.8
	50	88.7 ± 10.5	58.0 ± 2.1	104.7 ± 3.5	40.3 ± 4.1
	(e) 100	91.5 ± 9.5	40.0 ± 2.0	171.5 ± 26.5	62.5 ± 3.5
	150	81.0 ± 7.1	34.0 ± 4.0	235.7 ± 12.0	(f) 98.7 ± 10.7
	200	77.3 ± 2.8	28.3 ± 0.9	294.0 ± 9.0	(f) 127.3 ± 7.2
	300	49.3 ± 9.8	5.3 ± 2.0	460.0 ± 51.6	(f) 323.0 ± 36.5
Methyl methanesulfonate	5 nl/ml	66.3 ± 3.9	58.3 ± 5.2	582.0 ± 23.1	(f) 294.7 ± 21.9
<b>Trial 2</b>					
Dimethyl sulfoxide (d)	--	85.0 ± 4.6	100.3 ± 1.3	72.3 ± 1.4	28.5 ± 1.6
Nitrofurazone	25	74.7 ± 0.9	57.3 ± 7.3	82.3 ± 7.7	37.0 ± 3.2
	50	72.3 ± 5.2	43.3 ± 3.2	100.0 ± 3.1	(f) 46.3 ± 2.7
	100	96.0 ± 11.7	38.3 ± 1.2	189.7 ± 41.7	(f) 64.7 ± 6.7
	200	73.7 ± 3.4	14.3 ± 5.8	349.7 ± 47.4	(f) 160.0 ± 24.5
	(g) 300	48	4	352	247
	400	Lethal	--	--	--
Methyl methanesulfonate	5	81.3 ± 5.9	67.3 ± 9.8	312.0 ± 39.5	(f) 128.3 ± 13.6

(a) Study performed at Litton Bionetics, Inc. The experimental protocol is presented in detail by Myhr et al. (1985) and follows the basic format of Clive et al. (1979). The highest dose of study compound is determined by solubility or toxicity and may not exceed 5 mg/ml. All doses are tested in triplicate; the average for the three tests (unless otherwise specified) is presented in the table. Cells ( $6 \times 10^5$ /ml) were treated for 4 hours at 37° C in medium, washed, resuspended in medium, and incubated for 48 hours at 37° C. After expression,  $3 \times 10^6$  cells were plated in medium and soft agar supplemented with trifluorothymidine for selection of cells that were mutant at the thymidine kinase (TK) locus, and 600 cells were plated in nonselective medium and soft agar to determine the cloning efficiency.

(b) Mean ± standard error of replicate trials for approximately  $3 \times 10^6$  cells each. All data are evaluated statistically for both trend and peak response ( $P < 0.05$  for at least one of the three highest dose sets). Both responses must be significantly ( $P < 0.05$ ) positive for a chemical to be considered mutagenic. If only one of these responses is significant, the call is "questionable"; the absence of both trend and peak response results in a "negative" call.

(c) Mutant fraction (frequency) is a ratio of the mutant count to the cloning efficiency, divided by 3 (to arrive at MF per  $1 \times 10^6$  cells treated); MF = mutant fraction.

(d) Results presented are the average of four tests.

(e) Results presented are the average of two tests.

(f) Significant positive response; occurs when the relative mutant fraction (average MF of treated culture/average MF of solvent control) is greater than or equal to 1.6.

(g) Data presented are the results of one test; doses were lethal in two tests.

**TABLE E3. INDUCTION OF SISTER CHROMATID EXCHANGES IN CHINESE HAMSTER OVARY CELLS BY NITROFURAZONE (a)**

Compound	Dose (µg/ml)	Total Cells	No. of Chromosomes	No. of SCEs	SCEs/Chromosome	SCEs/Cell	Hours in BrdU	Relative SCEs/Cell (percent) (b)
<b>- S9 (c)</b>								
<b>Trial 1--Summary: Positive</b>								
Dimethyl sulfoxide	--	50	1,048	554	0.53	11.1	26.0	--
Nitrofurazone	0.25	50	1,049	667	0.64	13.3	26.0	119.8
	0.83	50	1,043	717	0.69	14.3	26.0	128.8
	2.50	50	1,048	713	0.68	14.3	26.0	128.8
	8.33	0	--	--	--	--	26.0	--
Mitomycin C	0.001	50	1,048	810	0.77	16.2	26.0	145.9
	0.010	5	105	249	2.37	49.8	26.0	448.6
<b>Trial 2--Summary: Positive</b>								
Dimethyl sulfoxide	--	50	1,048	544	0.52	10.9	26.0	--
Nitrofurazone	10	50	1,049	864	0.82	17.3	(d) 34.3	158.7
	12.5	50	1,046	1,033	0.99	20.7	(d) 34.3	189.9
	15	50	1,047	1,052	1.00	21.0	(d) 34.3	192.7
Mitomycin C	0.001	50	1,047	844	0.81	16.9	26.0	155.0
	0.010	5	105	309	2.94	61.8	26.0	567.0
<b>+ S9 (e)</b>								
<b>Trial 1--Summary: Positive</b>								
Dimethyl sulfoxide	--	50	1,040	497	0.48	9.9	26.0	--
Nitrofurazone	25	50	1,043	558	0.53	11.2	26.0	113.1
	83.3	50	1,047	610	0.58	12.2	26.0	123.2
	250	50	1,045	697	0.67	13.9	26.0	140.4
	833	0	--	--	--	--	26.0	--
Cyclophosphamide	0.4	50	1,047	732	0.70	14.6	26.0	147.5
	2	5	105	158	1.50	31.6	26.0	319.2

(a) Study performed at Litton Bionetics, Inc. SCE = sister chromatid exchange; BrdU = bromodeoxyuridine. A detailed description of the SCE protocol is presented by Galloway et al. (1985). Briefly, Chinese hamster ovary cells were incubated with study compound or solvent (dimethyl sulfoxide) as described in (c) or (e) below and cultured for sufficient time to reach second metaphase division. Cells were then collected by mitotic shake-off, fixed, air-dried, and stained.

(b) SCEs/cell in treated culture expressed as a percent of the SCEs/cell in the control culture

(c) In the absence of S9, Chinese hamster ovary cells were incubated with study compound or solvent for 2 hours at 37° C. Then BrdU was added, and incubation was continued for 24 hours. Cells were washed, fresh medium containing BrdU and colcemid was added, and incubation was continued for 2-3 hours.

(d) Because some chemicals induce a delay in the cell division cycle, harvest times are occasionally extended to maximize the proportion of second division cells available for analysis.

(e) In the presence of S9, cells were incubated with study compound or solvent for 2 hours at 37° C. Then cells were washed, and medium containing BrdU was added. Cells were incubated for a further 26 hours, with colcemid present for the final 2-3 hours. S9 was from the liver of Aroclor 1254-induced male Sprague Dawley rats.

TABLE E4. INDUCTION OF CHROMOSOMAL ABERRATIONS IN CHINESE HAMSTER OVARY CELLS BY NITROFURAZONE (a)

		Trial 1			Trial 2				
Dose (µg/ml)	Total Cells	No. of Abs	Abs/Cell	Percent Cells with Abs	Dose (µg/ml)	Total Cells	No. of Abs	Abs/Cell	Percent Cells with Abs
<b>- S9 (b)</b>					<b>- S9 (b)</b>				
Dimethyl sulfoxide					Dimethyl sulfoxide				
--	100	3	0.03	3	--	100	2	0.02	2
Nitrofurazone					Nitrofurazone				
20	100	3	0.03	3	25	100	19	0.19	17
23	100	21	0.21	17	30	100	22	0.22	19
25	25	13	0.52	24	40	50	56	1.12	44
30	25	9	0.36	28					
Summary: Positive					Summary: Positive				
Mitomycin C					Mitomycin C				
0.040	100	16	0.16	14	0.040	100	33	0.33	24
0.063	100	31	0.31	21	0.063	25	14	0.56	40
<b>+ S9 (c)</b>									
Dimethylsulfoxide									
--	100	0	0.00	0					
Nitrofurazone									
300	100	5	0.05	4					
400	100	5	0.05	5					
500	100	4	0.04	2					
600	0								
Summary: Negative									
Cyclophosphamide									
3.80	100	5	0.05	5					
12.50	25	7	0.28	16					

(a) Study performed at Litton Bionetics, Inc. Abs = aberrations. Harvest time--18.5 hours; because of chemical-induced cell cycle delay, incubation time before addition of colcemid was lengthened to provide sufficient metaphases at harvest. A detailed presentation of the technique for detecting chromosomal aberrations is found in Galloway et al. (1985). Briefly, Chinese hamster ovary cells were incubated with study compound or solvent (dimethyl sulfoxide) as indicated in (b) or (c). Cells were arrested in first metaphase by addition of colcemid and harvested by mitotic shake-off, fixed, and stained in 6% Giemsa.

(b) In the absence of S9, Chinese hamster ovary cells were incubated with study compound or solvent (dimethyl sulfoxide) for 8-10 hours at 37° C. Cells were then washed, and fresh medium containing colcemid was added for an additional 2-3 hours followed by harvest.

(c) In the presence of S9, cells were incubated with study compound or solvent (dimethyl sulfoxide) for 2 hours at 37° C. Cells were then washed, medium was added, and incubation was continued for 8-10 hours. Colcemid was added for the last 2-3 hours of incubation before harvest. S9 was from the liver of Aroclor 1254-induced male Sprague Dawley rats.

## APPENDIX F

### SENTINEL ANIMAL PROGRAM

	PAGE
TABLE F1 MURINE ANTIBODY DETERMINATIONS FOR RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE	167

# APPENDIX F. SENTINEL ANIMAL PROGRAM

---

## I. Methods

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals are untreated, and these animals and the study animals are both subject to identical environmental conditions. The sentinel animals come from the same production source and weaning groups as the animals used for the studies of chemical compounds.

Fifteen B6C3F<sub>1</sub> mice and 15 F344/N rats of each sex are selected at the time of randomization and allocation of the animals to the various study groups. Five animals of each designated sentinel group are killed at 6, 12, and 18 months on study. Data from animals surviving 24 months are collected from 5/50 randomly selected control animals of each sex and species. The blood from each animal is collected and clotted, and the serum is separated. The serum is cooled on ice and shipped to Microbiological Associates' Comprehensive Animal Diagnostic Service for determination of the antibody titers. The following tests are performed:

	<u>Hemagglutination Inhibition</u>	<u>Complement Fixation</u>	<u>ELISA</u>
Mice	PVM (pneumonia virus of mice) Reo 3 (reovirus type 3) GDVII (Theiler's encephalomyelitis virus) Poly (polyoma virus) MVM (minute virus of mice) Ectro (infectious ectromelia) Sendai (6, 18, 24 mo)	M. Ad. (mouse adenovirus) LCM (lymphocytic choriomeningitis virus) Sendai (12 mo)	MHV (mouse hepatitis virus) <i>M. pul.</i> ( <i>Mycoplasma pulmonis</i> )
Rats	PVM KRV (Kilham rat virus) H-1 (Toolan's H-1 virus) Sendai (6, 18, 24 mo)	RCV (rat coronavirus) (6, 12, 18 mo)	RCV (24 mo) Sendai (12 mo) <i>M. pul.</i>

## II. Results

Results are presented in Table F1.



TABLE F1. MURINE ANTIBODY DETERMINATIONS FOR RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE (a)

Interval (months)	No. of Animals	Positive Serologic Reaction for
<b>RATS</b>		
6	10/10	PVM
	10/10	Sendai
12	10/10	Sendai
18	10/10	PVM
	9/10	Sendai
24	10/10	PVM
	6/10	Sendai
	4/10	(b) <i>M. pul.</i>
<b>MICE</b>		
6	5/10	PVM
	6/10	Sendai
12	2/10	PVM
	8/9	Sendai
18	9/9	PVM
	8/9	Sendai
24	5/10	PVM
	10/10	Sendai

(a) Blood samples were taken from sentinel animals at 6, 12, and 18 months after the start of dosing and from the control animals just before they were killed; samples were sent to Microbiological Associates (Bethesda, MD) for determination of antibody titers.

(b) Further evaluation of this assay indicated that it was not specific for *M. pulmonis*, and these results were considered to be false positive.



## APPENDIX G

### FEED AND COMPOUND CONSUMPTION BY RATS AND MICE IN THE TWO-YEAR FEED STUDIES OF NITROFURAZONE

		PAGE
TABLE G1	FEED AND COMPOUND CONSUMPTION BY MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	170
TABLE G2	FEED AND COMPOUND CONSUMPTION BY FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	171
TABLE G3	FEED AND COMPOUND CONSUMPTION BY MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	172
TABLE G4	FEED AND COMPOUND CONSUMPTION BY FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE	173

**TABLE G1. FEED AND COMPOUND CONSUMPTION BY MALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

Week	Control		Low Dose				High Dose			
	Grams Feed/Day (a)	Body Weight (grams)	Grams Feed/Day (a)	Body Weight (grams)	Low/Control (b)	Dose/Day (c)	Grams Feed/Day (a)	Body Weight (grams)	High/Control (b)	Dose/Day (c)
4	16.9	231	15.9	227	0.9	22	14.8	220	0.9	42
8	14.3	291	14.7	292	1.0	16	14.4	278	1.0	32
12	16.6	326	12.6	328	0.8	12	12.4	308	0.7	25
17	15.8	361	15.2	357	1.0	13	15.0	334	0.9	28
21	14.5	386	14.6	372	1.0	12	14.1	355	1.0	25
25	15.9	401	15.6	387	1.0	12	15.2	365	1.0	26
30	14.1	410	13.6	396	1.0	11	13.5	370	1.0	23
34	14.5	416	14.5	405	1.0	11	14.2	376	1.0	23
39	15.1	428	13.9	412	0.9	10	13.7	377	0.9	23
43	15.2	438	14.0	417	0.9	10	13.9	385	0.9	22
47	15.1	437	13.3	412	0.9	10	13.6	381	0.9	22
52	13.9	440	13.9	415	1.0	10	12.5	378	0.9	21
56	13.7	439	16.4	414	1.2	12	13.7	380	1.0	22
61	14.2	438	14.6	419	1.0	11	12.6	376	0.9	21
66	14.8	441	13.7	422	0.9	10	13.3	381	0.9	22
70	14.8	441	13.9	419	0.9	10	13.0	377	0.9	21
74	13.8	441	12.8	412	0.9	10	12.4	374	0.9	21
78	14.5	441	13.7	417	0.9	10	12.8	370	0.9	21
82	13.9	445	13.1	422	0.9	10	11.7	369	0.8	20
87	13.0	433	12.0	410	0.9	9	11.2	353	0.9	20
91	13.2	427	12.5	407	0.9	10	11.1	346	0.8	20
96	13.4	429	13.2	407	1.0	10	13.1	340	1.0	24
100	13.7	431	12.9	404	0.9	10	10.4	323	0.8	20
Mean	14.6	407	13.9	390	1.0	11	13.2	353	0.9	24
SD (d)	1.0		1.1		0.1	3	1.3		0.1	5
CV (e)	6.8		7.9		10.0	27.3	9.8		11.1	20.8

- (a) Grams of feed removed from feed per animal per day. Not corrected for scatter.  
 (b) Grams of feed per day for the dosed group divided by that for the controls  
 (c) Estimated milligrams of nitrofurazone consumed per day per kilogram of body weight  
 (d) Standard deviation  
 (e) Coefficient of variation = (standard deviation/mean) × 100

TABLE G2. FEED AND COMPOUND CONSUMPTION BY FEMALE RATS IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

Week	Control		Low Dose				High Dose			
	Grams Feed/Day (a)	Body Weight (grams)	Grams Feed/Day (a)	Body Weight (grams)	Low/Control (b)	Dose/Day (c)	Grams Feed/Day (a)	Body Weight (grams)	High/Control (b)	Dose/Day (c)
4	10.9	162	10.0	158	0.9	20	10.9	156	1.0	43
8	9.8	179	9.4	175	1.0	17	9.4	171	1.0	34
12	8.1	190	7.6	187	0.9	13	7.3	180	0.9	25
17	10.4	204	9.9	198	1.0	16	9.8	190	0.9	32
21	9.9	218	9.2	208	0.9	14	9.0	199	0.9	28
25	9.8	222	9.6	213	1.0	14	9.4	204	1.0	29
30	9.8	229	9.2	218	0.9	13	9.1	209	0.9	27
34	9.8	234	8.9	223	0.9	12	9.1	213	0.9	26
39	10.1	239	9.2	227	0.9	13	8.8	217	0.9	25
43	9.7	246	8.4	233	0.9	11	8.3	223	0.9	23
47	10.8	253	10.1	239	0.9	13	9.8	226	0.9	27
52	10.5	263	10.2	250	1.0	13	9.6	233	0.9	26
56	11.0	269	10.5	255	1.0	13	9.8	235	0.9	26
61	9.4	280	10.0	265	1.1	12	9.6	242	1.0	25
66	11.1	290	9.7	273	0.9	11	9.9	246	0.9	25
70	11.3	293	10.5	278	0.9	12	10.0	247	0.9	25
74	11.6	302	9.7	285	0.8	11	9.8	253	0.8	24
78	11.2	313	10.0	290	0.9	11	9.3	253	0.8	23
82	11.0	318	10.4	298	0.9	11	9.5	261	0.9	23
87	10.8	319	10.1	302	0.9	10	9.1	262	0.8	22
91	11.0	325	9.5	301	0.9	10	10.6	263	1.0	25
96	11.0	329	9.9	304	0.9	10	9.2	264	0.8	22
100	11.1	333	9.5	304	0.9	10	8.9	265	0.8	21
Mean	10.4	261	9.6	247	0.9	12	9.4	227	0.9	26
SD (d)	0.8		0.7		0.0	2	0.7		0.1	5
CV (e)	7.7		7.3		0.0	16.7	7.4		11.1	19.2

- (a) Grams of feed removed from feed per animal per day. Not corrected for scatter.  
 (b) Grams of feed per day for the dosed group divided by that for the controls  
 (c) Estimated milligrams of nitrofurazone consumed per day per kilogram of body weight  
 (d) Standard deviation  
 (e) Coefficient of variation = (standard deviation/mean) × 100

**TABLE G3. FEED AND COMPOUND CONSUMPTION BY MALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE**

Week	Control		Low Dose				High Dose			
	Grams Feed/Day (a)	Body Weight (grams)	Grams Feed/Day (a)	Body Weight (grams)	Low/Control (b)	Dose/Day (c)	Grams Feed/Day (a)	Body Weight (grams)	High/Control (b)	Dose/Day (c)
6	3.4	28.7	3.5	29.0	1.0	18	3.6	29.2	1.1	38
10	3.6	30.3	3.6	30.7	1.0	18	2.8	30.8	0.8	28
20	4.1	33.0	3.9	33.1	1.0	18	4.4	33.1	1.1	41
23	3.8	34.3	5.0	34.3	1.3	22	6.3	35.2	1.7	55
28	4.0	35.9	3.9	35.7	1.0	16	4.2	36.8	1.1	35
33	4.0	36.4	4.0	35.8	1.0	17	4.0	37.0	1.0	34
37	3.8	37.3	3.7	36.4	1.0	15	4.0	38.2	1.1	32
42	3.6	37.1	3.7	36.4	1.0	15	3.8	38.3	1.1	31
46	4.1	38.6	3.8	38.1	0.9	15	4.2	39.6	1.0	33
49	3.9	38.3	4.3	38.8	1.1	17	3.7	40.4	0.9	28
54	3.8	39.2	3.8	38.8	1.0	15	3.9	39.5	1.0	31
58	3.7	39.0	3.7	39.1	1.0	14	3.9	39.9	1.1	30
64	5.0	38.7	3.5	38.7	0.7	14	3.8	40.0	0.8	29
68	3.6	38.3	4.1	38.6	1.1	16	4.4	39.1	1.2	35
72	3.9	37.9	3.8	39.0	1.0	15	3.9	40.2	1.0	30
77	3.8	39.1	3.7	39.6	1.0	14	4.0	40.2	1.1	31
80	3.9	38.9	3.5	39.0	0.9	13	3.5	39.2	0.9	28
84	3.7	39.9	3.7	39.2	1.0	14	3.6	40.0	1.0	28
89	3.6	37.1	3.7	37.6	1.0	15	3.9	38.0	1.1	32
93	3.8	38.5	3.4	37.7	0.9	14	3.9	37.6	1.0	32
98	3.7	39.1	3.4	36.7	0.9	14	3.8	38.2	1.0	31
102	3.7	39.4	3.5	37.6	0.9	14	3.9	38.6	1.1	31
Mean	3.8	37.0	3.8	36.8	1.0	16	4.0	37.7	1.0	33
SD(d)	0.3		0.4		0.1	2	0.6		0.2	6
CV(e)	7.9		10.5		10.0	12.5	15.0		20.0	18.2

- (a) Grams of feed removed from feed per animal per day. Not corrected for scatter.  
 (b) Grams of feed per day for the dosed group divided by that for the controls  
 (c) Estimated milligrams of nitrofurazone consumed per day per kilogram of body weight  
 (d) Standard deviation  
 (e) Coefficient of variation = (standard deviation/mean) × 100

TABLE G4. FEED AND COMPOUND CONSUMPTION BY FEMALE MICE IN THE TWO-YEAR FEED STUDY OF NITROFURAZONE

Week	Control		Low Dose				High Dose			
	Grams Feed/Day (a)	Body Weight (grams)	Grams Feed/Day (a)	Body Weight (grams)	Low/Control (b)	Dose/Day (c)	Grams Feed/Day (a)	Body Weight (grams)	High/Control (b)	Dose/Day (c)
6	3.3	22.6	2.9	22.8	0.9	19	3.3	22.5	1.0	45
10	2.9	23.4	3.1	24.5	1.1	19	2.8	23.9	1.0	36
20	3.2	27.3	3.1	27.1	1.0	17	3.3	26.5	1.0	39
23	3.2	28.6	3.3	28.1	1.0	18	3.4	27.7	1.1	38
28	3.5	31.0	3.4	29.6	1.0	17	3.5	29.4	1.0	37
33	3.3	31.1	3.4	29.8	1.0	17	3.4	29.4	1.0	36
37	3.2	32.3	3.2	30.7	1.0	16	3.1	31.4	1.0	31
42	3.5	33.6	3.3	32.6	0.9	15	3.3	32.8	0.9	31
46	3.7	34.9	3.6	32.8	1.0	16	3.5	34.1	0.9	32
49	3.6	35.7	3.5	34.8	1.0	15	3.4	35.9	0.9	29
54	3.3	37.1	2.8	35.7	0.8	12	3.2	37.2	1.0	27
58	3.5	37.3	3.3	36.6	0.9	14	3.3	38.4	0.9	27
64	3.7	37.9	3.7	37.4	1.0	15	3.5	39.7	0.9	27
68	3.9	38.2	3.5	38.6	0.9	14	3.5	40.5	0.9	27
72	3.1	39.0	3.7	39.3	1.2	14	3.2	41.5	1.0	24
77	3.4	39.6	3.5	41.1	1.0	13	3.3	42.1	1.0	24
80	3.1	39.2	3.0	41.5	1.0	11	2.9	42.3	0.9	21
84	3.2	40.4	2.9	42.1	0.9	10	3.1	43.5	1.0	22
89	3.3	39.6	3.1	41.3	0.9	11	3.0	41.9	0.9	22
93	3.7	40.3	3.2	41.8	0.9	11	3.4	42.5	0.9	25
98	3.8	41.7	3.2	42.5	0.8	11	3.4	44.1	0.9	24
102	3.9	42.7	3.3	43.0	0.8	12	3.2	43.5	0.8	23
Mean	3.4	35.2	3.3	35.2	1.0	14	3.3	35.9	1.0	29
SD (d)	0.3		0.3		0.1	3	0.2		0.1	7
CV (e)	8.8		9.1		10.0	21.4	6.1		10.0	24.1

- (a) Grams of feed removed from feed per animal per day. Not corrected for scatter.  
 (b) Grams of feed per day for the dosed group divided by that for the controls  
 (c) Estimated milligrams of nitrofurazone consumed per day per kilogram of body weight  
 (d) Standard deviation  
 (e) Coefficient of variation = (standard deviation/mean) × 100





**APPENDIX H**

**INGREDIENTS, NUTRIENT COMPOSITION, AND  
CONTAMINANT LEVELS IN  
NIH 07 RAT AND MOUSE RATION**

**Meal Diet: June 1981 to July 1983**  
**(Manufactured by Zeigler Bros., Inc., Gardners, PA)**

	PAGE
TABLE H1	INGREDIENTS OF NIH 07 RAT AND MOUSE RATION 176
TABLE H2	VITAMINS AND MINERALS IN NIH 07 RAT AND MOUSE RATION 176
TABLE H3	NUTRIENT COMPOSITION OF NIH 07 RAT AND MOUSE RATION 177
TABLE H4	CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION 178

**TABLE H1. INGREDIENTS OF NIH 07 RAT AND MOUSE RATION (a)**

Ingredients (b)	Percent by Weight
Ground #2 yellow shelled corn	24.50
Ground hard winter wheat	23.00
Soybean meal (49% protein)	12.00
Fish meal (60% protein)	10.00
Wheat middlings	10.00
Dried skim milk	5.00
Alfalfa meal (dehydrated, 17% protein)	4.00
Corn gluten meal (60% protein)	3.00
Soy oil	2.50
Dried brewer's yeast	2.00
Dry molasses	1.50
Dicalcium phosphate	1.25
Ground limestone	0.50
Salt	0.50
Premixes (vitamin and mineral)	0.25

(a) NIH, 1978; NCI, 1976

(b) Ingredients ground to pass through a U.S. Standard Screen No. 16 before being mixed

**TABLE H2. VITAMINS AND MINERALS IN NIH 07 RAT AND MOUSE RATION (a)**

	Amount	Source
<b>Vitamins</b>		
A	5,500,000 IU	Stabilized vitamin A palmitate or acetate
D <sub>3</sub>	4,600,000 IU	D-activated animal sterol
K <sub>3</sub>	2.8 g	Menadione
<i>d</i> -α-Tocopheryl acetate	20,000 IU	
Choline	560.0 g	Choline chloride
Folic acid	2.2 g	
Niacin	30.0 g	
<i>d</i> -Pantothenic acid	18.0 g	<i>d</i> -Calcium pantothenate
Riboflavin	3.4 g	
Thiamine	10.0 g	Thiamine mononitrate
B <sub>12</sub>	4,000 µg	
Pyridoxine	1.7 g	Pyridoxine hydrochloride
Biotin	140.0 mg	<i>d</i> -Biotin
<b>Minerals</b>		
Iron	120.0 g	Iron sulfate
Manganese	60.0 g	Manganous oxide
Zinc	16.0 g	Zinc oxide
Copper	4.0 g	Copper sulfate
Iodine	1.4 g	Calcium iodate
Cobalt	0.4 g	Cobalt carbonate

(a) Per ton (2,000 lb) of finished product

TABLE H3. NUTRIENT COMPOSITION OF NIH 07 RAT AND MOUSE RATION (a)

Nutrients	Mean $\pm$ Standard Deviation	Range	No. of Samples
Crude protein (percent by weight)	23.97 $\pm$ 1.16	21.7-26.3	27
Crude fat (percent by weight)	5.00 $\pm$ 0.46	4.2-6.0	27
Crude fiber (percent by weight)	3.38 $\pm$ 0.36	2.4-4.2	27
Ash (percent by weight)	6.56 $\pm$ 0.27	5.97-7.11	27
<b>Amino Acids (percent of total diet)</b>			
Arginine	1.260	1.21-1.31	2
Cystine	0.395	0.39-0.40	2
Glycine	1.175	1.15-1.20	2
Histidine	0.553	0.530-0.576	2
Isoleucine	0.908	0.881-0.934	2
Leucine	1.905	1.85-1.96	2
Lysine	1.250	1.20-1.30	2
Methionine	0.310	0.306-0.314	2
Phenylalanine	0.967	0.960-0.974	2
Threonine	0.834	0.827-0.840	2
Tryptophan	0.175	0.171-0.178	2
Tyrosine	0.587	0.566-0.607	2
Valine	1.085	1.05-1.12	2
<b>Essential Fatty Acids (percent of total diet)</b>			
Linoleic	2.37		1
Linolenic	0.308		1
Arachidonic	0.008		1
<b>Vitamins</b>			
Vitamin A (IU/kg)	12,163 $\pm$ 3,045	7,800-22,000	27
Vitamin D (IU/kg)	6,300		1
$\alpha$ -Tocopherol (ppm)	37.6	31.1-44.0	2
Thiamine (ppm)	1.82 $\pm$ 0.34	1.2-2.6	(b) 26
Riboflavin (ppm)	6.9	6.1-7.4	2
Niacin (ppm)	75	65-85	2
Pantothenic acid (ppm)	30.2	29.8-30.5	2
Pyridoxine (ppm)	7.2	5.6-8.8	2
Folic acid (ppm)	2.1	1.8-2.4	2
Biotin (ppm)	0.24	0.21-0.27	2
Vitamin B <sub>12</sub> (ppb)	12.8	10.6-15.0	2
Choline (ppm)	3,315	3,200-3,430	2
<b>Minerals</b>			
Calcium (percent)	1.24 $\pm$ 0.10	1.10-1.45	27
Phosphorus (percent)	0.97 $\pm$ 0.05	0.84-1.1	27
Potassium (percent)	0.809	0.772-0.846	2
Chloride (percent)	0.557	0.479-0.635	2
Sodium (percent)	0.304	0.258-0.349	2
Magnesium (percent)	0.172	0.166-0.177	2
Sulfur (percent)	0.278	0.270-0.285	2
Iron (ppm)	418	409-426	2
Manganese (ppm)	90.8	86.0-95.5	2
Zinc (ppm)	55.1	54.2-56.0	2
Copper (ppm)	12.68	9.65-15.70	2
Iodine (ppm)	2.58	1.52-3.64	2
Chromium (ppm)	1.86	1.79-1.93	2
Cobalt (ppm)	0.57	0.49-0.65	2

(a) One or two batches of feed analyzed for nutrients reported in this table were manufactured in January and/or April 1983.

(b) One batch (7/22/81) not analyzed for thiamine

TABLE H4. CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION

Contaminants	Mean $\pm$ Standard Deviation	Range	No. of Samples
Arsenic (ppm)	0.48 $\pm$ 0.13	0.21-0.74	27
Cadmium (ppm) (a)	<0.01	<0.01-0.01	27
Lead (ppm)	0.91 $\pm$ 0.75	0.27-2.93	27
Mercury (ppm) (a)	<0.05		27
Selenium (ppm)	0.28 $\pm$ 0.06	0.16-0.40	27
Aflatoxins (ppb) (b)	<5	<5.0-<10.0	27
Nitrate nitrogen (ppm) (c)	9.97 $\pm$ 4.64	0.6-19.0	27
Nitrite nitrogen (ppm) (c)	1.99 $\pm$ 1.23	0.4-5.3	27
BHA (ppm) (d)	5.42 $\pm$ 4.94	<2.0-20.0	27
BHT (ppm) (d)	3.19 $\pm$ 2.52	<1.0-13.0	27
Aerobic plate count (CFU/g) (e)	110,956 $\pm$ 82,794	7,000-310,000	25
Aerobic plate count (CFU/g) (f)	133,848 $\pm$ 114,587	7,000-420,000	27
Coliform (MPN/g) (g)	931.1 $\pm$ 973.4	<3->2,400	27
<i>E. coli</i> (MPN/g) (h)	6.89 $\pm$ 7.46	<3-23	26
<i>E. coli</i> (MPN/g) (i)	12.15 $\pm$ 28.51	<3-150	27
Total nitrosamines (ppb) (j)	3.73 $\pm$ 3.26	0.9-12.9	27
<i>N</i> -Nitrosodimethylamine (ppb) (j)	2.93 $\pm$ 2.89	0.7-12.9	27
<i>N</i> -Nitrosopyrrolidine (ppb) (k)	1.24 $\pm$ 0.60	<0.9-3.2	24
<b>Pesticides (ppm)</b>			
$\alpha$ -BHC (a,l)	<0.01		27
$\beta$ -BHC (a)	<0.02		27
$\gamma$ -BHC-Lindane (a)	<0.01		27
$\delta$ -BHC (a)	<0.01		27
Heptachlor (a)	<0.01		27
Aldrin (a)	<0.01		27
Heptachlor epoxide (a)	<0.01		27
DDE (a)	<0.01		27
DDD (m)	<0.01	0.05 (7/14/81)	27
DDT (a)	<0.01		27
HCB (a)	<0.01		27
Mirex (a)	<0.01		27
Methoxychlor (n)	<0.05	0.13 (8/25/81); 0.6 (6/24/82)	27
Dieldrin (m)	<0.01	0.02 (7/27/82)	27
Endrin (a)	<0.01		27
Telodrin (a)	<0.01		27
Chlordane (a)	<0.05		27
Toxaphene (a)	<0.1		27
Estimated PCBs (a)	<0.2		27
Ronnel (a)	<0.01		27
Ethion (a)	<0.02		27
Trithion (a)	<0.05		27
Diazinon (a)	<0.1		27
Methyl parathion (a)	<0.02		27
Ethyl parathion (a)	<0.02		27
Malathion (o)	0.10 $\pm$ 0.07	<0.05-0.34	27
Endosulfan I (a,p)	<0.01		25
Endosulfan II (a,p)	<0.01		25
Endosulfan sulfate (a,p)	<0.03		25

**TABLE H4. CONTAMINANT LEVELS IN NIH 07 RAT AND MOUSE RATION (Continued)**

---

- (a) All values were less than the detection limit, given in the table as the mean.
- (b) The detection limit was reduced from 10 ppb to 5 ppb after 7/81.
- (c) Source of contamination: Alfalfa, grains, and fish meal
- (d) Source of contamination: Soy oil and fish meal
- (e) Mean, standard deviation, and range exclude the very high value of 420,000 obtained for the batches produced on 3/23/83 and 7/12/83; CFU = colony-forming unit.
- (f) Mean, standard deviation, and range include the very high value given in footnote (e).
- (g) MPN = most probable number
- (h) Mean, standard deviation, and range exclude the high value of 150 obtained for the batch produced on 8/26/82.
- (i) Mean, standard deviation, and range include the high value given in footnote (h).
- (j) All values were corrected for percent recovery.
- (k) Values not detected for batches produced on 6/24/82, 6/22/83, and 7/12/83.
- (l) BHC = hexachlorocyclohexane or benzene hexachloride
- (m) One observation was above the detection limit. The value and the date it was obtained are listed under the range.
- (n) Two observations were above the detection limit. The values and the dates they were obtained are given under the range.
- (o) Twelve batches contained more than 0.05 ppm.
- (p) Two batches produced on 5/26/81 and 7/14/81 were not analyzed for endosulfan I, endosulfan II, and endosulfan sulfate.



## **APPENDIX I**

### **AUDIT SUMMARY**

## APPENDIX I. AUDIT SUMMARY

---

The experimental data, documents, and pathology materials for the 2-year studies of nitrofurazone in rats and mice were audited for accuracy, consistency, completeness, and compliance with Good Laboratory Practice (GLP) regulations of the Food and Drug Administration (fully implemented by the NTP beginning on October 1, 1981). The laboratory studies were conducted for the NTP by Physiological Research Laboratories, Minneapolis, Minnesota, under a subcontract with Tracor Jitco, Inc., until February 28, 1983, and then under contract with the NIEHS. Animal exposures to the chemical in feed began in June 1981 for rats and mice. The retrospective audit was conducted for the NIEHS at the NTP Archives in January and February 1987 by the Dynamac Corporation (J.C. Bhandri, D.V.M., Ph.D., Principal Investigator). Other individuals who conducted the audit are listed in the full audit report, which is on file at the NIEHS. The audit included a review of:

- (1) All records concerning animal receipt, quarantine, randomization, and disposition prior to study start.
- (2) Body weight, feed consumption, and clinical observation data for a random 10% sample of the study animals.
- (3) All inlife records including protocol, correspondence, environmental conditions, palpable masses, mortality, animal identification, and correlation of final inlife observation of masses, date of death, and disposition with necropsy records.
- (4) All chemistry records.
- (5) All postmortem records for individual animals concerning identification, disposition codes, condition codes, correlations between gross observations and microscopic diagnoses, and tissue accountability.
- (6) All wet tissue bags for inventory, and wet tissues from a random 20% sample of the study animals plus other relevant material to verify animal identification and to examine for untrimmed potential lesions.
- (7) Blocks and slides of tissues from a random 20% sample of study animals to examine for proper match and inventory.
- (8) Tabulated pathology diagnoses for a random 10% sample of study animals to verify computer data entry.
- (9) The preliminary draft Technical Report (February 1987).

Inlife procedures and events were documented adequately by the archival records, with the exception of the receipt of female rats and female mice, disposition of surplus animals, release of mice from quarantine, cage and rack changes, sanitation procedures, light cycle, and twice daily cage checks. The relatively few audit findings from the review of the inlife records were miscellaneous and minor in nature. Also, the mode of death entered into separate records maintained for animal census and clinical observations was either not internally consistent or sometimes not listed in both records for 29 rats and 14 mice; however, one of the two records was always in agreement with the disposition code listed on the necropsy record form. Minor errors in computing feed consumption were reported and corrected.

Inspection of wet tissues for individual animal identifiers showed that 63/76 rats and 57/68 mice were identified correctly by their residual tissues and that tissues were either partially present and correct or absent for the remaining animals. The audit identified 26 untrimmed potential lesions in the wet tissues of 22/76 rats examined and 15 untrimmed potential lesions in 12/68 mice examined. As a result, all wet tissues were reviewed for untrimmed lesions. This review resulted in the identification of the following neoplastic lesions: hepatic nodules in two control male rats, an adenoma of the pancreas in one control male rat, a squamous cell papilloma in a low dose female rat, a trichoepithelioma in the skin of a high dose male rat, several alveolar/bronchiolar adenomas or carcinomas in mice of each sex, and three forestomach papillomas in control and dosed mice. These diagnoses have been incorporated into the tables of the final version of this report and did not alter the interpretations. The



## APPENDIX I. AUDIT SUMMARY

---

correlation between gross observations and microscopic diagnoses was very good (four noncorrelations each in rats and mice). Full details about these and other audit findings are presented in the audit report.

In conclusion, the study records at the NTP Archives support the data and results presented in the NTP Technical Report.

NATIONAL TOXICOLOGY PROGRAM TECHNICAL REPORTS  
 PUBLISHED AS OF APRIL 1988

TR No.	CHEMICAL	TR No.	CHEMICAL
200	2,6-Toluenediamine Dihydrochloride	263	1,2-Dichloropropane
201	2,3,7,8-Tetrachlorodibenzo-p-dioxin (Dermal)	267	Propylene Oxide
202	1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin and 1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin (Dermal)	269	Telone II®
203	Phenol	271	HC Blue No. 1
204	Benzoin	272	Propylene
205	4,4'-Oxydianiline	273	Trichloroethylene (Four strains of rats)
206	Dibromochloropropane	274	Tris(2-ethylhexyl)phosphate
207	Cytembena	275	2-Chloroethanol
208	FD & C Yellow No. 6	276	8-Hydroxyquinoline
209	2,3,7,8-Tetrachlorodibenzo-p-dioxin (Gavage)	281	H.C. Red No. 3
210	1,2-Dibromoethane (Inhalation)	282	Chlorodibromomethane
211	C.I. Acid Orange 10	284	Diallylphthalate (Rats)
212	Di(2-ethylhexyl)adipate	285	C.I. Basic Red 9 Monohydrochloride
213	Butylbenzyl Phthalate	287	Dimethyl Hydrogen Phosphite
214	Caprolactam	288	1,3-Butadiene
215	Bisphenol A	289	Benzene
216	11-Aminoundecanoic Acid	291	Isophorone
217	Di(2-ethylhexyl)phthalate	293	HC Blue No. 2
219	2,6-Dichloro-p-phenylenediamine	294	Chlorinated Trisodium Phosphate
220	C.I. Acid Red 14	295	Chrysotile Asbestos (Rats)
221	Locust Bean Gum	296	Tetrakis(hydroxymethyl)phosphonium Sulfate and Tetrakis(hydroxymethyl)phosphonium Chloride
222	C.I. Disperse Yellow 3	298	Dimethyl Morpholinophosphoramidate
223	Eugenol	299	C.I. Disperse Blue 1
224	Tara Gum	300	3-Chloro-2-methylpropene
225	D & C Red No. 9	301	o-Phenylphenol
226	C.I. Solvent Yellow 14	303	4-Vinylcyclohexene
227	Gum Arabic	304	Chlorendic Acid
228	Vinylidene Chloride	305	Chlorinated Paraffins (C <sub>23</sub> , 43% chlorine)
229	Guar Gum	306	Dichloromethane
230	Agar	307	Ephedrine Sulfate
231	Stannous Chloride	308	Chlorinated Paraffins (C <sub>12</sub> , 60% chlorine)
232	Pentachloroethane	309	Decabromodiphenyl Oxide
233	2-Biphenylamine Hydrochloride	310	Marine Diesel Fuel and JP-5 Navy Fuel
234	Allyl Isothiocyanate	311	Tetrachloroethylene (Inhalation)
235	Zearalenone	312	n-Butyl Chloride
236	D-Mannitol	314	Methyl Methacrylate
237	1,1,1,2-Tetrachloroethane	315	Oxytetracycline Hydrochloride
238	Ziram	316	1-Chloro-2-methylpropene
239	Bis(2-chloro-1-methylethyl)ether	317	Chlorpheniramine Maleate
240	Propyl Gallate	318	Ampicillin Trihydrate
242	Diallyl Phthalate (Mice)	319	1,4-Dichlorobenzene
244	Polybrominated Biphenyl Mixture	320	Rotenone
245	Melamine	321	Bromodichloromethane
247	L-Ascorbic Acid	322	Phenylephrine Hydrochloride
248	4,4'-Methylenedianiline Dihydrochloride	323	Dimethyl Methylphosphonate
249	Amosite Asbestos	324	Boric Acid
250	Benzyl Acetate	325	Pentachloronitrobenzene
251	Toluene Diisocyanate	326	Ethylene Oxide
252	Geranyl Acetate	327	Xylenes (Mixed)
253	Allyl Isovalerate	328	Methyl Carbamate
255	1,2-Dichlorobenzene	329	1,2-Epoxybutane
257	Diglycidyl Resorcinol Ether	333	N-Phenyl-2-naphthylamine
259	Ethyl Acrylate	334	2-Amino-5-nitrophenol
261	Chlorobenzene		

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge (and while supplies last) from the NTP Public Information Office, National Toxicology Program, P.O. Box 12233, Research Triangle Park, NC 27709.